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ABSTRACT 
This thesis details the development and testing of a new library of phosphonium cation-based 
tracers for imaging apoptosis. The research aims to utilise the favourable conditions of the CuAAC 
reaction to readily radiolabel a series of phosphonium cations bearing an 18F labelled triazole moiety. 
The synthesis of the alkyne-phosphonium salts required for both reference compounds and the 18F 
labelled tracer, focusing on the carbon chain length and the functionalisation of the phenyl rings is 
described (Chapter 3). The reference compounds for seven newly proposed tracers were also 
successfully synthesised and discussed in Chapter 3. 
A fully automated set-up was designed and implemented to synthesise the library of novel 18F 
labelled phosphonium cations and is discussed in Chapter 4. The Advion NanoTek® LF micro-fluidic 
system was implemented to successfully synthesise the well-known 18F precursor, 
[18F]fluoroethylazide. Following this, the CuAAC reaction and purification via semi-prep HPLC 
afforded all seven tracers in high radiochemical purity. The range of lipophilicities was also 
determined by measuring the log D of each tracer. The synthesis of producing two or more tracers in 
one reaction vial is then described. 
The final two results chapters detail the in vitro and in vivo analysis that was carried out. Cellular 
assays were used to determine the uptake of the tracer which was found to be in relation with the 
tracer’s lipophilicity. Treatment with Cisplatin and the protonophore, CCCP was investigated and the 
results seen lead to the in vivo assessment of two of the tracers. Chapter 6 discusses the results 
obtain from the metabolic stability, biodistribution and PET/CT scanning studies for both tracers and 
compares the findings.  
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1.0 INTRODUCTION 
This thesis describes the development of novel fluorine-18 labelled phosphonium cations for a role 
in imaging apoptosis by targeting the mitochondrial membrane potential. This chapter aims to give 
an introduction into the different research topics that are involved in this work, starting with an 
overview of positron emission tomography. It will then proceed to discuss the processes involved in 
apoptosis and in particular the key role of the mitochondria before investigating the different 
methods in which to image it. 
1.1 Positron Emission Tomography 
Positron emission tomography (PET) is a non-invasive imaging technique that over the last 40 years 
has become an important tool in both a clinical setting and in the pharmaceutical industry.1,2,3 The 
technique allows the observation of physiological processes occurring in the body in real time and 
can therefore provide information about metabolism, receptor/enzyme function and biochemical 
mechanisms in living tissue.4,5 This can also allow the observation of chemical changes caused by 
diseases before any anatomical signs can be detected.4,6 More recently, the technique has been used 
in clinical microdosing studies to determine the pharmacokinetics (PK) of a drug in the tissue 
targeted for treatment.7  
1.1.1 How PET Works 
The concept of PET as a practical diagnostic tool was developed in the early 50s by Michael Ter-
Pogossian.8 PET utilises the instability of radionuclides; man-made radioactive isotopes that are 
unstable due to having too few neutrons and as a consequence, decay over time via positron 
emission. Positrons (the positively charged anti-matter to electrons) lose their kinetic energy in 
matter and interact with an electron. The positron and electron annihilate one another, giving rise to 
two annihilation photons travelling in approximately opposite directions (180 degrees) with an 
energy of 511 keV.9 The simultaneous registration of the two photons by scintillation detectors 
makes it possible to localise the decay along the ‘line of coincidence’, and hence approximate the 
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location of the probe in the body (Figure 1.1).10 This information enables image reconstruction to 
obtain an image indicating the position and concentration of the probe. 
 
First, the radionuclide must be produced using a cyclotron or a generator. For the more common 
short lived radionuclides used in the clinic, the former is needed.  
 
Figure 1.2: An image of a Siemens Eclipse™ HP Cyclotron taken from www.medical.siemens.com/siemens
11
 
The cyclotron accelerates charged particles (protons, deuterons, helium-3 or helium-4) using a high 
frequency, alternating voltage.12 A perpendicular magnetic field causes the particles to re-encounter 
the accelerating voltage many times creating a high energy beam.  The charged particles (more 
commonly protons) are then directed into a beam of gaseous or liquid molecules or onto a solid 
target (i.e. the relevant starting compound for the desired radionuclide) forming the desired, 
Figure 1.1: Schematic showing the release of a positron from a radionuclide followed by the annihilation with an 
electron to give 2 gamma rays. Reprinted with permission from reference 10
10
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relatively stable, easy to transport radionuclide. This can then be used directly via chemical 
incorporation into a biologically active molecule. 
1.1.2 Radionuclides 
There are a number of different PET active nuclides available, but the most common found in 
medical imaging tend to be the short-lived due to the nature of the imaging application. More 
recently though, longer lived isotopes such as copper-64 and zirconium-89 are increasingly used for 
longer occurring biological processes involving antibodies, peptides and nanoparticles.13,14 These 
isotopes are shown in Table 1.1.10 
Radionuclide Half-life, t1/2 (mins) Nuclear reaction Product 
11C 20.4 14N(p,α)11C [11C]CO2 
[11C]CH4 
13N 9.97 16O(p,α)13N [13N]NOx 
[13N]NH3 
15O 2.04 15N(d,n)15O [15O]O2 
18F 109.7 20Ne(d,α)18F 
18H2O(p,n)
18F 
[18F]F2 
18F- 
64Cu 762 64Ni(p,n)64Cu 64Cu 
89Zr 3.3 days 89Y(p,n) 89Zr 89Zr 
 
Table 1.1: The most commonly used short-lived radionuclides in PET, plus two examples of longer lived isotopes, their 
half-lives, nuclear reactions and target products 
Due to their half-lives, fluorine and carbon are more commonly used in a medical setting. Their half-
lives not only allow the synthesis and purification of the tracer but also time for quality control 
confirmation, administration to a subject and imaging before the signal to noise ratio becomes too 
low. The time allowance for this process is usually regarded as three half-lives.  
Chapter 1 
 
5 
 
Carbon and fluorine nuclides have both positive and negative features. 11C can be incorporated into 
the desired probe without interfering with the chemical structure and the biocompatibility, but due 
to the short half-life the chemistry is restricted. It also has high positron energy (0.96 MeV, cf. 18F at 
0.64 MeV) which in theory leads to a low spatial resolution, but in the reality of PET imaging this is 
found to be insignificant.15,16 Fluorine atoms on the other hand are not present in many natural 
occurring compounds; this means greater investigation into how the radionuclide will affect the 
biorecognition, kinetics, performance and toxicity of the drug needs to be taken.  That said, 
fluorine’s positive aspects outweigh its potential disadvantage. 18F has the ability to alter the 
lipophilicity (can change the biological activity e.g. increasing drug activity or altering metabolic 
pathways) and it can form strong bonds with carbon, which make it more resistant against metabolic 
pathways in the body.15,17 18F often replaces H or OH groups of a compound due to it having a similar 
radius to H, is isoelectronic with OH and offers similar hydrogen bonding properties. The 
electronegativity of fluorine also allows it to react with many organic and inorganic compounds.18 
Finally, the longer half-life allows greater time to carry out the synthesis of the probe, which can 
provide a wider variety of chemical reactions. It also means that a cyclotron is not necessarily 
required on site as the activity/labelled compound can delivered. Due to these reasons 18F will be 
the main radionuclide used throughout this research project. 
There are two main ways in which 18F radionuclide can be produced in the cyclotron. These can 
either give rise to [18F]F2 or 
18F- as shown in Table 1.1. Both products have very different chemical 
properties and therefore can carry out very different chemistry. [18F]F2 is electrophilic whereas 
18F- is 
nucleophilic. 
[18F]F2 which relies on a carrier added (CA) system is prepared from deuterium irradiation of neon. 
This requires added fluorine to give rise to the 18F labelled fluorine gas. The 18F* (radiolabelled 
fluorine atom) is often concentrated on a nickel target before being flushed with F2 to increase the 
recovery of the radioactivity (Figure 1.3). Even so, with the need of a carrier, the specific activities 
Chapter 1 
 
6 
 
achievable for electrophilic reactions are very low and sometimes not optimal for certain 
pharmaceuticals.  
 
 
 
 
In electrophilic fluorination reactions, the labelling of an aromatic ring is achievable provided there is 
a strong leaving group and a highly electron donating group in the para-position (Figure 1.4). 
 
Figure 1.4: General scheme to show electrophilic fluorination 
As mentioned above, F2 is commonly the source of the reactive F
+ species but it can also be reacted 
further with ammonium acetate to form a secondary precursor, [18F]CH3COOF (Figure 1.5).
19  
 
Figure 1.5: Synthesis of [
18
F]CH3COOF 
The most well-known PET tracer synthesised via this method is [18F]F-DOPA.20 This is the fluorine 
analogue of the Parkinson’s drug L-DOPA. A number of different methods to synthesise this probe 
have been developed in the past but the most common one in current practice is to start with the F-
DOPA precursor, triboc-L-DOPA ethyl ester.21 This is an aryl trimethyl tin derivative and a 
destannylation reaction takes place during the radiofluorination (Figure 1.6).18  
20
Ne(d,α) 
18
F* 
18
F-F 
F2 
Ni 
18
F-Ni 
F2 
Figure 1.3: Schematic to show the formation of [
18
F]F2 from Ne 
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Figure 1.6: Synthesis of [18F]fluoro-L-FDOPA 
Even with the success of this probe in the clinic, the chemistry with electrophilic fluorine is limited. 
The gas is highly reactive and destructive which can lead to poor selectivity and low activity. There 
are also the issues of poor solubility, low radiochemical yields (normally ~50%) and most 
importantly, the low specific activity. 
Nucleophilic substitution reactions with 18F- do however offer many advantages over [18F]F2.
20  They 
do not require the addition of a carrier (NCA), offering maximum radiochemical yields and can 
obtain high specific activities. The activity is also produced in aqueous solutions making it easier to 
handle and offers a wide range of reactions. 
In aqueous solution, fluoride ions are highly hydrated [F-(H2O)n] and this causes the negative charge 
to be ‘quenched’, resulting in a very poor nucleophile. It therefore has to be activated to increase its 
solubility and lipophilicity. This is typically achieved by reacting it with a metal or a positively charged 
ion. The metals usually used are alkali metals (K+, Cs+, Rb+) and these must be coordinated to 
cryptands or polyaminoethers (kryptofix 2,2,2 being the most common). Alternatively tetra-
alkylammonium has also been used but can cause issues due to the instability of tertra-
alkylammonium fluoride, which can lead to the production of volatile HF. These large counter ions 
allow the separation of charge and provide weak solvation, promoting strong nucleophilicity when in 
polar aprotic solvents such as acetonitrile.  Finally, all residual water is removed via azeotropic 
distillation to give the reactive ‘naked’ fluoride species. The route from the cyclotron to this is 
depicted in Figure 1.7.  
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As already mentioned, using 18F- offers a wider range of reactions. The nucleophilic substitution 
reaction can be carried out with both aromatic and aliphatic groups (Figure 1.8). 
 
Figure 1.8: General scheme for both aliphatic and aromatic nucleophilic substitution reactions with fluorine 
These two reactions offer a technique to synthesise a large variety of compounds and can offer good 
radiochemical yields and specific activities. Other functional moieties that have been extensively 
researched for the radiolabelling of fluorine-18 are heteroaromatic groups. When considering 
compounds that have a fluoropyridinyl moiety, nucleophilic substitution at the ortho-position with 
NCA [18F]fluoride is thought to be the most efficient radiosynthesis of radiotracers when compared 
to both homoaromatic and aliphatic nucleophilic reactions.22 There is also no requirement for 
electron withdrawing groups to activate the aromatic ring and so only a good leaving group is 
required. 
[
18
O]H
2
O(p,n) 
In cyclotron 
18
F
-
(H
2
18
O)
n
 
Aqueous [
18
F]fluoride 
Anion exchange resin 
K
2
CO
3
 added, H
2
0 recycled- 
PURIFICATION 
[
18
F]KF (CH
3
CN/H
2
O) 
Aqueous [
18
F]fluoride 
Kryptofix addition (K
222
) 
Removal of water- 
ACTIVATION 
‘Naked 
fluoride’ 
Figure 1.7: A schematic to show the steps taken to produce the 'naked fluoride' 
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Figure 1.9: Nucleophilic reactions involving heteroaromatic fluorine labelling 
Groups such as thiazoles have also been investigated as they are regarded as being isosteric with 
benzene and pyridine. It is believed that the replacement of a phenyl or pyridinyl group with a 1,3-
thiazolyl group may lead to an improved drug or receptor ligand.23 Although these groups are found 
to be susceptible to metabolism via oxidative ring opening, the addition of the fluorine has shown to 
increase the resistance to metabolism in vivo.24,25 
Hence there are many more options open when looking at labelling methods using the nucleophilic 
fluoride route and due to the increased specific activities and increased selectivity, this is now the 
preferred method used.26 
After the production of a reactive 18F species the following steps are carried out in what is called a 
‘hot cell’ (Figure 1.10) or behind lead bricks. A ‘hot cell’ is a lead lined enclosed cell where an 
automated device is used to not only synthesise the ‘naked’ fluorine but also the final tracer itself. 
The cell makes working with far safer as the handing time is greatly reduced although some 
institutions still rely on manual methods due to lack of facilities and equipment. 
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Figure 1.10: Photo of a ‘hot cell’ at Imanova Ltd, Hammersmith Hospital, London 
1.1.3 From Radionuclide to Image 
Once the final radiolabelled probe has been synthesised it is then placed into a small vial and put in a 
lead container prior to being removed from the ‘hot cell’. Before the administration into a patient, 
steps must be taken to ensure the purity of the compound. This involves a series of HPLC (high 
performance liquid chromatography) measurements and QC (quality control) tests to ensure the 
tracer’s purity. To pass QC, the tracer must have high radiochemical purity. Another property that 
must be analysed and controlled is the specific activity as it can have an effect on the amount of 
tracer that reaches the target site. This is currently defined as the radioactivity of a radionuclide 
divided by the mass (or molar amount) of the sum of all radioactive and stable nuclides (present in 
the same chemical and physical form) of the element present.27 In terms of a labelled tracer it is 
typically quoted as GBq/µmol, and is the amount of activity divided by the total concentration of the 
tracer in both its radioactive and stable form (e.g. 19F and 18F compound). The amount of 
radioactivity administered is also very important; the danger is tissue damage from large amounts of 
radiation passing through the body. The doses administered must therefore be kept as low as 
possible; this is achievable given the sensitivity of the technique. Thus, doses can be given to the 
patient in less than 50 nmol concentrations; which is unlikely to cause any adverse effects.28 
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In order to get from the administration of the tracer to the final image that can be analysed, image 
reconstruction steps must be carried out. The main problem that must be considered in image 
acquisition is the attenuation of radioactivity emanating from the tracer in tissues of different 
densities and the amount of tissue penetrated. When the photon travels through the body it 
interacts differently according to tissue type and thicknesses, which can cause the intensity of an 
energy beam to be reduced. This causes deeper structures to appear to have lower concentrations 
of the tracer than in reality. Another issue is that the gamma rays are often scattered by interactions 
with different tissues. One method to circumvent these problems is to combine PET with CT 
(computerised tomography).29 CT has a very high contrast resolution and relies on differences in 
tissue density to form a 3D image. The CT image can be used to estimate the amount and density of 
tissues throughout the entire body and correct for any scattering and attenuation. This enables a 
more quantitative assessment of labelled compound distribution and kinetics to be reconstructed 
compared to an image built solely from the PET data.  
As already mentioned, PET is an important tool in both biomedical imaging and in the 
pharmaceutical industry for drug development.  
When designing a new tracer, there are a number of factors that must be considered: 
 Ease of Labelling - The molecular structure of the proposed radiotracer should be amenable 
to rapid labelling with the appropriate radionuclide.30 The parameters that have to be 
considered are; position of radiolabel, expected radiochemical yield, availability of starting 
materials and the total reaction time.31 
 Lipophilicity - The lipophilicity of a radiotracer is an important consideration since it 
determines the ability of the molecule to cross cell membranes and other barriers such as 
the blood–brain barrier (BBB). The lipophilicity is usually expressed as the partition 
coefficient between n-octanol and water (log P).31 A balance has to be met when looking at 
the lipophilicity; probes with a low log P will not be able to cross the cell membrane whilst 
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those with a high log P are thought to result in high non-specific binding caused by 
hydrophobic interactions with lipids and proteins.32,33 This can either lead to not enough 
activity reaching the target site or the background signal becoming high, resulting in loss of 
contrast. 
 Metabolism and pharmacokinetics - The body is full of enzymes that will try and metabolise 
any exogenous compounds that enter the body in order to remove them as quickly as 
possible.  The probe therefore needs to be able to withstand this process for long enough 
that it can reach the site of action; hence rapid metabolism is generally undesirable. 
Moreover, the effects of the metabolites produced must also be considered. Even though 
the metabolite(s) can be directly monitored in the plasma from the blood during a scan, the 
contribution of the labelled metabolites in the tissue cannot, which can give misleading 
data.34 Finally, the probe should have fast kinetics, allowing it to reach the target site as 
quickly as possible. 
 Affinity and non-specific binding (NSB) – If the compound is required to bind to a receptor 
then the affinity of this binding must be considered. A high affinity is needed to produce high 
contrast images. The probe must also have low non-specific binding (binding to other non-
targeted sites) to reduce background signal.35 This is one of the biggest problems in imaging 
and research is currently being carried out to try and reduce this effect.36 
1.1.4 Why Use PET? 
Like all imaging modalities, PET has its positive and negative features. When comparing these to 
other molecular imaging techniques currently used in a clinical setting, PET’s particular features 
justify its status as a competitive imaging modality. Molecular imaging, which allows the visualisation 
of cellular function rather than anatomical imaging has attracted significant research and 
development over the past century. The four main areas of interest are currently: MRI, optical, PET 
and single photon emission computed tomography (SPECT) imaging. 
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MRI is used heavily in a clinical setting for imaging internal anatomical structures in the body in great 
detail due to its high spatial resolution. This modality provides good contrast between soft tissues 
which allows it to be a very useful tool for imaging the brain, muscles, heart and cancerous tumours. 
Figure 1.11 shows an example of a typical MRI image. 
 
Figure 1.11: A typical MRI image of a human head. Picture taken from http://commons.wikimedia.org
37
 
 In order for MRI to be used in molecular imaging a contrast agent must be introduced. These tend 
to be either gadolinium- or iron oxide-based and usually results in a positive and negative image 
enhancement respectively. The two main disadvantages to this technique are sensitivity and toxicity 
as high concentrations of the probe are required at the target site to cause a significant change in 
signal and the metals must be tightly bound by chemical structures to avoid poisoning.  
The use of optical imaging in a clinical setting is less common than MRI due to its lack of depth 
penetration. This is especially a problem when working at visible wavelengths as penetration can be 
as low as a few millimetres due to the interaction with blood and tissue. Research is ongoing into 
near infrared dye-labelled probes which would reduce this problem but as the dye tends to be 
chemically bulky this can often cause issues in targeting. 
SPECT, like PET is a nuclear molecular imaging technique. One of the main benefits of SPECT over 
PET is that the nuclides are sometimes easily produced by using a generator. 99mTechnetium is the 
most commonly used and generators can be bought and placed on site. However, this technique 
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often lacks good spatial and temporal resolution due to the detection of only one photon (over two 
in PET). 
One of the major disadvantages of PET is that most of the common radionuclides used must be 
generated via a cyclotron. These tend to have a half-life measured in minutes or a few hours, which 
means the cyclotron ideally needs to be on site. Hence PET, can be a costly technique as not only is a 
cyclotron very expensive to buy but the maintenance costs are measured in millions of pounds per 
year.  
That aside, PET imaging does have many advantages though with the most important being its 
sensitivity, as a typical PET scanner can detect between 10−11 mol/L to 10−12 mol/L concentrations. 
The other key advantage is that the contrast agents used can closely resemble or be identical to 
natural compounds and current drug molecules. This is crucial when considering the biocompatibility 
of the probe, as well as providing a much wider range of compounds that can be used. Unlike MRI 
and some SPECT contrast agents, the introduction of large and potentially toxic metals is not 
required.  
1.1.5 PET in Action 
Currently the most commonly used PET probe within a clinical setting is known as [18F]FDG (deoxy-
glucose derivative labelled with 18F radionuclide), shown in Figure 1.12. 
 
Figure 1.12: Chemical structure of [
18
F]FDG 
FDG is currently used for the detection of malignant tumours. The probe is found to have a greater 
uptake into tumour cells over healthy tissue because of the increased energy demand needed for 
rapid cell proliferation. It is also used for detecting non-anatomical defects in the body such as 
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(dis)functional processes in the brain. As PET is a real time imaging technique, it allows the brain 
activity to be monitored by the uptake of glucose. This is beneficial when looking at patients with 
forms of dementia, epilepsy and other neurodegenerative diseases as these are currently difficult to 
be observed by other techniques. Typical PET images of both healthy and diseased brains are shown 
in Figure 1.13. 
 
Figure 1.13: Three examples of PET images of the brain in different patients. Picture taken from 
www.mghradrounds.org
38
 
[18F]FDG is the most successful molecular probe in oncology and is available for routine use in the 
nuclear medicine clinic.39 However, although it offers highly sensitive information regarding 
malignancy, it often has limited specificity due to the enhanced accumulation in inflammation in 
granulomatous diseases and autoimmune diseases.40 This causes problems in certain diagnoses and 
as a result research continues into other methods of oncology detection. 
Recently there has been increased focus on the use of PET in the pharmaceutical industry as a tool in 
drug development. Drug failure at late stages of clinical trials costs pharmaceutical companies 
millions of pounds and valuable time given bringing a drug into human trials can take 10 years.  
The main reason for drug failure in late stage of development is inappropriate pharmacokinetics and 
toxicity. Absorption, distribution, metabolism and excretion (ADME) must all be considered, but can 
be hard to determine until the probe is studied in in vivo testing. Utilising the ability to observe 
biological processes with radiotracers in real time via PET can help predict ADME and toxicity in early 
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stages of drug development. PET also provides an important tool for determining drug dosages.41 
Drug dosing is normally optimised during phase I–II human studies, but determining the optimal 
therapeutic dose is an inexact process.42 There are few methods available that are able to provide a 
direct relationship between the drug occupancy at the target, the dose of drug administered and the 
effectiveness of the drug, PET imaging is one such option. It can indicate whether the drug reaches 
its target, if there is a linear relationship between dose and target occupancy, if occupancy reflects 
drug levels in plasma, and how long the drug remains at its target, thus maximising the chances of 
optimising drug dosage in a rational manner.41 
1.2 Apoptosis 
One of the main biological processes that would benefit from PET methodology in helping to 
understand the mechanism is apoptosis. Apoptosis is the most common form of programmed cell 
death and is a key mechanism in numerous pathologies such as cancer, diabetes, obesity, 
neurodegenerative disorders, and ischemia–reperfusion injury.43 Currently there are very few 
effective non-invasive methods available for apoptosis imaging. Apoptotic cell death is also the key 
mechanism of action of numerous anticancer drugs and imaging biomarkers.44 Enabling early 
detection and quantitative assessment of the apoptotic process could be a valuable tool for the 
assessment of response to treatment.45 Currently, treatment efficacy is usually measured by tracking 
tumour size via anatomical imaging (CT scan or MRI). However, changes in tumour size may be 
observed only several weeks to several months after completion of treatment. Meanwhile, in cases 
where there is no response, the patient is unnecessarily exposed to the treatment's side effects, and 
precious time lost before the initiation of an alternative, potentially more beneficial line of therapy. 
Therefore, there is need for better tools to monitor tumour response to anti-cancer treatments.46 
During apoptosis there are a series of chemical and morphological changes which lead to the 
fragmentation of the cell into small vesicular bodies.47 These are then removed by being taken up by 
macrophages. 48 This process has been found to proceed via two pathways: 
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Type I: Extrinsic pathway 
First, signal molecules known as ligands (mostly members of the tumour necrosis factor receptor 
(TNFR) superfamily) found in the plasma membrane of most cell types are released by other cells 
and bind to transmembrane ’death receptors’ (eg. CD95/fas, DRS) on the target cell (Figure 1.14).49  
This triggers multiple receptors to aggregate together on the surface of the target cell, which lead to 
the activation of the inhibitor caspase 8. This initiates the apoptotic pathway by proteolytically 
(cleaved by enzymes at the site) cleaving the proapoptotic bcl 2 (known to have pro- or anti-
apoptotic effects) family member BID; which in turn initiates permeabilisation of the mitochondrial 
membrane.50 This leads to the release of cytochrome c (an essential component of the mitochondrial 
respiratory chain) and the activation of caspase 9.51,52 
Type II: Intrinsic pathway 
The mitochondria membrane becomes permeablised, leading to the release of the proapoptotic 
signalling molecule, cytochrome c from the intermembrane space to the cytosol (Figure 1.14). This is 
followed by subsequent inner mitochondrial membrane depolarization (loss of the inner membrane 
potential).53  This may be initiated by a number of factors. The first set groups as cellular stress, such 
as DNA damage, heat shock, oxidative stress, and many other forms of cellular damage. The second 
set share the presence of chemicals such as of oxidants, ceramide (lipid molecule found in cell 
membranes), high [Ca2+], or the proapoptotic Bcl-2 protein familty such as Bax, Bid and Bak.54 Both 
sets result in the activation of inhibitor caspase 9 which activates caspase 3, 6 and 7. 
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Figure 1.14: Essential pathways to caspase activation and cell death. Reprinted with permission from reference 49
49
 
Both pathways lead to the activation of a cascade of cysteine aspartic acid proteases, called 
caspases.55 It is thought that cytochrome c exerts its effects by acting as a co-factor for the assembly 
of a large caspase-activating complex in the cytosol that has been termed the apoptosome (formed 
of cytochrome c, Apaf-1 and caspase 9).48,51,56 These caspases (apoptosomes) then cleave functional 
and structural intracellular proteins.57 First the structure of the cytoskeleton is modified through 
proteolysis (directed degradation) of different substrates. Typically, apoptosis is characterised by 
specific changes such as cell shrinking, chromatin condensation, nucleus fragmentation, and 
morphological changes of cell membrane.58 It also results in the exposure of phosphatidylserine (PS) 
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on the outside of the cell membrane, which serves as an ‘‘eat me” signal for phagocytes.59 It is also 
important in the apoptosis process that the cell remains are membrane bound otherwise an 
unwanted inflammatory response may be triggered.54  
The permeablisation/ collapse of the mitochondrial inner-membrane potential (ΔΨm) that can occur 
during both pathways of apoptosis is a point of no return in the process of apoptosis and is thought 
to be the earliest point at which it can be detected.60 This demonstrates the crucial role of the 
mitochondria during apoptosis. 
1.3 Mitochondria 
Mitochondria (Figure 1.15) are membrane bound organelles found in most eukaryotic cells and are 
said to be at the heart of cell life and death.43 Their central role is the production of ATP which is 
formed from a series of chemical transfer reactions. They are also responsible for many other 
processes such as; cell signalling, cellular growth, cellular differentiation and cell death.  
 
Figure 1.15: Cartoon image of the mitochondria highlighting important features. Picture taken from 
www.amarabiotech.com
61
 
The mitochondria consist of two phospholipid bilayers making up five different compartments of 
interest.62 
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The outer membrane which encloses the organelle contains large numbers of integrated proteins 
known as porins. These allow molecules which are less than 6 kD into the intermembrane space.63 
Larger molecules can only traverse the outer membrane by active transport via mitochondrial 
membrane transport proteins. The membrane also contains a number of enzymes which are 
involved in multiple processes carried out by the mitochondria. 
The inner membrane is freely permeable to oxygen, carbon dioxide, and water. Its structure is highly 
complicated, including all of the complexes of the electron transport system and transport proteins. 
Its lipid bilayer contains a high proportion of the ‘double’ phospholipid cardiolipin, which has four 
fatty acids rather than two and may help to make the membrane especially impermeable to ions.64 
This membrane also contains a variety of transport proteins that make it selectively permeable to 
those small molecules that are metabolised or required by the many mitochondrial enzymes 
concentrated in the matrix.  
The intermembrane space is the space between the outer and the inner membrane. Due to the 
outer membrane being freely permeable to small molecules, the concentrations of small molecules 
such as ions and sugars in the intermembrane space is the same as the cytosol. Other larger 
compounds are able to enter this space by assisted transport via a variety of protein structures. 
Cristae are the internal compartments formed by the inner membrane of a mitochondrion. The folds 
create a maximum surface area for chemical reactions to occur within the mitochondria and contain 
proteins, including ATP synthase and a variety of cytochromes. This allows cellular respiration 
(aerobic respiration since the mitochondria requires oxygen) to occur. 
The matrix is the space enclosed by the inner membrane and contains a highly concentrated mixture 
of many different enzymes, special mitochondrial ribosomes, tRNA, and several copies of the 
mitochondrial DNA genome. The most important of the enzymes are those that are needed to carry 
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out the oxidation of pyruvate and fatty acids, and the citric acid cycle. Both of these functions are 
responsible for the production of ATP and hence energy for the cell.  
The mitochondrial involvement in respiration and the production of ATP was greatly investigated in 
the early 60s but it was not until 1969 that the chemiosmotic coupling hypothesis (diffusion of ions 
across a selectively permeable membrane) was believed to be the mechanistic explanation of 
mitochondrial oxidative phosphorylation.65,66 This means that there is a movement of photons across 
the inner membrane of the mitochondria resulting in a membrane potential and a pH gradient 
(termed the ‘mitochondrial inner membrane potential’ or ‘∆Ψm’).67 
Since the late 60s delocalised lipophilic cations have been used to prove the existence of the 
membrane potential by showing their accumulation in the matrix in response to the ∆Ψm. Initially 
the lipophilic cation used was a dibenzylammonium cation but this showed poor results and required 
the presence of a  lipophilic tetraphenylborate anion (TPB).67 Following this, Skulachev et al looked 
into using simple triphenyl phosphonium cations (Figure 1.16) which would not need the TPB to 
facilitate uptake.68,69 They were able to prove that these types of lipophilic cations could accumulate 
in the mitochondria matrix without the assistance of ionophores (lipid soluble molecules used to 
transport ions across the lipid bilayer). This lead to the introduction of triphenyl phosphonium 
cations to mitochondrial biology.  
 
Figure 1.16:  Structures of two triphenyl phosphonium cations; tetratriphenyl phosphonium cation and methyltriphenyl 
phosphonium cation 
Lipophilic cations where the charge is delocalised over a large radius are able to pass though the 
membrane because of reduced electrostatic forces (known as the Born energy (WB)) needed to 
remove solvating water molecules from the cation upon transfer from the aqueous environment to 
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the lipid core of the membrane.70 These compounds therefore have a lower electric field at their 
surface, giving it less ability to polarize water molecules. This has been quantified by Ross et al to 
give a simplified Born Energy equation (Equation 1.1):66 
   
     
 
 
Equation 1.1: Simplified Born energy equation where Z is the charge of cation  
This means that the enthalpy required to move the ion into the membrane is inversely proportional 
to the ionic radius (r) and therefore due to its large radius, phosphonium salts have reduced WB 
compared to other cations such as Na+.71 Due to the hydrophobicity of the lipophilic salts there is 
also an attractive force due to the increase in entropy (loss of water structure) on moving a molecule 
into the lipid region.66 This provides a driving force for the salt to enter the membrane. It will then 
hit the potential energy well before jumping rapidly through the hydrophobic core to the potential 
energy well on the opposite surface of the membrane before exiting the membrane into the matrix. 
This mechanism enables lipophilic cations to pass easily through phospholipid bilayers and thus 
these cations can traverse the mitochondrial inner membrane and access the matrix even in the 
absence of ∆Ψm.66 However, in the presence of ∆Ψm the distribution of lipophilic cations across the 
membrane will be dependent on the ∆Ψm leading to the extensive accumulation of the cation in the 
mitochondrial matrix. The extent of this is given by the Nernst equation (equation 1.2). 
             {
[      ]  
[      ]   
} 
Equation 1.2: Nernst equation where     is the Membrane potential 
In living cells this potential is found to be around 130-150 mV due to ATP synthesis and 
translocation. As this is found to be much higher than in other organelles in cells, the lipophilic 
cations accumulate selectively in the mitochondria. Equation 1.2 states that with every 61.5 mV 
increase in membrane potential there is a ten-fold increase in cation concentration in mitochondria. 
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Therefore, the concentration of such cations is expected to be two to three log units higher in the 
mitochondrial matrix than in the cytosol. 
It has also been discovered that the mitochondria membrane potential does not just alter during 
apoptosis but also when the other extreme is examined. It is known that cancerous cells proliferate 
rapidly without ever destroying themselves, removing the ability to undergo cell death. The increase 
in energy requirement results in an increase in Ψm. The difference in membrane potential between 
normal epithelial cells and many carcinoma cells is found to be at least 60mV.72 According to the 
Nernst equation this leads to nearly a 10-fold increase in cation uptake. This gives promising results 
for detecting tumours and may lead to finding an imaging probe with multiple positive 
characteristics.  
1.4 Imaging Apoptosis 
Having discussed the use of lipophilic cations and in particular phosphonium cations in mitochondrial 
biology as well as the importance of PET in medical imaging, this section will bring the two ideas 
together. It starts with a brief overview of other methods currently being researched to image 
apoptosis. 
As mentioned above the importance of fully understanding the process of apoptosis is crucial and 
has led to a wide scope of research areas. The three main areas of interest that have been used to 
image and target apoptosis are depicted in Figure 1.17.73 
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Figure 1.17: Illustration of the different processes that could be used to image apoptosis 
Currently there are very few imaging agents used to observe apoptosis under clinical investigation. 
The first one to reach clinical trials was annexin V.73 Annexin V (also known as annexin A5) is a 
natural human cellular protein which targets the externalisation of membranous phosphatidylserine 
(PS).74 During apoptosis there is found to be an over expression of PS on the cell surface.73  This 
event is found to take place in the later stages of apoptosis and can often give inconclusive results 
due to the passive nature of the expression of PS. Despite this, annexin V has become a popular 
compound for observing apoptosis and various different imaging techniques have been utilised with 
this protein.  
The main method of labelling annexin V is with the SPECT isotope 99m-technetium.75 99mTc-Annexin 
V is believed to be the first non-invasive imaging method to observe apoptosis.76 Over the past 
decade this probe has progressed through various stages of clinical trials. Tarik Belhocine et al in 
2002 carried out a phase I study to confirm the safety and the feasibility of 99mTc-Annexin V for 
imaging chemotherapy-induced apoptosis in human cancers immediately after the first course of 
chemotherapy.77 Following these trails, phase II clinical trials have also been undertaken.78  
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An alternative probe has also been developed and labelled with fluorine-18 in order to carry out PET 
studies. This was first reported by Yoshihiro Murakami et al in 2004 who believed the shorter half-
life of the PET isotope was required to examine the time course of apoptosis.79 The following year 
Yagle et al preformed a study whereby healthy rats were treated with cycloheximide (induces liver 
apoptosis) and then the uptake of [18F]-annexin V was compared to that of the control rats.80 Their 
results indicate that [18F]-annexin V binds specifically to apoptotic tissues in this model of chemically 
induced apoptosis in rat liver. They also state that the ‘short physical half-life of [18F]-annexin V and 
the rapid clearance of its metabolites to the urinary system suggest that it will be useful in early 
assessment of the clinical response to cancer therapy in individual patients.ʼ80 
However, a review by Nui and Chen in 2009, states several issues with annexin V that limits further 
use in a clinical setting.81 Firstly they believed that the radiolabeled annexin V protein offered 
suboptimal pharmacokinetics, especially the high background activity in the abdominal region. They 
also voiced concerns regarding the ability of the probe to differentiate between apoptosis and 
necrosis as PS is also exposed during necrosis because of the disruption of plasma membrane 
integrity. Finally it is noted that for optimal binding of annexin V to phosphatidylserine, requires a 
micromolar concentration of Ca2+.81 Due to these reasons other probes to target different processes 
during apoptosis have been investigated by researchers. 
The other process of significant interest to researchers’ apoptosis imaging over the last decade has 
been targeting the caspase activation step using isatin sulphonamide analogues.82 Although isatin 
has been known to inhibit the process of apoptosis (by interfering with the caspase cascade) for over 
a decade, only in the last 5 years has it been combined with radionuclides and used in PET 
imaging.83,84 Aboagye et al and Zhou et al have researched radiolabelling isatin analogues with both 
11C and 18F radionuclides. Aboagye et al have characterised [18F]ICMT-11 (the caspase-3/7 selective 
isatin sulfonamide labeled with 2-[18F]fluoroethylazide) as a PET imaging radiotracer for the 
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assessment of tumour apoptosis that could find utility in anticancer drug development and the 
monitoring of early responses to therapy (structure shown in Figure 1.18).85 
 
Figure 1.18: Chemical structure of [
18
F]ICMT-11
85
 
Zhou et al have investigated both 11C and 18F labelling of the following isatin analogue (Figure 1.19) 
as a potential PET radiotracer. They have proven that these compounds are potential radiotracers 
for imaging caspases3/7 activation in apoptosis.84 
 
Figure 1.19: 
18
F and 
11
C labeled isatin analogues synthesised by Zhou et al
84
 
A problem that has emerged with these compounds is that there is an apparent substantial drop in 
probe affinity when going from in vitro (isolated protein systems) to in vivo and whole cell models.86 
Higher concentrations of the isatin compounds are needed to inhibit the caspase which suggest 
there might be potential non-specific binding occurring.87 
Another issue when trying to image apoptosis by targeting the release of caspase is that the time 
window for viewing this event is limited. As it is not a permanent signal, careful consideration of 
when to scan must be taken. Getting this wrong could lead to false results as it may lead to the 
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thought that apoptosis has not been induced when in fact the release of caspase has already 
occurred and been cleared. 
Another probe that has being widely investigated for imaging apoptosis is the PET probe, 18F labelled 
2-(5-fluoropentyl)-2-methyl malonic acid or ML-10 as it is more commonly known (Figure 1.20). ML-
10 is an 18F-labelled small molecule and because of its ability to pass the blood brain barrier, it has 
become a promising tool for imaging brain tumours.88 
 
Figure 1.20: Chemical structure of 
18
F-ML-10 
It is derived from the Aposense family which were designed to selectively bind and accumulate in 
cells that demonstrate the ‘apoptotic membrane imprint’.86 This comprises the acidification of the 
external membrane due to the exposure of PS, permanent membrane depolarisation, irreversible 
loss of intracellular pH control and the activation of the phospholipid scrambling mechanism. This 
also occurs while the membrane integrity is still preserved and is the commitment point for 
apoptosis and also how cells can be differentiated from cells undergoing necrosis.89,90 
Preclinical models have already shown that 18F-ML-10 offers selective binding to apoptotic cells, high 
stability and favourable biodistribution.88 The positive results from these studies allowed this tracer 
to be the first small-molecule probe for imaging apoptosis via PET in humans. 
Whilst the research into imaging apoptosis by targeting the caspase involvement and the use of ML-
10 is ongoing, the idea of trying to utilise the involvement of the mitochondria membrane has also 
been of interest over the past decade. 
As already discussed, during the early stages of apoptosis there is a depletion of the inner 
mitochondrial membrane potential which is a point of no return to cell death.53 The membrane 
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potential provides a net negative charge inside the matrix of the mitochondria and as a result 
attracts lipophilic cations which selectively accumulate there. By imaging the uptake of the cations 
into the matrix as a result of the ΔΨm, the early detection of apoptosis and tumour detection could 
be achieved. 
As far back as the 1980s, scientists have been able to track radiolabelled phosphonium cations in 
several different cell types under in vitro studies and show the accumulation within the 
mitochondria.91 The studies have focused on imaging cancer cells given their higher accumulation. 
The probe that has been studied most extensively historically is a tetraphenyl phosphonium cation 
labelled with a beta (-) emitting 3H atom.40 More recently, research has turned to phosphonium 
cations labelled with a positron emitting fluorine-18. This offers significant advantages over 3H 
where the longer half-life allows extra more time for synthesis and administration, making it more 
viable for use in humans. 
Madar et al are currently looking into the use of 18F labelled probes of this kind. They have carried 
out multiple studies on a novel PET voltage sensor, [18F]p-fluorobenzyl triphenylphosphonium 
bromide ([18F]FBnTP)( Figure 1.21).92  
 
Figure 1.21: Chemical structure of [
18
F]FBnTP 
Madar et al investigated the uptake of this compound with multiple tissue samples under different 
conditions. The main requirement was to observe the effect of altering the mitochondria membrane 
potential on the cellular uptake of [18F]FBnTP. This can be investigated by inducing apoptosis in 
cancer cells with anti-cancer drugs or protonophores, before measuring the difference in uptake of 
the probe. A decrease in accumulation of the tracer during apoptosis would be expected due to a 
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potential gradient to attract the cation to cross into the mitochondria no longer existing.93 Their 
experiments showed positive results and in vitro tests were carried out to confirm the collapse of 
the membrane potential with other markers of apoptosis such as the release of cytochrome c and 
the Bax-to-Bcl-2 ratio.45 [18F]BnTTP has also been shown to be selectively taken up into cancer cells 
and not cells that are inflamed, which has proven to be a problem with FDG.93  
Since the publication of this probe, other similar lipophilic phosphonium cations have been reported 
in the literature. Cheng et al in 2005 wrote a paper describing the synthesis of  4-[18F]fluorophenyl 
triphenylphosphonium (Figure 1.22) and followed up with a US patent describing the ability of this 
probe to act as an imaging agent of apoptosis by the uptake being dependent on the mitochondrial 
membrane potential.94,72 Following this, no further references to this probe have been made in the 
literature. This is surprising as they state that this probe can be radiolabelled in one step, having an 
advantage over [18F]FBnTP which requires four steps. 
 
Figure 1.22: Structures of other fluorine-18 labelled phosphonium cations in the literature 
More recently, the other phosphonium cations shown in Figure 1.22 were synthesised by Kim et al in 
2012.95,96,97 All three analogues have been shown to act as potential myocardial imaging agents, 
where they exhibit preferential uptake into the myocardium of BALB/c healthy mice. They were all 
achieved with radiochemical yields of greater than 15% (decay corrected) via a two-step labelling 
synthesis in less than one hour.95,96,97  
The results and analysis of the phosphonium cations described in literature have all been positive 
and demonstrate the scope of these types of compounds in molecular imaging.  
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1.5 ‘Click’ Chemistry 
When considering [18F]FBnTP, the main drawback of this probe is the multiple steps involved in the 
synthesis. This results in long reaction times and poor radiochemical yields, supporting the 
investigation of alternative radiolabelled lipophilic salts that are easier to synthesise whilst retaining 
good imaging properties. Using a different synthetic method that reduces the number of steps to 
obtain the labelled radiotracer could overcome these issues.  
One option is to utilise the conditions of ‘click’ chemistry. The idea was first introduced by Sharpless 
in 2001 and is a term given when a reaction offers the following positive features; high yielding, mild 
conditions, readily available starting materials, purification without chromatography, stereospecific, 
carried out in benign solvent and wide in synthetic scope.98 
One of the most well-known ‘click’ reactions unearthed was the discovery that Cu(I) catalyses the 
Huisgen 1,3-dipolar cycloaddition of terminal alkynes and organic azides to form 1,2,3- triazoles.99 
This reaction, now referred to as the ‘CuAAC’ (copper-catalysed alkyne-azide cycloaddition) reaction 
has led to wide-ranging applications in combinatorial chemistry (Figure 1.23).100,101  
 
Figure 1.23: The 1,3-cycloaddition of an azide and terminal alkyne to give the 1,4-regioselective 1,2,3-triazole. 
Several different methods have been described for the synthesis of [1,2,3]-triazoles. These include 
the intramolecular cyclization of bishydrazones or mixed hydrazones and miscellaneous oxidations 
but the 1,3-dipolar cycloaddition of azides to alkynes offers great advantages.102 The CuAAC reaction 
can afford high yields under mild conditions and are highly regiospecific.103 Reactions carried out by 
Tornøe et al in 2002 have shown full conversion and high purity products in a wide range of solvents 
e.g. acetonitrile, dichloromethane, tetrahydrofuran, toluene, N,N-dimethylformamide, and neat N-
ethyldiisopropylamine.102 
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The catalytic mechanism is still not fully understood, but as it is known that copper(I) readily inserts 
into terminal alkynes in the presence of base, e.g. in the Sonogashira coupling, predictions can be 
made.104 Tornøe et al believed that the copper(I) centre becomes covalently bound to the terminal 
triple bond, which causes polarisation and hence catalyses the reaction in a step-wise addition. To 
help confirm this theory, they used Cu(I) on internal alkynes. However, this did not catalyse the 
reactions and only starting material remained. It may therefore be concluded that the 1,3-dipolar 
cycloaddition of terminal alkynes to azides is catalysed by copper(I) salts through a preformed 
copper-acetylide complex followed by a stepwise or concerted addition to an azide (Figure 1.24).102 
 
Figure 1.24: Reaction scheme of copper(I)-catalysed 1,3-dipolar cycloaddition of alkynes to azides indicating the 
predicted copper-acetylide complex 
A more detailed mechanism was then devised by Fokin et al in 2005 with the help of density 
function theory (DFT) calculations.105 They revealed a unique qualitative and quantitative framework 
for understanding the mechanistic pathway shown in Figure 1.25. 
 
Figure 1.25: Proposed reaction mechanism by Fokin et al. Modified from reference 105 
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They state that this proposed mechanism accounts for the key experimental observations. Copper 
catalysed synthesis of 1,2,3-triazoles has a much higher reaction rate which agrees with the 
computed activation barriers (Step A is 11.7 kcal/mol lower (in water) than in the corresponding 
concerted cycloadditions).105 Step B was found to be nearly thermoneutral computationally whereas 
Step C, although found to have a calculated barrier of 18.7 kcal/mol is considerably lower than that 
for the uncatalysed (approx. 26.0 kcal/mol) reaction resulting in the increase in reaction rate 
observed.100 Since this report, Nolte et at have also isolated a copper(I) triazolide complex as 
evidence of such structures which had previously only been assumed as an intermediate.106 Also, the 
exclusive regioselectivity of the copper(I)-catalysed processes is both predicted computationally and 
observed experimentally.105  Further development from this group has also introduced the possibility 
of a dinuclear copper(I) acetylides, which was found to further drop in the activation barrier by 
approximately 3–6 kcal/mol concluding that this reaction is mechanistically very complex.100   
While a number of copper(I) sources can be used directly and provide good results, Rostovtsev et al 
in 2002 found that the catalyst is better prepared in situ by the reduction of Cu(II) salts which are 
less costly and often purer than Cu(I) salts e.g. CuSO4.5H2O. The reducing agent typically used is 
either ascorbic acid or sodium ascorbate. Results from these reactions have allowed the preparation 
of a ‘broad spectrum of 1,2,3-triazole products in high yields and purity at 0.25-2 mol% catalyst 
loading.’107 
Although no research has been carried out on triazole-functionalised phosphonium cations and their 
uptake into the mitochondria, other compounds containing a triazole show promising 
characteristics. They appear to offer good resistance to metabolic degradation, favourable in vivo 
pharmacokinetics, are easily labelled with radionuclides and can offer high radiochemical yields and 
high specific activity.57,103 
Glaser and Arstad in 2007 looked into developing more flexible ways of 18F-labelling methods.108 
They examined the CuAAC reaction method to form 18F-labelled 1,2,3-triazoles. They synthesised 2-
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[18F]fluoroethylazide ([18F]FEA) by nucleophilic fluorination of 2-azidoethyl-4-toluenesulfonate to act 
as the labelling agent (Figure 1.26). 
 
Figure 1.26: Radiosynthesis of 2-[
18
F]FEA followed by a 1,3-dipolar cycloaddition with a terminal alkyne 
The [18F]FEA was produced in high yields via a one-step synthesis before being coupled with a series 
of small molecules and peptides to give the corresponding [18F]fluoroethyl-1,2,3-triazole. These 
compounds were achieved in excellent yields under mild conditions in short reaction times.108 Since 
then, a wide range of compounds have been developed using this labelling agent with the paper 
achieving more than 115 citations (data from Scifinder.org on 23rd January 2014). 
The research in this thesis will look to develop a new 18F labelled phosphonium tracer with the 
potential to act as an imaging agent for apoptosis whilst introducing a radio-labelling method that 
utilises the favourable reaction conditions of the CuAAC reaction. 
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2.0 THESIS AIMS AND SUMMARY 
This chapter will outline the aims and objectives of this research and then summarise the chapters 
presented in this thesis.  
2.1 Aims and Objectives 
The primary aim of this work is to investigate the use of novel lipophilic phosphonium cations as 
targets for imaging the process of apoptosis. It will focus on compounds with the ability to 
incorporate the radionuclide, fluorine-18, as positron emission tomography will be the imaging 
modality of interest. The radiolabelled cations must demonstrate: 
(A) Rapid and efficient radiolabelling with the positron-emitting isotope fluorine-18. This 
requires a radiosynthetic route with few synthetic steps and short reaction times. The ability 
to isolate the pure labelled compound is also a necessity and is usually achievable via semi-
preparative HPLC. Both high radiochemical yields and radiochemical purities must be 
attainable and specific activities must be suitable for in vivo studies. 
(B) Demonstrating suitable membrane transport in cell assays and show suitable change in 
uptake into the mitochondria dependent on the membrane potential. Lipophilicity is one of 
the key features of a compound that can determine whether it will enter the cell or not and 
will therefore need to be taken into consideration. If the cation is too lipophilic it may get 
stuck in the cell membrane and give rise to non-specific binding and if it is too hydrophilic 
may remain in the blood stream. Once confirming good cell uptake, determination as to 
whether the uptake is dependent on the mitochondrial membrane potential will need to be 
carried out.  
(C) Demonstrate metabolic stability and undergoing minimal defluorination in both in vitro and 
in vivo studies. Problems are faced when the fluorine isotope is too labile and becomes 
detached during metabolism in the body. This causes problems as 18F- is a highly sensitive 
bone seeking PET tracer and will therefore interfere with the PET image and prevent the 
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imaging of target sites in the body. The formation of metabolites can also affect the 
suitability of the probe as they may alter the specific target of the drug or make it more 
prone to excretion. Metabolite and biodistribution studies can be carried out on live subjects 
to observe whether either of these potential issues will be a problem for that particular 
tracer. 
2.2 Thesis Summary 
The chapters of this thesis are separated into the different disciplines that were carried out during 
the research. It will start by discussing the chemistry that was needed in order to synthesise the new 
tracers. This involved preparing both the precursors required to carry out the radiolabelling steps 
and also the reference compounds.  
The novel design of the new tracer involved a triphenylphosphonium core with an 18F label attached 
via a triazole moiety. Initially synthesis involved the preparation of the phosphonium cations 
functionalised with a terminal alkyne in order to allow for the CuAAC reaction with fluoroethylazide. 
Following the successful preparation of 3 new reference tracers with varying chain length between 
the phosphorus atom and the triazole, the design moved on to developing a series of analogues with 
functionalised phenyl rings. The preparation of the functionalised phosphines had to take place, 
initially starting with fluorine functionalisation before moving on to methylated versions. The later 
then went to be converted into alkynyl-phosphonium cations and then coupled with the 
fluoroethylazide to give a further four reference tracers.  
The chapter discusses the various challenges that were faced throughout the chemistry research, 
including the search to find the most suitable catalyst for the CuAAC reaction. Finally, the chapter 
concludes with an idea of how to take this design further and introduce a different functional moiety 
which could potentially lead to a multi-modal imaging tracer. 
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The radiochemistry chapter proceeds by describing the set-up used for the fluorine-18 labelling and 
how the Advion NanoTek® equipment and a valve system was utilised to enable a fully automated 
synthesis. The chapter discusses the success of labelling seven different tracers with 18F using the 
same versatile method and proves successful isolation with high radiochemical yields for all. An 
investigation as to whether it would be possible to synthesise two or more of these tracers in the 
same reaction vial and separate using HPLC was carried out and with successful results this proved a 
very viable method. 
The following two chapters present the data obtained from performing both in vitro and in vivo 
characterisation on some of the new tracers. The in vitro work looks into cellular uptake in various 
cell lines and trying to alter the accumulation inducing apoptosis or altering the mitochondrial 
membrane potential. The in vivo chapter specifically looks at two of the tracers, investigating the 
metabolic profile, the biodistribution data and analysis of dynamic scan data of each. 
Finally, the thesis will conclude by summarising the work presented and then discuss any future 
work that could help further this research. 
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 3.0 THE CHEMISTRY OF NOVEL PHOSPHONIUM CATIONS 
This chapter will discuss the chemistry that has been carried out in order to form novel compounds 
which have the potential to be used as PET tracers for imaging apoptosis. The original design of 
these compounds was influenced by the research published on the 18F labelled tracer, p-fluorobenzyl 
triphenylphosphonium bromide ([18F]FBnTP).1 
Initially the chapter starts by discussing the synthesis of FBnTP and two analogues, in order to 
understand the chemistry and to gain ideas on how best to design a set of novel compounds. The 
new design utilises the ease and one-step synthesis of the ‘click’ reaction and more specifically in 
this case, the copper-catalysed alkyne azide cycloaddition (CuAAC) reaction (Figure 3.1). 
 
Figure 3.1: Proposed reaction to form novel phosphonium cations bearing a fluorine labelled triazole moiety 
The synthesis of the alkyne precursors were investigated using a simple triphenyl phosphine starting 
material and varying carbon chain lengths of halide alkynes. Four phosphonium salts were 
successfully synthesised with terminal alkyne chains with 3-6 carbons. Following the synthesis of 
fluoroethylazide, the CuAAC reaction and different catalysts will be discussed.  
The chapter then moves on to discuss the possibility of increasing the lipophilicity further by 
functionalising the phenyl rings attached to the phosphorus. This was initially attempted using 
fluorine atoms but then changed to methyl groups due to the electron withdrawing nature of the 
fluorine atoms hindering the synthesis of the phosphonium salt. 
Once a small library of functionalised alkyne phosphonium salts were synthesised, these were used 
in the CuAAC reaction and the triazole derivatives successfully synthesised. 
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The chapter will end by giving a brief overview into how this design can be taken one step further 
and potentially introduce a new moiety into the tracer. 
3.1: Using FBnTP as a Starting Point 
Over a decade ago, Madar et al first published the synthesis of FBnTP (Figure 3.2) and since then the 
group have gone on to prove its suitability as a PET tracer in various disease models.2,3,4 As discussed 
in chapter one, the lipophilic and cationic nature of the structure allows it to be taken up into the 
mitochondria with respect to the membrane potential.  
 
Figure 3.2: Chemical Structure of FBnTP (1) 
The success of this compound lead to it being the starting platform for this research.5 As with the 
synthesis of any labelled tracer, the reference compound must also be synthesised. This involves 
producing the 19F analogue so a stable compound in which to compare the labelled one to (via QC 
HPLC) can be used. 
The synthesis of 1 followed a method by Bruncko et al and involved a very simple nucleophilic 
addition reaction between triphenylphosphine and 4-fluorobenzyl bromide in toluene and heated to 
reflux.6 This yielded the product as a white solid in moderate yields. Various analytical techniques 
were performed including; NMR (1H, 31P{1H}, 19F, 13C{1H}), mass spectrometry and elemental analysis 
in order to confirm the desired product and purity. 
Following this, two analogues (Figure 3.3) were synthesised in the hope of determining whether the 
carbon chain length between the phosphorus centre and the fluorophenyl moiety altered the 
properties of the tracer.  
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Figure 3.3: Chemical structures of two analogues (2, 3) of FBnTP 
p-Fluorophenyl triphenylphosphonium iodide (2) was synthesised according to the synthesis of p-
bromophenyltriphenylphosphonium iodide by Lambert et al in 2001.7 Palladium acetate was used to 
catalyse the reaction which was carried out in p-xylene. The literature stated to purify using semi-
preparative HPLC with methanol but due to lack of equipment the crude product was dissolved in 
methanol and then any solid removed by filtration. The solvent was removed under vacuum to give 
a cream coloured product. This was recrystalised in ethanol/petroleum ether and dried using diethyl 
ether. The product was isolated in high yields (72%) and analysis of the compound corresponded to 
that in the literature.8  
p-Fluorophenethylbromide was then used in order to synthesise p-fluorophenethyl 
triphenylphosphonium bromide (3) using the same reaction conditions as for compound 1. The 
crude product was impure and required purification, which involved multiple recrystallisations in 
acetonitrile to remove unreacted triphenylphosphine. The recrystallisation filtrate was placed in the 
freezer to encourage the product to precipitate. Off-white crystals were produced and the novel 
compound and purity confirmed via NMR, MS and EA. 
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Figure 3.4: 
1
H NMR (DMSO-d6) of compound 3  
The 1H NMR spectrum of 3 in Figure 3.4 showed that the correct peaks were present. There were 
two distinct multiplets in the alkyl region relating to the protons at position c and d. Both of them 
showed coupling, although these were not distinguishable due to both the coupling to the 
phosphorus and through the aromatic region to the fluorine.  There are then three areas in the aryl 
region, one large for the three phenyl rings directly attached to the phosphorus and then 2 for the 
protons attached to the phenyl ring bearing the fluorine atom. In this crude NMR there was still a 
small amount of triphenylphosphonium present. The 31P{1H} NMR showed a singlet at 23.42 ppm 
and the 19F spectrum a singlet at -116.07 ppm.   
The 18F labelled analogues of both 1 and 2 have been previously synthesised by Madar and Cheng 
respectively.2,8 [18F]1 involves a multi-step synthesis which relies on the formation of [18F]p-
fluorobenzyl bromide before reacting this with triphenylphosphine. As for [18F]2, it appears to be a 
more straightforward synthesis as Cheng et al state that it can be made via a one-step synthesis 
between p-nitrophenyltriphenylphosphonium and the dried [18F]Fluoride (Figure 3.5).8 
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Figure 3.5: Synthetic scheme for [
18
F]2 
Both of these methods have been attempted but with very little success and due to both being held 
under the IP of US patents, it was felt there was little point in continuing to work on these 
compounds. Instead a new design of phosphonium cation was developed which attempts to use a 
different and more straightforward radiolabelling technique.  
3.2 New Design of Phosphonium Cations 
As mentioned in chapter one, the use of ‘click’ chemistry and in particular the CuAAC reaction could 
allow the introduction of a 18F labelled 1,2,3 triazole moiety into a phosphonium cation. Glaser and 
Arstad in 2007 developed a method that could successfully synthesise 2-[18F]fluoroethylazide 
([18F]FEA) (Figure 3.6) by nucleophilic fluorination of 2-azidoethyl-4-toluenesulfonate which could 
then be used to act as the labelling agent.9 
 
Figure 3.6: Chemical structure of 2-[
18
F]FEA 
Following the production of this, it could then be reacted with a terminal alkyne under CuAAC 
conditions to yield a [18F]fluoroethyl-1,2,3-triazole in excellent yields under mild conditions and in 
short reaction times.9 
In order to maintain the positive characteristics of FBnTP that enable it to be accumulated in the 
mitochondria, the triphenylphosphonium core remained unchanged. Instead of the fluorobenzyl 
group, a fluoroethyl-1,2,3-triazole functionality was investigated. The design for the new set of 
phosphonium cations is shown in Figure 3.7. 
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Figure 3.7: Structure of proposed new design of phosphonium cation 
3.2.1 The Synthesis of the Alkyne Phosphonium Precursors  
Initially, the aim was to synthesise a library of phosphonium salts with varying terminal alkyne chain 
lengths (Figure 3.8). The reason behind choosing to alter the chain length was to investigate whether 
this would have any effect on the CuAAC reaction and to see the overall effect on the tracer. By 
increasing the carbon chain length an increase the lipophilicity would be expected (see section 4.7) 
and therefore might alter the uptake of the tracer in in vitro models. 
 
Figure 3.8: Chemical structure of phosphonium cations bearing a terminal alkyne of varying chain lengths 
First, triphenylpropargylphosphonium bromide (4) was prepared according to Bagdasaryan et al.10 
This involved an acid-catalysed reaction between triphenylphosphine and propargylbromide in 
dioxane to produce a white powder in high yield. Bagdasaryan states that three different 
compounds could be made; alkyne, dialkene and an oxidised ketone. The product was analysed via 
proton, phosphorus and carbon NMR spectroscopy, infra-red spectroscopy, MS and elemental 
analysis. All analytical techniques indicated the production of the phosphonium cation bearing the 
terminal alkyne and showed no signs of the other predicted products. 
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Figure 3.9: 
13
C{
1
H} NMR (CDCl3) of compound 4 
The 13C{1H} NMR for compound 4 (Figure 3.9) showed clearly the expected peaks for this type of 
compound. By starting upfield of the spectrum in the alkyl region, there was a doublet present due 
to the CH2 coupling to the phosphorus. Next, there were two peaks relating to the two carbons 
involved in the triple bond (a and b). These were also found to be doublets due to the coupling back 
to the phosphorus. The coupling constants for these peaks were interesting as they gave 3JPC 
coupling to be larger than 2JPC.
11 This was found to be true when the phosphorus loses its lone pair 
and becomes +5 oxidation state. The doublet seen at 118 ppm was due to the carbon d and had a 
1JPC coupling (87.4 Hz) expected of that for an ipso-carbon to the phosphorus. The other three peaks 
were also as expected with the ortho-carbon being further downfield with a larger coupling constant 
than the peak seen for the meta-carbon and the para-carbon giving a 4JPC of 3.0 Hz.
11 
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But-3-ynyltriphenylphoshonium bromide (5) was then prepared by a simple nucleophilic addition 
between the corresponding alkyne and triphenylphosphine in dry toluene. This method was 
modified from that described by Dharanipragada et al (Figure 3.10).12 
 
Figure 3.10: Reaction scheme to synthesise 5 
The reaction was left to heat to reflux for 24 hours and a yellow solid was extracted by filtration and 
then washed with more toluene (remove any unreacted triphenylphosphine) to give 5 in moderate 
yield (54%). The 1H NMR data were in agreement with that already reported in literature but no 
other analysis of the compound was given.12 In order to have the full analysis data for 5, the 31P and 
13C NMR (all found to be closely related to the spectra obtained for 4), MS and elemental analysis 
were also performed.  
To prepare the pentynyl (6) and hexynyl (7) triphenylphosphonium cations the corresponding alkyne 
iodides had to be prepared from the alkyne chlorides that could be purchased from Sigma Aldrich. 
This provided a more labile leaving group to aid the nucleophilic reaction with TPP. This involved 
reacting 1 eq of chloropentyne or chlorohexyne with 3 eq of sodium iodide in acetone under reflux 
conditions for 24 hours (Figure 3.11).  
 
Figure 3.11: Reaction scheme to exchange a chloride for an iodide leaving group 
Brown coloured oils were formed which at temperatures just below room temperature solidified to 
give bright red solids. The iodo-alkynes were then reacted with triphenylphosphine in toluene 
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heated to reflux for 24 hours and then left to cool. Cream solids were filtered off in moderate yields 
and then washed with toluene to remove any unreacted triphenylphosphine.  
Analysis of all NMR (1H, 31P{1H} and 13C{1H}) spectra and mass spectrometry showed the correct 
peaks. The 1H NMR spectrum in Figure 3.12 clearly showed the peaks relating to the protons present 
in compound 6. The triplet seen for the terminal alkyne proton indicated that a 4JHH coupling was 
occurring via the triple bond.  
 
 Figure 3.12: 
1
H NMR spectrum of 6 in CDCl3 
The elemental analysis results however, indicated a low carbon and hydrogen contribution 
compared to calculated values. This was believed to be because of inorganic impurities and due to 
unrecovered NaI and NaCl. The compounds were recrystallised in acetone/toluene in an attempt to 
remove the impurities. Following this, elemental analysis was repeated on compound 6 and 7 and 
the experimental data were now in line with calculated values. 
Having successfully prepared the alkynes, the next step was to synthesise the azide. 
Chapter 3 
 
51 
 
3.2.2 The Synthesis of Fluoroethylazide 
In order to synthesise the fluoroethylazide (9), fluoroethanol must be converted to the 
corresponding tosylate (8) and then to the azide (Figure 3.13). 
 
Figure 3.13: General reaction scheme to synthesise 8 and 9 
 The first step was carried out following a method described by Parenty et al which involved 
performing the reaction in pyridine at low temperatures.13 This method proved to be successful and 
produced the desired product in high yield (81%) and gave the 1H NMR spectrum shown in Figure 
3.14 .  
 
Figure 3.14: 
1
H NMR (CDCl3) spectrum of 8 
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Coupling was seen between the protons and the fluorine atom giving rise to two sets of peaks 
around 4.5 ppm which the 2JHF being larger than that of 
3JHF as expected. Correct integration 
between these peaks and those that belonged to the tosylate group confirmed a successful reaction. 
To synthesise the fluoroethyl azide (9), sodium azide and the fluoroethyltosylate were reacted in 
DMF at room temperature under nitrogen for 48 hours and then any precipitation filtered off.9 Due 
to the explosive nature of low mass azides, the product could not be isolated and was thus used in 
the next step without modification or purification. 
3.3 Copper-Catalysed Alkyne Azide Cycloaddition Reaction 
As an initial attempt at a CuAAC reaction, 4 was used as the terminal alkyne and the reaction was 
carried out using a similar preparation method described by Glaser and Arstad (Figure 3.15).9 This 
method was chosen as it used the same azide starting material which unlike many of these types of 
CuAAC reactions, had the presence of DMF.  
 
Figure 3.15: Proposed reaction scheme to synthesise compound 10 
Copper(I) iodide was used as the catalyst and the reaction mixture was stirred at room temperature 
for 2 hours. Due to the small amounts of oil-like product produced, characterisation was carried out 
without purification. Analysis of the 31P{1H} NMR spectrum showed a singlet peak at δ 29.48 ppm 
showing a shift from the starting material (δ 21.81 ppm) and also two small peaks at δ 15.37 and 
10.95 ppm. The 1H NMR spectrum on the other hand showed no clear peaks. There were very small 
peaks present where the protons on the fluoroethyl group would be expected but these were being 
masked by larger peaks. The main peak of interest would be the peak belonging to the CH in the 
triazole ring; this was predicted to be a singlet around δ 8 ppm. Unfortunately, due to the large 
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amount of aromatic signals present, this area was heavily congested and so it was difficult to 
conclude if the peak was present. MS of the compound was also inconclusive, showing the major 
peak (M+) to have an m/z of 342 (and 579) when the expected value would be 390.41. 
The same reaction was carried out on a larger scale in the hope of having enough product to allow 
for purification. Unfortunately the reaction again resulted in very low yields of a brown coloured oily 
substance. Characterisation showed large amounts of DMF to be present which could be preventing 
the formation of a solid. An ethyl acetate and water extraction was attempted to remove the 
unwanted solvent but it was unclear whether the desired product was soluble in ethyl acetate. 
Heating under vacuum at 100oC was then attempted and the dried product was analysed but still did 
not confirm the formation of the triazole. 
Different conditions were therefore attempted to see if more decisive results could be achieved. 
Another method described by Glaser using the Cu(II) catalyst, copper sulfate and L-ascorbic acid (4 
equivalents) as the reducing agent in water was carried out.9 The reaction mixture was left to stir at 
room temperature for 16 hours. An aliquot of the reaction mixture was analysed by MS before 
attempted isolation to identify if the product was present (Figure 3.16). 
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Figure 3.16: Mass spectrum (ESI) of the crude reaction mixture for the CuAAC reaction between 4 and 9 
The peaks show no formation of 10 which was expected to give a peak at 390. The main peak at 279 
was predicted to belong to triphenylphosphine oxide (MW 278) and could also account for the 
31P{1H} NMR peak at around δ 29 ppm as phosphine oxides tend to fall in this region.  
Characterisation of the starting alkyne was repeated to check its stability. The alkyne was however, 
found to be stable with no presence of the phosphine oxide. It was concluded that the reaction was 
unsuccessful via both synthetic routes using CuI and CuSO4. 
This prompted a literature search to find out if there were different catalysts or conditions that may 
be more suitable to the precursors being used. Until recently little attention had been paid to 
cuprous salts due to their inherent thermodynamic instability and the formation of undesired 
alkyne-alkyne coupling products observed in their presence.14 It was found that ligands containing 
atoms such as nitrogen and phosphorus could however protect the Cu(I) centre during the 
cycloaddition reaction and even alter the reactivity of the copper salt.15,16 With this in mind, Diez-
Gonzalez et al investigated NHC (N-heterocyclic carbene) containing transition-metal complexes as 
catalysts for a large scope of reactions.17 They reported the high efficiency of [(NHC)CuCl] complexes 
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in the hydrosilylation of carbonyl compounds and the remarkable stability of these complexes 
towards heat, oxygen and moisture prompted them to investigate their use as catalysts for the 
Huisgen cycloaddition.18,14 
The group investigated a range of NHC copper complexes (Figure 3.17) and found promising results 
for a variety of terminal alkynes and azides.19  Reaction times varied from 20 minutes to 5 hours but 
all efficiencies were above 85%. 
 
Figure 3.17: NHC ligand library formed by Diez-Gonzalez et al
19
 
From these results of Diez-Gonzalez et al, different catalysts from the traditional CuI and CuSO4 were 
investigated. Two different catalysts were chosen to ascertain whether there was an effect on the 
reactions. These were [(IAd)CuI] and [(Ph3P)3CuBr].  
The first attempt was to carry out an in-situ reaction where the azide and then the triazole are 
formed in the same reaction vessel.14 With the azide having an explosive nature when isolated, it is 
beneficial to have a method that avoids this isolation. This also avoids the use of DMF which caused 
a problem in the previous studies, due to its difficult removal. 
In a reaction vial, triphenylpropargylphosphonium bromide (4), sodium azide and fluoroethyl 
tosylate (8) were added with the copper catalyst, either ([(IAd)CuI] or [(Ph3P)3CuBr]), and water. This 
was then left to stir at room temperature for 24 hours. The reaction mixture was analysed via MS 
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but unfortunately, for both reactions, there was no sign of the azide forming as the tosylate was left 
unreacted.  
As confirmation to ensure that a CuAAC reaction under these conditions can be successful a reaction 
from the literature was attempted.19  A well known click reaction between benzyl azide and phenyl 
acetylene was chosen (Figure 3.18). 
 
Figure 3.18: Synthesis of 1-benzyl, 4-phenyl triazole (11) from benzyl azide and phenyl acetylene 
The reaction was carried out in water at room temperature with the [(iAd)CuI] catalyst (2 mol %). 
After 4 hours the desired triazole (yellow coloured powder) had precipitated and was obtained in 
92% yield. This was confirmed by 1H NMR, MS and elemental analysis.  
With the success of this reaction, benzyl azide was reacted with the four alkyne TPP (compounds 4, 
5, 6 and 7) cations to prove that they would undergo CuAAC reactions (Figure 3.19) and to see if the 
problem could be the fluoroethyl azide (9) formation.  
 
Figure 3.19: Chemical structure of expected product formed from benzyl azide and alkyne phosphonium analogues 
The reactions were carried out in water at room temperature with 2 mol % loading of [(PPh3)3CuBr] 
in glass vials. Each reaction was monitored by 1H NMR spectroscopy and MS. After 24 hours starting 
alkyne material remained but small signs of the formation of the triazole were appearing. After 4 
days all the reactions, except the propyne analogue, appeared to be fully converted to the 
corresponding triazole which could be isolated in moderate/high yields.  
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Although these reactions were not directly related to this work and therefore an in-depth analysis 
was not performed, carrying out this set of reactions provided some useful observations. First, the 
phosphonium salts were able to undergo the CuAAC reaction but reaction rates were slower than 
anticipated and secondly, the phosphonium salts bearing the terminal propyne was unable to form 
the desired triazole. This this in mind, the synthesis of the other analogues was attempted. 
3.3.1 Catalytic Study to Determine the Most Suitable Catalyst 
The initial study was carried out on compound 5 in order to form [1-(2-fluoroethy),1H[1,2,3]triazole 
4-ethylene] triphenylphosphonium bromide (12) (Figure 3.20).  
 
Figure 3.20: Reaction scheme for the synthesis of [1-(2-fluoroethy),1H[1,2,3]triazole 4-ethylene] triphenylphosphonium 
bromide (12) 
To compare the efficiency of the four different catalysts, reactions were set up using the same 
catalyst loadings (2 mol %), starting azide and alkyne (CuSO4 also had 4 equivalents of L-ascorbic acid 
added). The reactions were sampled after 24 hours and then analysed by 31P{1H} NMR spectroscopy 
and MS.  
 
Catalyst [(iAd)CuI] [(PPh3)3CuBr] CuI 
CuSO4 L-ascorbic 
acid 
 
D
ay
 1
 
 31P NMR peak 23.58 23.58 23.38 (23.58) 23.42 
MS peak 315 (404-5%) 315 (404-4%) 404 404 
D
ay
 2
 
31P NMR peak 23.54 (23.46) 23.55 (23.46) 23.38  23.42 
MS peak 315 (404-5%) 315 (404-8%) 404 404 
D
ay
 3
 
31P NMR peak 23.58 (23.38) 23.57 (23.49) 
  MS peak 315 (404-20%) 315 (404-12%) 
  
D
ay
 4
 
31P NMR peak 23.56 (23.48) 23.58 (23.68) 
  MS peak 315 (404-29%) 315 (404-20%) 
  
D
ay
 7
 
31P NMR peak 10 peaks 23.58 (23.52) 
  MS peak 315 (404-37%) 315 (404-28%) 
  Table 3.1: 
31
P{1H} NMR spectra peaks and MS (ESI) results for the analysis of the formation of compound 12 with 
different catalysts. Molecular ion peak (m/z) for desired compound is 404 and starting material at 315 
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The main observation was that the reactions with CuI and CuSO4 were stopped after 2 days as the 
data suggested full conversion to give [1-(2-fluoroethy),1H[1,2,3]triazole 4-ethylene] 
triphenylphosphonium bromide. Unfortunately, the 31P{1H} NMR data revealed that the product 
peak lies very close to that of the starting material (~δ 23.38 ppm and ~ δ 23.58 ppm respectively) 
which makes it difficult to make any firm conclusions. The MS spectrum however showed only peaks 
at mass of 404 which is correct for the desired product.  
Looking at the reactions where [(iAd)CuI] or [(PPh3)3CuCl] was the catalyst, it can be seen that the 
reaction kinetics were slower and it took longer for the product to form. Even after a week the 
reactions did not appear to have gone to completion. Overall, this data suggests that the original 
catalysts (CuI and CuSO4.5H2O) are more efficient catalysts for this reaction.  
3.3.2 The Synthesis of Triazole Phosphonium Cations 
The initial reaction conditions attempted for the synthesis of the three triazole analogues (Figure 
3.21) was with the use of copper sulfate as the catalyst and L-ascorbic acid as the reducing agent. 
 
Figure 3.21: Structures of triazole compounds 12, 13 and 14 
After carrying out various different conditions and purification techniques, the following method 
became the most effective and reliable synthesis route. 
In one reaction vial, copper sulfate and L-ascorbic acid were dissolved in 0.2 ml of water giving a lime 
green solution. In another vial, the alkyne was dissolved in 0.5 ml of DMF and then this was 
transferred to the catalyst vial. The fluoroethyl azide was then added to the mixture (0.5 M in DMF) 
and the reaction sealed and left to stir at room temperature for 48 hours.  
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For isolation of the triazoles, the most effective method was to remove as much solvent on a rotary 
evaporator under vacuum before using a Kugelrohr to remove any of the remaining water and DMF. 
Once the reaction mixture was fully dry, methanol was added and any remaining solid removed via 
filtration through Celite. The methanol was then removed under vacuum and chloroform added. The 
precipitate was removed again along with solvent removed under vacuum. This isolated the triazoles 
(12-14) as dark brown oils (yields: 48-77%). The products were analysed by NMR spectroscopy (1H, 
31P{1H}, 19F, 13C{1H}), mass spectrometry (including accurate mass) and elemental analysis. The 1H 
NMR spectra for compound 12 is shown in Figure 3.22.  
 
Figure 3.22: 
1
H NMR (CDCl3) spectrum of compound 12 clearly showing the distinctive triazole proton peak at 8.62 ppm 
The spectrum clearly shows the addition of the fluoroethyl group with two set of doublets of triplets 
in the region around 4.5 ppm. Both the 2JHF and 
3JHF coupling constants were determined and found 
to be 46.8 and 25.6 Hz respectively whilst both giving the same 3JHH values. The other important peak 
was that seen for the lone proton on the triazole ring. This was found to be shifted downfield from 
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the aromatic region and gave a sharp singlet at 8.62 ppm. All other peaks were present with the 
correct integrals. The 31P{1H} and 19F NMR spectra, also confirmed a pure sample (Figure 3.23). 
 
 
Figure 3.23: 
31
P{
1
H} and 
19
F NMR spectra of compound 12 
In the 31P{1H} NMR spectrum a single peak was observed at 23.40 ppm which although only showed 
a small shift from the alkyne starting material, 5 (23.62 ppm), this was to be expected as the 
phosphorus centre has undergone very little change. The 19F NMR spectrum however, clearly 
showed a multiplet around -222 ppm, and the spitting is due to the coupling with the protons 
present on the ethyl chain. 
3.4 Fluorine-Functionalised Triphenylphosphines 
In the event that the triphenyl phosphonium cations containing the triazole are not lipophilic enough 
to pass through the lipid bilayer, different functional groups were investigated to try to increase the 
log P value (partition coefficient).  
The lipophilicity of the compounds is an important factor that should be considered when designing 
a tracer that has to enter cells and pass through a lipid membrane. This can be calculated using the 
‘shake flask method’ which measures the ratio of the compound in octanol and water. The 
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measurement is given as a log P value and it has been proposed that the partition coefficient of a 
proposed drug should be below log P = 5 and ideally between log P = 1 and log P = 3. This is 
considered to be an optimum value to enter the bilayer.20,21  
As fluorine atoms are known to increase the lipophilicity of aromatic compounds, the initial studies 
will look to incorporate F atoms in the phenyl rings (Figure 3.24).22 Fluorine atoms also offer strong 
bonds to carbon atoms which should help to protect the compound against metabolic pathways in 
the body.23 
 
Figure 3.24: General structure of triazole phosphonium species, with functionalised phenyl rings, where R is a fluorine 
derivative 
First, the functionalised phosphine compounds had to be synthesised before the preparation of the 
phosphonium salts. 
 
Figure 3.25: Structures of compound 15, 16 and 17 
Three different phosphorus compounds (Figure 3.25) were synthesised with varying amounts of 
fluorine atoms attached. They were prepared by the initial formation of the corresponding Grignard 
reagent. This was made by reacting magnesium turnings in either dry diethyl ether or THF with the 
different bromo-fluoro phenyl compounds, whilst maintaining constant reflux conditions. After 
leaving the Grignard to stir at room temperature for one hour, phosphorus trichloride in dry diethyl 
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ether or THF was added dropwise and then left to stir for a further two hours. The reaction mixture 
was  hydrolyzed with dilute hydrochloric acid or water and the crude material isolated. Purification 
using different methods, such as recrystalisation or sublimation was then carried out. 
The synthesis of 15 was carried out in dry diethyl ether, followed by hydrolysis with dilute HCl and 
then the ether removed under vacuum and the crude product filtered off. The purification was 
carried out via sublimation at 110oC and 300 Pa to yield white crystals in a moderate yield. 31P{1H},19F 
NMR spectroscopy (see Figure 2.26) and elemental analysis confirmed a pure product and MS 
showed the correct molecular ion peak. The 31P{1H} NMR spectrum showed a multiplet coupling 
pattern due to the interactions between the phosphorus atom and the inequivalent fluorine atoms. 
 
Figure 3.26: 
31
P{
1
H} NMR and 
19
F NMR spectrum of 15 
16 was synthesised in dry THF, hydrolysed with water, and then the organic layer removed and the 
aqueous layer washed with diethyl ether. The organic layers were combined and the solvent 
removed under vacuum to give the crude product as a yellow oil. This was then purified via 
recrystallisation in hot ethanol to yield colourless crystals. All NMR spectra and MS confirm a pure 
product. Finally, 17 was prepared using the same method as 15 but in dry diethyl ether to give pure 
colourless crystals without further purification. 
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3.5 Alkyne Synthesis with Fluorine-Functionalised Phosphines 
The next step was to react the three phosphines with a bromo-alkyne to form the phosphonium 
salts.  
 
Figure 3.27: Structures of fluorine-functionalised phosphonium alkynes, 18, 19 and 20 
The formation of the compounds shown in Figure 3.27 was attempted using the same method as 
described by Dharanipragada et al. whereby triphenyl phosphine was mixed with 1-bromo-3-butyne 
in toluene and heated to reflux for 24 hours.12 In all three cases, after 24 hours, 31P{1H} NMR showed 
mainly starting material was present with a small (<2%) peak for the desired product. The reactions 
were repeated with extended reaction times (3 days) but still no improvement was seen in the 
product yields.  
The reason behind the very poor yields was believed to be due to the effect the fluorine atoms have 
on the lone pair of the phosphorus atom. The electron withdrawing ability of the fluorine atoms 
could reduce the ability of the phosphorus centre to act as a nucleophile.24 
In the late 1970’s, Tolman looked into the electronic parameter of the phosphorus lone pair on 
phosphines. He found that the empty d orbitals on the phosphines can act as π-acceptor orbitals and 
that this becomes important when the R-groups are electron-withdrawing.25 Tolman devised a 
method whereby the electron-donating ability of a phosphine ligand could be determined by 
measuring the carbonyl VCO IR stretch of a nickel phosphine complex (Figure 3.28).
24 
 
Figure 3.28: The structure of Ni(CO)3(phosphine) 
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The complex can be made by simply adding one equivalent of the phosphine to Ni(CO)3 in 
chloroform and taking an IR spectrum. The A1 carbonyl mode was chosen as it gives a sharp high 
energy mode. The frequency of the stretch is found to be dependent on the amount of electron 
density of the phosphine ligand that is donated to the metal centre. The higher the νCO value the 
lower the donating ability of the phosphine (best π-acceptor). 
Tolman carried out these measurements on a large series of different phosphines including two of 
the above fluorine-functionalised phosphines (15 and 16). Unfortunately no value can be found for 
compound 17 and due to the toxicity of nickel carbonyls, measurements can no longer be carried 
out. By comparing the values of the two phosphines with triphenyl phosphine it gave some 
indication as to why the simple nucleophilic reaction was unsuccessful (Table 3.2). 
Phosphine ν, cm-1 
PPh3 2068.9 
P(p-F-C6H4)3 2071.3 
P(C6F5)3 2090.9 
 
Table 3.2: Tolman’s electronic parameter values taken from reference 21  
The increase in νCO means that the donating ability of the phosphine is lower compared to that of 
PPh3 and thus may not be strong enough to act as a nucleophile and attack bromo alkyne to yield a 
salt under the reaction conditions used. One method that was tried to overcome this was to change 
the bromide to a better leaving group. The equivalent alcohol was converted into a tosylate using a 
method described by Erixon et al (Figure 3.29.26  
 
Figure 3.29: Reaction scheme for the synthesis of but-3-ynyl toluene-4-sulfonate, 21 
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Reactions with 15, 16 and 17 were then carried out using the same method as before (heating to 
reflux in toluene) but again results were found to be very similar as only starting materials were 
recovered.  
3.6 Alternative Functionalised Triphenylphosphines 
The findings above resulted in a change of direction for the functionalised triphenyl phosphines 
work. Electron donating R groups on the phenyl rings were needed in order to allow the formation 
of phosphonium salts via nucleophilic addition. To help with deciding on the new series, the 
Tolman’s electronic parameters were considered. If the VCO is smaller than that of triphenyl 
phosphine then the donating ability of the phosphorus atom should be appropriate to carry out the 
reaction.  
 
Figure 3.30: The structures of methylated phenyl analogues 
The first three phosphines shown in Figure 3.30 were purchased from Sigma Aldrich but compounds 
22 and 23 were synthesised. Although both these compounds have been reported in the literature, 
no full analysis could be found on either.27,28,29 They were also synthesised using a different method. 
Tris(4-tert-butylphenyl) phosphine (22) and tris(3,5-dimethylphenyl) phosphine (23) were prepared 
using a similar method to that used for the fluorine-functionalised phosphines. Firstly, a Grignard 
was formed from the reaction of the corresponding functionalised 1-bromo-benzene analogue and 
magnesium turnings followed by the addition of PCl3. Both products were obtained in moderate 
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yields and confirmed via NMR spectroscopy (1H, 31P{1H}, 13C{1H}), MS and EA. These compounds will 
be used later to synthesise the alkyne phosphonium salts (section 3.7).  
3.6.1 Selenium-Phosphorus Complexes 
As mentioned above, the functional groups on the phenyl rings can have an effect on the donating 
power of the phosphorus lone pair. Another method that can be used to investigate this is to 
determine the coupling constant between selenium and phosphorus (1J(77Se-31P)) via 31P{1H} NMR 
spectroscopy. It is well known that tertiary phosphines can react readily with selenium to form 
phosphine selenides.30 Previous research has shown that the magnitude of the coupling constant 
between the phosphorus and selenium atoms is very much dependent on the substituents bound to 
the phosphorus. It is believed that the effect is due to the degree of occupation of the lone pair of 
the phosphorus 3s orbital as there is found to be little P3dπ–Se4dπ character.
31 This means that when 
an electron withdrawing group is attached to the phosphorus centre, there is an increase in s 
character of the lone pair resulting in an increase in the coupling constant. Electron donating groups 
on the other hand should show a decrease in s character leading to smaller JPSe values.
32  
To form the phosphine selenides, each phosphine was dissolved in chloroform and then selenium 
powder added. The mixture was then stirred at room temperature for 48 hours, then a small sample 
was taken from each and an 31P{1H} NMR spectrum taken. The results are shown in Table 3.3. 
Compound 1JP-Se (Hz) 
Ph3P 728.08 
(MePh)3P 718.8 
(3,5MePh)3P 713.76 
(tBuPh)3P 710.53 
(OMePh)3P 711.11 
(2,4,6Me3Ph)3 Oxide 
(F-Ph)3P 744.7 
(penta-FPh)3P SM 
(CF3Ph)3P 765.82 
 
Table 3.3: Coupling constants (Hz) of the P-Se bond in different phosphines 
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It can be seen that the majority of the complexes were formed, though for tris-
(pentafluorophenyl)phosphine and the tris-(2,4,6-trimentylphenyl)phosphine this did not seem 
possible.  It was found that the latter preferentially formed the phosphine oxide. This could be due 
to the increased sterics around the phosphorus atom which results in a widening of the intervalence 
angle. Selenium, compared to oxygen, may be too large to bind to the phosphorus. The tris-
(pentafluorophenyl)phosphine reaction did not appear to form any other product after 48 hours and 
so was heated at reflux temperatures for 2 hours to see if this could encourage the complexation, 
but no reaction was apparent. 
Analysing the table, it can be concluded that introducing fluorine atoms onto the phenyl groups does 
increase the coupling constant. This is due to the electron withdrawing nature of highly 
electronegative fluorine atoms, which following Bent’s Law, increases the s character of the lone 
pair.30 The successful methylated phosphines exhibit a smaller coupling constant compared to 
triphenylphosphine. This is an encouraging result when considering the next stage in the synthesis 
i.e. formation of the alkyne phosphonium salts. 
3.7 Alkyne Synthesis with Alternative Functionalised Phosphines 
The next step was to synthesise the phosphonium salts bearing a terminal alkyne (Figure 3.31).  
 
Figure 3.31: Structures of compounds 24-28 
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The synthesis involved reacting the phosphine with 1-bromo-3-butyne in dry toluene under reflux 
for 24 hours. For compounds 24 and 25, an oily layer was present after 24 hours in the reaction vial. 
The solvent was removed via pipette and the oil washed with dry toluene and then extracted with 
ethyl acetate. The solvent was removed under vacuum to yield white crystalline solids in both cases. 
Upon exposing the products to air the crystals became oily suggesting that the compounds were 
hydroscopic. Analysis after exposure via NMR spectroscopy did not show any degradation and so the 
stable compounds were stored under vacuum. Both 24 and 25 were obtained in high yields (64% and 
94% respectively) and confirmed by 1H, 31P{1H} and 13C{1H} NMR spectroscopy and MS ((ES+) m/z: 357 
(M+) and 405 (M+) respectively). The elemental analysis result for 25 was found to be slightly lower 
than expected but this was thought to be due to water present in the sample. 
The synthesis of compound 26 resulted in insufficient amounts of product being obtained. The 
reaction for the formation of 26 was analysed by aliquots after 3 days as no oil layer or solid had 
formed. The 31P{1H} NMR spectrum of this showed only starting material and so the reaction was left 
to stir under reflux conditions for a further 7 days. At the end of this time there was still no sign of 
the desired product. A possible reason for this is the increased sterics around the phosphorus 
centre, which is supported by the result seen for the selenium complexation. 
For compound 27, no precipitate had formed after 24 hours so an aliquot was taken and the 31P{1H} 
NMR spectrum did reveal some product formation. To the mixture, more 1-bromo-3-butyne was 
added to investigate whether more of the starting phosphine could be reacted. The reason behind 
the lack of full conversion could be due to the volatile nature of the bromo-alkyne. With this in mind 
the reaction vessel was sealed under nitrogen to prevent any loss of reagent. Another issue that 
arose when analysing the crude mixture, was the presence of the phosphine oxide. In order to purify 
27, it was recrystallised in benzene to give a white solid in moderate yields and full characterisation 
of this compound was carried out. Finally the synthesis of 28 was carried out and as with 27, no 
precipitate had formed. The toluene was removed under vacuum and then the solid washed with 
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diethyl ether and hexane to give the product as a white solid. Again, full analysis confirmed the 
compound had been formed and required no further purification.  
3.8 Triazole Synthesis with Alternative Functionalised Phosphonium salts 
Now that a library of various functionalised phosphonium salts bearing a terminal alkyne had been 
prepared, the next step was to synthesise the reference triazole compounds. 
 
Figure 3.32: Reaction scheme for the CuAAC reaction to form functionalised phosphonium salts bearing a fluorine 
labelled triazole moiety  
This involved a CuAAC reaction where the reaction conditions were investigated, optimised and 
discussed previously in section 3.3.2 (Figure 3.32). The four compounds shown below in Figure 3.33 
were all successfully synthesised. 
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Figure 3.33: Structures of compounds 29-32 
Again, full characterisation of each compound was carried out. The 1H NMR spectra now had the 
distinctive triazole proton peak at >8 ppm and the fluoroethyl protons giving rise to the two doublet 
of triplets at between 4.5-5 ppm. As already mentioned, the 31P{1H} NMR peak showed very little 
shift from the previous phosphonium precursor and so this was not the best indicator to determine 
the success of the reaction. The 19F NMR spectra for all four compounds did now however, show a 
multiplet at around -222 ppm indicating the presence of the fluorine label. The 13C{1H} NMR 
spectrum showed the loss of the carbon triple bond peaks and the triazole carbons further 
downfield at around 125 ppm. For all four compounds however, the experimental element analysis 
contributions for carbon, hydrogen and nitrogen were all lower than the calculated results. This 
suggested that there were impurities present in the samples but given the other analysis data, this 
was more likely to be small amounts of solvent in the samples (water and DMF). In order to fully 
back up the successful synthesis of 29-32, accurate mass spectrometry was performed on all 
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samples. In all cases the 100% peak belonged to the [M+] form of the compound and the mass was 
confirmed to 4 decimal places. 
3.9 Introduction to a More Flexible Tracer  
In recent years, the idea of multi-modal imaging has become a well discussed topic in the literature. 
Combining two or more different imaging techniques into one tracer can result in it having many 
positive features. What characteristic that cannot be offered from one technique can be 
implemented by introducing another modality that can.33 It is known for example, that PET offers 
very high sensitivity but lacks special resolution. If a PET tracer could be combined with another 
modality that could offer good special resolution, the localisation of the tracer could be determined 
more accurately.  
With this in mind, the idea was to modify the original main design by targeting the triphenyl 
phosphine core and therefore leaving the radiolabelling method unchanged. By removing one of the 
phenyl rings from the phosphorus centre and replacing it with a different function group, a new 
characteristic could be introduced to the tracer. The choice of group could vary from a different 
imaging modality, e.g. a fluorophore, to a chemical group to alter the lipophilicity or even a 
targeting/uptake enhancement moiety. The proposed design is shown in Figure 3.34. 
 
Figure 3.34: Replacement of a phenyl ring on the phosphorus atom could provide a functional arm to incorporate a 
different modality or functional group 
In order to synthesise this new design of phosphonium cation, the first steps involved the production 
of a functionalised phosphine. It was decided that the phosphine would be functionalised with a 
terminal alkyne in order to allow easier synthesis of a library of compounds. This would then be 
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followed by the addition of the new functional group and finally the CuAAC reaction to form the 
labelled/unlabelled triazole moiety. The proposed steps are shown in Figure 3.35. 
 
Figure 3.35: Proposed general reaction scheme to synthesise a diphenyl analogue 
The first step was to synthesise an alkynyl-diphenylphosphine. Following a literature search, a 
research group had previously made the butyne and pentyne versions.34,35 Simone et al used a 
method whereby they created the lithium diphenylphosphine by reacting triphenylphosphine and 
lithium metal in THF in an ultrasonic bath for 24 hours. Instead of carrying out this step, it was found 
that LiPPh2 could be purchased from Sigma Aldrich in a THF solution. Thus, LiPPh2 was reacted 
directly with 1-chloro-4-pentyne to synthesise pent-4-ynediphenylphosphine (Figure 2.36).  
 
Figure 2.36: Structure of pent-4-ynediphenylphosphine 
The solution of LiPPh2 was added dropwise to 1-chloro-5-pentyne at 0 
oC over 20 minutes before 
being left to stir at room temperature for 17 hours. The solvent was then removed to give a white 
oily solid which was taken up in dry toluene (25 ml) and washed with water (3 x 10 ml). The organic 
layer was dried over magnesium sulfate before being filtered and the solvent removed to give a pale 
yellow oil. The product was analysed via NMR spectroscopy and analysis of the 31P{1H} spectrum 
showed a singlet around -16 ppm which was similar to that noted in literature.35 The 1H NMR 
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spectrum showed some impurities and solvent peaks present which hindered full peak assignment. 
Due to this compound being readily oxidised, purification via column chromatography had to be 
avoided. Instead the compound was used directly in the next stage of the synthesis due to the 
production of the stable salt allowing easier isolation and purification. 
As an effort to show that the phosphine could be used to react with a corresponding R group, a 
simple small molecule was chosen. Benzylbromide was reacted with the phosphine in toluene to 
give (4-pentyne)diphenyl(benzyl)phosphonium bromide, using similar conditions to previous 
phosphonium salt formation in this chapter.  
Following being heated to reflux in dry toluene, a white precipitate formed and this was removed by 
filtration. The product was analysed via the common techniques which lead to some confusing data. 
The 31P{1H} NMR spectrum did show the expected shift in signal from -16 ppm to around 27 ppm and 
initially the 1H NMR spectrum appeared to be as expected.  
 
Figure 3.37: 
1
H NMR (DMSO-d6) spectrum of expected (4-pentyne)diphenyl(benzyl) phosphonium bromide sample 
By interpreting the spectrum shown in Figure 3.37 it can be seen that there were 2 peaks with a total 
integration of 6 hydrogen atoms present due to the three CH2 units on the alkyne chain and then a 
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doublet further downfield from the CH2 attached to the phenyl ring. A triplet with an integration of 1 
was noted at around 4.5 ppm which was originally assumed to be due to the terminal alkyne proton 
but given the shift of this signal which would have been expected to be around 3 ppm, further 
analysis was required. This was also needed as the large water solvent peak could have been 
obstructing other peaks. Alternatively the sample was re-run in D2O to see if there were any hidden 
signals. 
 
Figure 3.38: 
1
H NMR (D2O) spectrum of expected (4-pentyne)diphenyl(benzyl) phosphonium bromide sample 
Figure 38 shows the 1H spectra now run in a D2O solution. The 6 alkyl protons and the 2 next to the 
phenyl ring were still present but instead of the triplet being present around 4.5 ppm there was now 
one seen at 3.42 ppm but with double the proton integration. The MS analysis also gave the main 
molecular ion to have an m/z of 6 greater than the desired compound (m/z of 349 instead of 343). 
Initially it was thought that a lithium atom was replacing the terminal alkyne proton but given the 
instability of a Li-CΞC bond this was soon ruled out. After carrying out further analysis using 13C{1H} 
NMR spectroscopy there was still no firm conclusion as to whether the desired product had formed. 
The 13C{1H} NMR spectrum showed a peak at around 65 ppm which was in the correct region for 
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terminal alkyne carbons but unfortunately there was no peak for the other alkyne carbon (expected 
around 85 ppm).  
In an attempt to gather conclusive data, a crystal structure of the sample was obtained (Figure 3.39). 
 
Figure 3.39: The crystal structure of (butan-4-ol)diphenyl(benzyl) phosphonium bromide 
The crystal structure revealed that the desired compound had not been formed and that instead of 
the alkyne chain there was an alcohol group. It was thought that the lithium diphenyl phosphine had 
reacted with the THF in the bottle from Sigma which caused the THF to ring open and become 
attached to the phosphorus centre. The (butan-4-ol)diphenylphosphine had then reacted with the 
benzyl bromide to yield (butan-4-ol)diphenyl(benzyl)phosphonium bromide (33). 
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Figure 3.40: Proposed reaction scheme to give 33 
This finding explained the results seen in the different analytical methods carried out. The 1H NMR 
data in D2O gave the correct spectrum for this compound and explains the triplet seen with the 
integration of 2. The 1H NMR spectrum in DMSO-d6 suggested that the final CH2 peak was being 
masked by the water solvent peak and that the triplet (1 proton) seen downfield belonged to the OH 
group. The OH was not observed in the D2O spectra due to the rapid exchange of protons.  The 
alcohol group, also accounts for the peak at around 65 ppm in the carbon NMR and the 6 m/z 
difference in the mass spectrometry analysis (there now being one less carbon in the chain and the 
alcohol group now replacing the alkyne moiety).  
Although the discovered compound was not usable at the time of this research as the focus was on 
using an alkyne in the CuAAC, it could be a useful route to synthesising similar compounds using 
direct labelling of the alcohol. Alternatively, the alcohol could be converted into a tosylate leaving 
group and also labelled directly with [18F]fluoride. 
 Now that the synthesis using Sigma Aldrich purchased lithium diphenylphosphine was not a viable 
route, other methods were investigated. Instead, lithium metal was reacted directly with 
triphenylphosphine in THF using vigorous stirring. As the reaction progressed, the solution became 
red and continued to darken in colour. An excess of lithium ensured all triphenylphosphine had 
reacted and aliquots were analysed by 31P{1H} NMR spectroscopy to confirm completion. The 
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solution was then cannulated to remove any unreacted lithium and then to this t-butylchloride was 
added. The t-butylchloride is believed to react selectively with any phenyllithium produced and 
eliminate it as it is expected to be a stronger base than lithium diphenylphosphine.36 The mixture 
was then added dropwise over a period of 20 minutes to 1-chloro-4-pentyne at 0oC and then left to 
stir at room temperature for 17 hours.  
 
Figure 3.41: Structure of 34 
Once isolated, the pale yellow oil was analysed. This time the 1H NMR spectrum had the correct 
peaks indicating that the alkyne was now attached. 
 
Figure 3.42: [
1
H] NMR spectra of 34  
The triplet was now seen with the correct shift and integration. Both the MS and 31P{1H} NMR 
spectrum were also as expected. The same synthesis was then carried out to form the shorter chain 
alkyne. 1-Bromo-3-butyne was used instead and (3-butyne)diphenylphosphine (35) was isolated and 
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characterised. This phosphine was then reacted with both benzyl bromide and 4-fluorobenzyl 
bromide to prove the formation of the phosphonium salt (Figure 3.43). 
 
Figure 3.43: Reaction scheme to synthesise 36 and 37 
Reactions were carried out in dry toluene at refluxing temperatures for 24 hours. Once cooled the 
white precipitate was removed via filtration and NMR spectroscopy and mass spectrometry 
confirmed that the two desired products had been synthesised.  
Now that this method of synthesising a diphenyl phosphonium cation had been proven successful, 
the next step was to attempt to attach a more complicated functional group. As mentioned at the 
beginning of this chapter, having a multi-modal imaging probe can be very beneficial. One of the 
techniques that would aid analyses in in vitro testing would be to combine PET with a fluorescent 
target. This would help determine the location of the tracer and in particular, prove the 
accumulation in active mitochondria. 
As rhodamine-based fluorescent probes are commonly used to image the mitochondria, this was the 
first dye that was investigated.37 Although rhodamine-123 is more commonly used in cellular assays, 
due to the difference in purchasing cost, rhodamine-B (RH-B) was chosen to be modified instead.38 
Another reason for this choice was that the ethyl groups attached to the amines on the xanthene 
ring system prevent the need to protect them from possible side reactions.39  
To connect the rhodamine moiety to the phosphorus centre, the carboxylic arms on the RH-B 
needed to be modified. A synthesis to replace this with a bromoethyl amino group was reported by 
Borbas and Bruce and should introduce a suitable leaving group to form the phosphonium salt.40  
Chapter 3 
 
79 
 
 
Figure 3.44: Reaction scheme to synthesise 38 
The synthesis of 38 was carried out in accordance to the literature preparation and the pink solid 
was achieved in similar yields (Figure 3.44). 1H and 13C NMR spectroscopy corresponded with that in 
literature and confirmed the formation of the product.40 
The next step was to react the modified RH-B with compound 35 using the similar conditions used to 
synthesise 36 and 37 (Figure 3.45).  
 
Figure 3.45: Reaction scheme to synthesise alkyne diphenylphsophonium cation functionalised with RH-B 
The two starting compounds were dissolved in toluene and heated to reflux. Unfortunately after 
taking aliquots and analysing by 31P{1H} NMR spectroscopy there was no indication of the formation 
of the phosphonium salt. Due to the lack of time left for this research, no further attempts were 
made. This work has however, proven that a diphenyl version with a varying R group can be 
prepared. The preparation of the phosphine with a terminal alkyne allows for the simple addition of 
various small molecules providing a fast route to a library of compounds and after some 
optimisation, should hopefully allow for the introduction of a different imaging modality moiety.  
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3.10 Summary 
The successful synthesis of seven new reference triazole containing phosphonium cations has been 
carried out. The initial design contained a triphenylphosphonium core and focused on varying the 
carbon chain length between the phosphorus centre and the triazole ring. Both the alkyne precursor 
(5-7) and the reference compound (12-14) for three different chain lengths were prepared. For 
making the reference compound, the most suitable copper catalyst was researched and an 
appropriate purification method found. 
The chapter then focused on functionalising the phenyl rings to vary to lipophilicity of the 
compounds. Initially, fluorine atoms were introduced but failure to successfully synthesise the 
alkyne phosphonium cation meant that the focus was turned to methyl-functionalisation. Four 
different phosphines were used (22-23 prepared) to synthesise the alkyne phosphonium salts (24-
28) before going on to form the reference tracer compound (29-32).  
The chapter concludes by introducing the idea to prepare a more flexible tracer which could see the 
addition of a different imaging modality. The removal of one of the phenyl rings attached to the 
phosphorus centre was investigated and the successful synthesis of an alkyne-diphenylphosphine 
meant that another functional group could be added to make the phosphonium cation. Initially this 
was tested with both benzyl bromide and 4-fluorobenzyl bromide which proved that the route of 
synthesis was a viable method. Next, the idea was to attach a fluorophore to allow for optical 
imaging as well as PET and rhodamine-B was chosen. RH-B was modified with a bromo-alkyl group to 
give the point of attack required for the reaction with the phosphine. Unfortunately, initial attempts 
to form the rhodamine-phosphonium cation were unsuccessful and therefore require further 
investigation.   
3.11 Experimental  
All starting materials were of reagent grade and were purchased from Sigma Aldrich. These were 
used without any further purification. All NMR spectra (1H, 31P{1H}, 19F, 13C{1H}) were recorded on a 
Chapter 3 
 
81 
 
Bruker AV 400 MHz spectrometer. Elemental analyses were performed by Stephen Boyer at the 
Science Centre, London Metropolitan University. ES mass spectra were recorded on a Mircromass 
LCT Premier Spectrometer by either John Barton or Lisa Haigh. Crystal structure obtained by Andrew 
White. 
Where literature methods were followed, references have been given. Where any modifications of 
the method were carried out, these have been detailed. 
3.11.1 Synthesis of FBnTP and Analogues 
4-Fluorobenzyl triphenyl phosphonium bromide 16 
Yield 4.90 g, 53%. 1H NMR (400 MHz, DMSO), δ, ppm, 5.25 (d, 2JHP = 15.5 Hz, 2H, PCH2), 7.03 (m, 2H, 
PhF), 7.12 (m, 2H, PhF) 7.65-7.79 (12H, PPh3), 7.92 (m, 3H, PPh3). 
31P{1H} NMR (162 MHz, DMSO), δ, 
ppm, 23.13. 19F NMR (377 MHz, DMSO), δ, ppm, -113.19. 13C{1H} NMR (101 MHz, DMSO), δ, ppm, 
27.8 (d, 1JPC = 46.5 Hz, PCH2), 116.2 (d, 
2JFC  = 23.2 Hz, o-PhF), 118.1 (d, 
1JPC = 85.9 Hz, Ph P-C), 124.6 (d, 
2JFC = 8.3 Hz, o-PhF), 130.6 (d, 
3JPC = 13.4 Hz, m-PhP), 133.3 (t, 
4JFC = 6.9 Hz, p-PhF), 134.5 (d, 
3JPC = 9.9 
Hz, m-PhP), 135.6 (d, 4JPC = 3.1 Hz, p-PhP), 163.4 (d, 
1JFC = -245.4 Hz, Ph F-C). MS (ES
+) m/z: 371 (M+). 
Elemental analysis (calc %): C (66.50), H (4.61), (actual %):  C (66.36), H (4.90) 
4-Fluorophenyl triphenyl phosphonium iodide 27  
Compound purified by dissolving the crude product in methanol and removing any impurities via 
filtration before removing the methanol under vacuum. Yield 1.54 g, 72%. 1H NMR (400MHz, DMSO), 
δ, ppm, 7.76-7.99 (Ar). 31P{1H} NMR (DMSO), δ, ppm, 21.73. 19F NMR (377 MHz, DMSO), δ, ppm, -
101.83. 13C{1H} NMR (101 MHz, CDCl3), δ, ppm, 117.3 (d, 
1JPC = 89.9 Hz, Ph P-C), 118.9 (dd, 
2JFC = 23.3 
Hz, 3JPC = 14.3 Hz, o-PhF), 130.9 (m, m-PhF), 131.0 (d, 
3JPC = 15.2 Hz, m-PhP ), 134.1 (m, FPh P-C), 
134.5 (d, 3JPC = 10.6 Hz, o-PhP), 135.9 (d, 
4JPC = 3.2 Hz, p-PhP ), 137.7 (m, FPh F-C). MS (ES
+) m/z: 357 
(M+). Elemental analysis (calc %): C (59.50), H (3.96), (actual %):  C (59.26), H (3.73) 
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4-Fluorophenethyl triphenyl phosphonium bromide 3 
A solution of triphenylphosphine (3.62 g, 10 mmol) and 4-fluorophenethyl bromide (1.34 ml, 10 
mmol) was refluxed overnight in toluene (25 ml) and allowed to cool to room temperature. The next 
day the solvent was removed to leave a yellow oily/ glue-like substrate. 31P NMR revealed that 
triphenyl phosphine was still present and so the crude product was recrystallised in acetonitrile to 
remove any starting material. A yellow sticky solid still remained. Further recrystallisation in ethanol 
took place to yield a cream solid (yield 3.10g, 45%). 1H NMR (400 MHz, CDCl3), δ, ppm, 2.90 (m, 2H), 
4.20 (ddd, 2H, 4JHH = 5.8 Hz, 
3JHH = 7.1 Hz, 
3JPH = 11.8 Hz ), 7.68-7.76 (4H, Ph-F),  7.79-7.94 (15H, PPh3). 
31P{1H} NMR (162 MHz, DMSO), δ, ppm, 23.43. 19F NMR (377 MHz, DMSO), δ, ppm, -116.07. 13C{1H} 
NMR (101 MHz, DMSO), δ, ppm, 23.2 (d, 1JPC = 48.5 Hz, PCH2), 27.2 (s, CH2Ph), 115.7 (d, 
2JFC = 21.2 Hz, 
o-PhF), 118.8 (d, 1JPC = 85.9 Hz, Ph P-C), 129.2 (d, 
3JFC = 13.2 Hz, m-PhF), 130.8 (d, 
3JPC = 13.1 Hz, m-
PhP ), 133.5 (s, p-PhF ), 134.2 (d, 2JPC = 10.1 Hz, o-PhP), 135.5 (s, p-PhP), 161.6 (d, 
1JFC = -243.4, Ph F-
C). (ES+) m/z: 385 (M+). Elemental analysis (calc %): C (66.53), H (4.69), (actual %):  C (66.60), H (4.72) 
3.11.2 Synthesis of Alkyne Phosphonium Salts 
Triphenylpropargylphosphonium bromide 410 
 Yield 4.51 g, 83%. 1H NMR (400 MHz, DMSO), δ, ppm, 3.46 (d,t, 4JHP = 6.6 Hz, 
4JHH = 3.6 Hz, 1Н, CΞCН), 
5.26 (dd, 2JHP = 16.7 Hz, 
4JHH = 3.6 Hz , 2Н, РСН2), 7.6–7.9 (15Н, PPh3) .
31Р{1H}  NMR (162 MHz , DMSO), 
δ, ppm: 21.81. 13C{1H} NMR (101 MHz, CDCl3), δ, ppm, 15.2 (d, 
1JPC = 55.4 Hz, PCH2), 73.1 (d, 
3JPC = 
13.9 Hz, ΞCH), 78.9 (d, 2JPC = 9.5 Hz, CΞCH), 118.0 (d, 
1JPC = 87.4 Hz, Ph P-C), 130.7 (d, 
3JPC = 13.6 Hz, 
m-Ph), 134.2 (d, 2JPC = 10.1 Hz, o-Ph), 135.9 (d, 
4JPC = 3.0 Hz, p-Ph).MS (ES
+) m/z: 301 (M+). Elemental 
analysis (calc %): C (66.25), H (4.75), (actual %):  C (66.14), H (4.76) 
But-3-ynyltriphenylphosphonium bromide 512  
1 -Bromo but-3-yne (3.46 g, 18.5 mmol) and triphenylphosphine (7.35 g, 27.5 mmol) were dissolved 
in dry toluene (25 ml). The mixture was heated to reflux for 24 h when two layers were formed. 
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After being left to cool to room temperature the bottom layer became solid.  This was filtered off 
and washed with toluene (25 ml) to remove any unchanged starting material and then dried under 
vacuum. A yellow solid was obtained (yield 3.95 g, 54%). The product was recrystallised in 
acetonitrile. m.p. 153-156 °C. 1H NMR (400 MHz , DMSO), δ, 2.58 (m, 2H, PCH2), 3.01 (t, 
4JHH = 3.6 Hz, 
1H, CΞCH), 3.92 (m, 2H, CH2) and 7.76-7.94 (15H, PPh3). 
31P{1H} NMR (162 MHz , DMSO), δ, ppm: 
23.63. 13C{1H} NMR (101 MHz, CDCl3), δ, ppm, 14.0 (s, CH2), 23.5 (d, 
1JPC = 53.5 Hz, PCH2), 73.5 (s, 
ΞCH), 80.4 (s, CΞCH), 117.9 (d, 1JPC = 86.9 Hz, PhP-C), 130.4 (d, 
3JPC = 13.8 Hz, m-Ph), 134.0 (d, 
2JPC = 
10.2 Hz, o-Ph), 135.1 (d, 4JPC = 3.2 Hz, p-Ph). MS (ES
+) m/z: 315.13 (M+). Elemental analysis (calc %): C 
(66.83), H (5.15), (actual %): C (66.83), H (5.10) 
1-Iodo-4-pentyne41 
1-Chloro-4-pentyne (2 ml, 20 mmol, 1eq) and sodium iodide (9 g, 3eq) were dissolved in acetone (25 
ml) and heated to reflux for 24 hours. The reaction was left to cool to room temperature and the 
white solid filtered off and washed with ether. The filtrate was then placed under vacuum to remove 
the solvent. 5-Iodopentyne was obtained as a brown oil. 1H NMR (400 MHz, CDCl3), δ, 3.00 (m, 2H 
CH2), 3.38-3.42 (3H, CH2/ ΞCH), 3.72 (t, 2H, 
3JHH =  6.7 Hz, CH2)                     
1-Iodo-5-hexyne41 
1-Chloro-5-hexyne (2 ml, 20 mmols, 1eq) and sodium iodide (7.7 g, 3eq) were dissolved in acetone 
(25 ml) and heated to reflux for 24 hours. The reaction was left to cool to room temperature and the 
white solid filtered off and washed with ether. The filtrate was then placed under vacuum to remove 
the solvent. 6-Iodohexyne was obtained as a brown oil. 1H NMR (400 MHz, CDCl3), δ, 1.64-1.72 (2H, 
ICH2), 1.88-1.95 (2H, CH2), 3.23-3.30 (2H, CH2), 3.36 (t, 1H, 
4JHH =  3.6 Hz, ΞCH), 3.66 (t, 2H, 
3JHH =  6.8 
Hz, CH2)    
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Pent-4-ynyltriphenylphoshonium iodide 642  
Triphenylphosphine (3.7 g, 13.73 mmol) and 5-iodopentyne (1.8 g, 9.25 mmol) were heated to reflux 
in dry toluene for 24 hours. The reaction was then left to cool to room temperature and then the 
cream solid (crude yield 1.02 g, 34%) removed via filtration. The crude product was recrystallised in 
acetone/toluene to give cream coloured crystals (yield 0.71 g, 24 %). 1H NMR (400 MHz, DMSO), δ, 
1.73 (m, 2H, CH2), 3.09 (t, 1H, 
4JHH = 3.4 Hz, CΞCH), 3.40 (m, 2H, CH2) 3.62 (m, 2H, CH2) and 7.78-7.92 
(15H, PPh3). 
31P{1H} NMR (162 MHz, DMSO), δ, ppm: 23.84. 13C{1H} NMR (101 MHz, CDCl3), δ, ppm, 
19.3 (d, 2JPC = 18.4 Hz, PCH2 CH2), 21.9 (s, CH2), 21.9 (d, 
1JPC = 52.0 Hz, PCH2), 70.5 (s, ΞCH), 83.6 (s, 
CΞCH), 117.9 (d, 1JPC = 86.9 Hz, PhP-C), 130.6 (d, 
3JPC = 13.7 Hz, m-Ph), 133.7 (d, 
2JPC = 10.2 Hz, o-Ph), 
135.3 (d, 4JPC = 3.0 Hz, p-Ph). MS (ES
+) m/z: 329 (M+). Elemental analysis (calc %): C (59.56), H (4.65), 
(actual %): C (60.25), H (4.86) 
Hex-5-ynyltriphenylphoshonium iodide 742  
Triphenylphosphine (3.7 g, 13.73 mmol) and 6-iodohexyne (1.93 g, 9.25mmol) were heated to reflux 
in dry toluene for 24 hours. The reaction was then left to cool to room temperature and the cream 
solid (crude yield 1.62 g, 51%) was removed via filtration, and recrystallised in acetone/toluene to 
give cream coloured crystals (yield 1.11 g, 35%). 1H NMR (400 MHz, DMSO), δ, 1.64 (m, 4H, CH2CH2), 
3.62 (m, 2H, PCH2), 3.79 (t, 1H, 
4JHH = 3.5 Hz, CΞCH), 3.61 m (2H, CH2) and 7.15-7.94 m (15H, PPh3). 
31P{1H} NMR (62 MHz, DMSO), δ, ppm: 23.96. 13C{1H} NMR (101 MHz, CDCl3), δ, ppm, 17.6 (s, CH2),  
21.1 (s, CH2),  23.5 (d, 
1JPC = 50.5 Hz, PCH2), 28.0 (d, 
2JPC = 17.0 Hz, PCH2 CH2), 69.3 (s, ΞCH), 83.3 (s, 
CΞCH), 118.2 (d, 1JPC = 86.9 Hz, PhP-C), 130.5 (d, 
3JPC = 13.7 Hz, m-Ph), 133.8 (d, 
2JPC = 10.1 Hz, o-Ph), 
135.1 (d, 4JPC =  3.0 Hz, p-Ph). MS (ES
+) m/z: 343 (M+). Elemental analysis (calc %): C (60.19), H (5.06), 
(actual %): C (61.27), H (5.15) 
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3.11.3 Synthesis of Fluoroethylazide 
2-Fluoroethyltosylate 813 
 Yield 3.78 g, 81%. 1H NMR (400 MHz, CDCl3), δ, 2.44 (s, 3H, CH3), 4.23 (m, 2H, CH2), 4.54 (m, 2H, 
CH2), 7.35 (d, 
3JHH = 8.2 Hz, 2H, Ar), 7.78 (d, 
3JHH = 8.3 Hz, 2H, Ar) 
Fluoroethylazide 99 
To a solution of 2-fluoroethyltosylate (128 mg, 0.586 mmol) in DMF (10 ml) sodium azide (114 mg, 
1.76 mmol) was added, and the resulting mixture was stirred at ambient temperature for 48 h. The 
reaction mixture was filtered, and the filtrate containing the title compound was used without 
isolation for subsequent reactions. 
3.11.4 Phosphonium Triazole Synthesis 
[1-(2-Fluoroethy),1H[1,2,3]triazole 4-methylene] triphenylphosphonium bromide 10 
Reactions attempted did not yield the desired compound. 
1-benzyl-4-phenyl triazole 1119 
Yield 0.22 g, 92%. 1H NMR (400 MHz, CDCl3); δ, ppm, 5.60 (s, 2H, CH2), 7.32-7.44 (m, 8H, Ph), 7.86 (s, 
1H, triazole), 7.82 (m, 2H, Ph). MS (ES+) m/z: 236 (M+). Elemental analysis (calc %): C (76.56), H 
(5.57), N (17.87), (actual %): C (76.62), H (5.66), N (17.77) 
General procedure of 12-14: In one reaction vial, copper sulfate pentahydrate (1.35 mg, 0.0053 
mmol) and L-ascorbic acid (9.5 mg, 0.053 mmol) were dissolved in 0.2 ml of water giving a lime 
green solution. In another vial, the alkyne (0.253 mmol) was dissolved in 0.5 ml of DMF and then this 
transferred to the catalyst vial. The fluoroethyl azide (0.253 mmol) was then added to the mixture 
(0.5 M in DMF) and the reaction sealed and left to stir at room temperature for 48 hours. All the 
solvent was then removed under vacuum and then Kugelrohr apparatus was used to ensure all DMF 
had been removed. Methanol (5 ml) was then added and any undissolved solid removed by filtration 
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through Celite. The methanol was then removed and chloroform (5 ml) added. The precipitate was 
then filtered again and then the solvent removed under vacuum. Compounds 12-14 were isolated as 
dark brown oils. 
 [1-(2-Fluoroethy),1H[1,2,3]triazole 4-ethylene] triphenylphosphonium bromide 12 
Yield 95 mg, 77%. 1H NMR (400 Hz, DMSO); δ, 3.16 (m, 2H, CH2), 4.03 (m, 2H, CH2), 4.58 (dt, 2H, 
3JHF = 
25.6 Hz, 3JHH = 4.9 Hz, CH2), 4.74 (dt, 2H, 
2JHF = 46.8 Hz,
 3JHH = 4.8 Hz CH2F), 7.66-7.82 (15H, PPh3), 8.62 
(s, 1H, CH triazole). 31P{1H}  NMR (162 Hz, DMSO); δ, 23.40 (s). 19F NMR (377 Hz, DMSO); δ, -223.26 
(m). 13C{1H} NMR (101 MHz, CDCl3), δ, ppm, 18.9 (s, PCH2CH2), 20.8 (d, 
1JPC = 51.5 Hz, PCH2), 50.5 (d, 
1JFC = 18.9 Hz, FCH2), 83.3 (s, FCH2CH2), 118.6 (d, 
1JPC = 86.0 Hz, Ph P-C), 121.2 (s, triazole-C), 123.6 (s, 
triazole-CH), 130.7 (d, 3JPC = 13.3 Hz, m-Ph), 134.2 (d, 
2JPC =  10.2 Hz, o-Ph), 135.5 (s, p-Ph). Accurate 
MS (ES+) m/z: 404. 1694 (M+, 100%), calc. mass: 404.1693. Elemental analysis (calc %): C (59.51), H 
(4.99), N (8.68), (actual %): C (59.67), H (5.01), N (8.78) 
 [1-(2-Fluoroethy),1H[1,2,3]triazole 4-propylene] triphenylphosphonium iodide 13 
Yield 66 mg, 48%. 1H NMR (400 Hz, DMSO); δ, 1.89 (m, 2H, CH2), 3.85 (m, 2H, CH2), 3.67 (m, 2H, CH2), 
4.78 (m, 4H, CH2CH2F), 7.84-7.99 (m, 15H, PPh3), 8.53 (s, 1H, CH triazole). 
31P{1H} NMR (162 Hz, 
DMSO); δ, ppm: 24.09. 19F NMR (377 Hz, DMSO); δ, -223.27 (m). 13C{1H} NMR (101 MHz, CDCl3), δ, 
ppm, 21.7 (s, PCH2CH2), 22.2 (s, CH2),  25.4 (d, 
1JPC = 18.0 Hz, PCH2), 50.5 (d, 
2JHF = 20.4 Hz, FCH2), 82.4 
(s, FCH2CH2), 117.9 (d, 
1JPC = 86.1 Hz, Ph P-C), 125.9 (s, triazole-C), 128.6 (s, triazole-CH), 130.6 (d, 
3JPC 
= 12.5 Hz, m-Ph), 133.6 (d, 2JPC = 10.0 Hz, o-Ph), 135.2 (s, p-Ph). Accurate MS (ES
+) m/z: 418. 1830 
(M+, 100%), calc. mass: 418.1848. Elemental analysis (calc %): C (55.06), H (4.81), N (7.70), (actual %): 
C (56.29), H (4.91), N (7.54)  
[1-(2-Fluoroethy),1H[1,2,3]triazole 4-butylene] triphenylphosphonium iodide 14 
Yield 75 g, 53%.1H NMR (400 Hz, DMSO); δ, 1.59 (m, 2H, CH2), 1.80 (m, 2H, CH2), 3.67 (m, 2H, PCH2), 
3.66 (m, 2H, CH2), 4.72 (m, 4H, CH2CH2F), 7.83-8.01 (15H, PPh), 8.57 (s, 1H, CH triazole). 
31P{1H} NMR 
Chapter 3 
 
87 
 
(162 Hz, DMSO); δ, ppm: 24.07. 19F NMR (377 Hz, DMSO); δ, -223.11 (m). 13C{1H} NMR (101 MHz, 
CDCl3), δ, ppm, 21.5 (s, PCH2CH2), 21.6 (s, CH2),  23.7 (d, 
1JPC = 51.1 Hz, PCH2), 24.6 (s, CH2),  50.5 (s, 
FCH2), 83.4 (s, FCH2CH2), 118.1 (d, 
1JPC = 86.0 Hz, Ph P-C), 120.8 (s, triazole-C), 123.2 (s, triazole-CH), 
130.5 (d, 3JPC = 13.4 Hz, m-Ph), 133.7 (d, 
2JPC = 10.0 Hz, o-Ph), 135.1 (s, p-Ph). Accurate MS (ES
+) m/z: 
433.2021 (M+, 100%), calc. mass: 433.2005. Elemental analysis (calc %): C (55.82), H (5.05), N (7.51), 
(actual %): C (55.64), H (5.15), N (7.41)    
3.11.5 Synthesis of Fluorine Functionalised Phosphines 
General Procedure of 15-17: All the compounds were prepared by adding phosphorus trichloride to 
the specific Grignard reagent.43 A solution of the corresponding bromo Grignard starting material 
(20.24 mmol, 3 eq) in dry diethyl ether or THF (10 ml) was added dropwise to a suspension of Mg 
turnings (20.66 mmol, 3 eq) in dry diethyl ether (5 ml) at a rate to keep the solution under a gentle 
reflux. After addition was complete, the solution was heated to gentle reflux for 1 hour. After 
cooling to room temperature, phosphorus trichloride (6.86  mmol, 1 eq) in dry diethyl ether or THF 
(15 ml) was added dropwise to the dark brown solution. The solution was further stirred for 3 h.  
Tris-(pentafluorophenyl)-phosphine 1544  
The general method above was followed using dry diethyl ether as solvent.  The solution was 
hydrolyzed with dilute hydrochloric acid. The ether was removed under reduced pressure and the 
precipitates were filtered, washed with water, dried in vacuum. The crude compound was then 
purified via sublimation (110 oC, 300 Pa) to give white crystals. Yield 1.10 g, 31%. 31P{1H} NMR (162 
MHz, CDCl3); δ, -74.30 (m). 
19F NMR (377 MHz, CDCl3); δ, -159 (m, 2F), -147 (t, 1F, 
3JFF =  20.5 Hz), -
129 (m, 2F). MS (ES+) m/z: 532 (M+, 100%). Elemental analysis (calc %): C (40.63), (actual %):  C 
(40.47) 
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Tris(4-fluorophenyl) phosphine 1645 
The general method was followed using dry THF as solvent.  The solution was hydrolyzed with water, 
the organic layer removed and the aqueous layer washed with diethyl ether. The organic layers were 
combined and the solvent removed under vacuum. The crude product which had a definite orange 
colour was recrystallised from hot ethanol to yield a white crystalline product (1.11 g, 40%). 1H NMR 
(400 MHz, CDCl3); δ, 7.07 (td, 12H, 
3JHH = 8.6 Hz, 
3JFH = 3.6 Hz, m-PhP), 7.26 (m, 12H, o-PhP). 
31P{1H} 
NMR (162 MHz,, CDCl3); δ, -9.13 (s). 
19F NMR (377 MHz, CDCl3); δ, -111.99 (s). 
13C{1H} NMR (101 MHz, 
CDCl3), δ, ppm, 115.9 (dd, 
2JFC = 21.0 Hz, 
3JPC = 7.9 Hz, o-Ph), 132.4 (d, 
1JPC = -12.1 Hz, PhP-C), 135.4 
(dd, 2JPC = 21.3 Hz, 
3JFC = 8.0 Hz, m-Ph), 163.4 (d, 
1JFC = -250.5 Hz, PhC-F). MS (ES
+) m/z: 316 (M+, 
100%). Elemental analysis (calc %): C (66.36), H (3.82), (actual %):  C (66.48), H (3.68) 
Tris(4-trifluoromethylphenyl)phosphine 1746,47 
The general method was followed using dry diethyl ether as solvent.  The solution was hydrolysed 
with water, the organic layer removed and the aqueous layer washed with ether. The organic layers 
were combined and the solvent removed under vacuum. The crude product which had a yellow 
colour was recrystallised from hot ethanol to yield a white crystalline product (0.42 g, 13%). 1H NMR 
(400 MHz, DMSO); δ, 7.52 (t, 2H, 3JHH = 7.6 Hz), 7.81 (d, 2H, 
3JHH = 7.9 Hz). 
31P{1H}  NMR (162 MHz, 
DMSO); δ, -6.85 (s). 19F NMR (377 MHz, DMSO); δ, -61.39 (s). 13C{1H} NMR (101 MHz, CDCl3), δ, ppm, 
125.6 (dq, 2JFC = 7.0 Hz, 
4JPC = 3.6 Hz, p-Ph), 127.9 (s, PhP-C), 131.6 (q, 
1JFC = 33.4 Hz, CF3), 134.0 (d, 
3JPC 
= 20.1 Hz, m-Ph), 140.3 (d, 2JPC = 14.4 Hz, o-Ph). MS (ES
+) m/z: 466 (M+, 100%). Elemental analysis 
(calc %): C (54.09), H (3.59), (actual %):  C (53.91), H (3.44) 
3.11.6 Attempted Alkyne Synthesis with Fluorine Functionalised Phosphines 
General procedure of 18-20: 1 -Bromobut-3-yne (4.26 mg, 0.032 mmol) and the corresponding 
fluorine functionalised triphenylphosphine (0.032 mmol) were dissolved in dry toluene (5 ml) and 
left to heat to reflux for a minimum of 24 hrs. The solvent was removed under vacuum and the 
sample analysed via 31P{H} and 19F NMR. 
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But-3-ynyl(tris-pentafluorotriphenyl)phosphonium bromide 18 
Only starting material recovered. 
But-3-ynyl(tris-4-fluoro triphenyl)phosphonium bromide 19 
Mainly starting material recovered but with small evidence of product. 31P{1H} NMR (162 MHz, 
CDCl3); δ, -10.81 (s, starting material, 88%), 23.85 (s, product, 12%). 
19F NMR (377 MHz, CDCl3), δ; -
113.02 (s, starting material, 88%), -107.07 (s, product, 12%) 
But-3-ynyl(tris-4-trifluoromethylphenyl)phosphonium bromide 20 
Only starting material recovered. 
But-3-ynyl toluene-4-sulfonate 2126 
Yield 3.70 g, 34%. 1H NMR (400 MHz, CDCl3); δ, 1.99 (t, 1H, HCΞC, 
4JHH = 3.6 Hz), 3.48 (s, 3H, CH3), 3.58 
(td, 2H, CH2, 
3JHH = 7.0 Hz, 
3JHH = 3.6 Hz), 4.13 (t, 2H, CH3, 
3JHH = 7.0 Hz), 7.38 (d, 2H, Ph, 
3JHH = 8.1 Hz), 
7.83 (d, 2H, Ph, 3JHH = 8.3 Hz) 
3.11.7 Synthesis of Alternative Functionalised Phosphines 
Tris(4-tert-butylphenyl) phosphine 2229 
Magnesium turnings (0.57 g, 23.5 mmol) were placed in a round bottomed flask under nitrogen. To 
this a solution of 1-bromo-4-tert-butylbenzene (5 g, 23.5 mmol) in dry THF (10 ml) was added 
dropwise at a rate to maintain reflux. The mixture was then left to stir at room temperature for 2 
hours. Phosphorus trichloride (1.08 g, 7.8 mmol) in dry THF (15 ml) was added dropwise to the 
mixture again maintaining reflux and then left at room temperature for a further 2 hours. The 
reaction mixture was quenched with water and the organic layer extracted and solvent removed to 
give a pale yellow solid. This was purified via recrystalisation in hot ethanol. Yield 1.45 g, 43%. 1H 
NMR (400 MHz, CDCl3); δ, 1.34 (s, 9H, 
tBu), 7.26-7.29 (2H, Ph), 7.37-7.39 (2H, Ph). 31P{1H} NMR (162 
MHz, CDCl3); δ, -8.98 (s). 
13C{1H} NMR (101 MHz, CDCl3), δ, ppm, 31.4 (s, CH3), 34.7 (s, CMe3), 131.9 
(d, 3JPC = 10.0 Hz, m-PhP), 133.5 (d, 
2JPC = 19.3 Hz, o-PhP), 134.1 (d, 
1JPC = -9.0 Hz, PhP-C), 151.6 (s, 
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PhC-tBu). (ES+) m/z: 431.2864 (M+), 447.283 (P = O). Elemental analysis (calc %): C (77.46), H (7.78), 
(actual %):  C (77.84), H (7.21) 
Tris(3,5-dimethylphenyl) phosphine 2327 
Magnesium turnings (0.66 g, 27 mmol) were placed in a round bottomed flask under nitrogen. To 
this a solution of 1-bromo-4-tert-butylbenzene (5 g, 27 mmol) in dry THF (10 ml) was added 
dropwise at a rate to maintain reflux. The mixture was then left to stir at room temperature for 2 
hours. Phosphorus trichloride (1.24 g, 9 mmol) in dry THF (15 ml) was added dropwise to the mixture 
again maintaining reflux and then left at room temperature for a further 2 hours. The reaction 
mixture was quenched with water and the organic layer extracted and solvent removed to give a 
pale yellow solid. This was purified via recrystalisation in hot ethanol. Yield 3.21 g, 24%. 1H NMR (400 
MHz, CDCl3); δ, 3.29 (s, 18H), 6.97 (s, 3H, p-H), 6.97 (d, 6H, o-H, 
3JHP = 13.2 Hz). 
31P{1H}  NMR (162 
MHz, CDCl3); δ, -4.85 (s). 
13C{1H} NMR (101 MHz, CDCl3), δ, ppm, 21.2 (s, CH3), 137.1 (d, 
3JPC = 10.2 Hz, 
m-PhP), 137.2 (s, PhC-Me), 137.7 (d, 1JPC = -7.3 Hz, PhP-C), 138.0 (d, 
2JPC = 12.8 Hz, o-PhP). MS (ES
+) 
m/z: 347 (M+, 40%), 363 (M = O+, 100%). Elemental analysis (calc %): C (83.20), H (7.86), (actual %):  C 
(83.97), H (7.68) 
3.11.8 Alkyne Synthesis with Alternative Functionalised Phosphines 
General procedure of 24-28: 1-Bromo-3-butyne (359 mg, 3.57 mmol) and corresponding methyl-
functionalised triphenylphosphine (3.82 mmol) were dissolved in dry toluene (10 ml) and left to heat 
to reflux for a minimum of 24 hrs. After this time an oil layer formed and the solvent was pipetted 
off. The oil washed with dry toluene (2 x 10 ml) and then dissolved in ethyl acetate (10 ml). The 
solvent was removed under vacuum to yield white solids. 
But-3-ynyl (tris-4-methylphenyl)phosphonium bromide 24 
Yield 0.30 mg, 69%. 1H NMR (400 MHz, CDCl3); δ, 1.79 (t, 1H, HCΞC,
 4JHH = 3.7 Hz), 3.49 (s, 9H, CH3), 
3.83 (dtd, 2H, PCH2CH2, 
3JPH = 20.5 Hz, 
3JHH = 6.6 Hz, 
4JHH = 3.8 Hz ), 3.98 (dt, 2H, PCH2, 
2JPH = 11.8 Hz, 
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3JHH = 6.6 Hz), 7.42-7.49 (6H, Ph), 7.70-7.76 (6H, Ph). 
31P{1H} NMR (162 MHz, CDCl3); δ, 23.60 (s). 
13C{1H} NMR (101 MHz, CDCl3), δ, ppm, 13.9 (s, CH2), 21.9 (s, CH3), 23.3 (d, 
1JPC = 50.1 Hz, PCH2), 73.2 
(s, ΞCH), 81.1 (s, CΞCH), 114.8 (d, 1JPC = 89.9 Hz, PhP-C), 131.0 (d, 
3JPC = 13.1 Hz, m-PhP), 133.8 (d, 
2JPC 
= 13.6 Hz, o-PhP), 146.3 (s, p-Ph). MS (ES+) m/z: 357 (M+, 100%). Elemental analysis (calc %): C 
(68.66), H (5.99), (actual %):  C (63.55), H (5.04) 
But-3-ynyl (tris-4-methoxyphenyl) phosphonium bromide 25 
Yield 0.49 mg, 92%. 1H NMR (400 MHz, CDCl3); δ, 1.82 (t, 1H, HCΞC,
 4JHH = 3.7 Hz), 3.81 (dtd, 2H, 
PCH2CH2, 
3JPH = 20.2 Hz, 
3JHH = 6.6 Hz, 
4JHH = 3.7 Hz ), 3.87 (dt, 2H, PCH2, 
2JPH = 11.8 Hz, 
3JHH = 6.8 Hz), 
3.92 (s, 9H, CH3), 7.55-7.65 (6H, Ph), 7.75-7.81 (6H, Ph). 
31P{1H} NMR (162 MHz, CDCl3); δ, 23.20 (s). 
13C{1H} NMR (101 MHz, CDCl3), δ, ppm, 13.9 (s, CH2), 33.7 (d, 
1JPC = 51.2 Hz, PCH2), 55.9 (s, OCH3), 
73.1 (s, CΞCH), 77.23 (s, CΞCH), 116.0 (d, 1JPC = 24.4 Hz, PhP-C), 135.1 (d, 
3JPC = 13.2 Hz, m-PhP) 135.8 
(s, 2JPC = 13.0 Hz, o-PhP), 164.7 (s, p-Ph). MS (ES
+) m/z: 405 (M+, 100 %). Elemental analysis (calc %): C 
(61.87), H (5.40), (actual %):  C (61.62), H (5.56) 
Buy-3-ynyl(tris-2,4,6-trimethylphenyl)phosphonium bromide 26 
< 3% yield. 1H NMR (400 MHz, CDCl3); δ, 1.37 (s, 27H, CH3), 1.70 (t, 1H, HCΞC,
 4JHH = 3.7 Hz), 3.82-3.91 
(2H, CH2), 4.08-4.14 (2H, CH2), 7.68-7.71 (6H, Ph), 7.80-7.86 (6H, Ph). 
31P{1H} NMR (162 MHz, CDCl3); 
δ, 23.81 (s). MS (ES+) m/z: 441 (M+, 100 %)   
But-3-ynyl (tris-4-tertbutylphenyl)phosphonium bromide 27 
Yield 1.53 g, 71%. 1H NMR (400 MHz, CDCl3); δ, 1.35 (s, 27H, CH3), 1.70 (t, 1H, HCΞC,
 4JHH = 3.7 Hz), 
3.82-3.91 (2H, CH2), 4.08-4.14 (2H, CH2), 7.68-7.71 (6H, Ph), 7.80-7.86 (6H, Ph). 
31P{1H} NMR (162 
MHz, CDCl3); δ, 23.893 (s). 
13C{1H} NMR (101 MHz, CDCl3), δ, ppm, 25.6 (s, CH2), 29.7 (s, CH3), 31.2 (s, 
CMe3), 34.8 (d, 
1JPC =  36.7 Hz, PCH2,), 68.0 (s, CΞCH), 77.1 (s, CΞCH), 129.6 (d, 
1JPC = 105.6 Hz, PhP-C), 
132.0 (d, 3JPC = 10.3 Hz, m-PhP), 133.5 (d, 
2JPC = 19.3 Hz, o-PhP), 155.2 (d, 
4JPC = 3.7 Hz, PhC-tBu). MS 
(ES+) m/z: 484.3 (M+, 100%)   
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But-3-ynyl (tris-3,5-dimethylphenyl)phosphonium bromide 28 
1-Bromo-3-butyne (307 mg, 3.321 mmol) and tris(3,5-dimethyltriphenyl) phosphine (800 mg, 3.321 
mmol) were dissolved in dry toluene (10 ml) and left to heat to reflux for a minimum of 24 hrs. After 
this time white precipitate had formed and the mixture was left to cool to room temperature. The 
solid was then filtered off and washed with toluene and hexane. Yield 0.32 g, 30%. 1H NMR (400 
MHz, CDCl3); δ, 1.78 (t, 1H, HCΞC,
 4JHH = 3.7 Hz), 3.43 (s, 18H, CH3), 3.87 (m, 2H, CH2), 4.00 (m, 2H, 
CH2), 7.38 (s, 3H, p-H), 7.42 (d, 6H, o-H, 
3JHP = 15 Hz). 
31P{1H}  NMR (162 MHz, CDCl3); δ, 24.03 (s). 
13C{1H} NMR (101 MHz, CDCl3), δ, ppm, 14.0 (s, CH3), 21.5 (s, CH3), 32.0 (d, 
1JPC = 34.1 Hz, PCH2), 71.5 
(s, ΞCH), 77.2 (s, CΞCH), 118.0 (d, 1JPC = 88.2 Hz, PhP-C), 131.2 (d, 
3JPC = 9.9 Hz, m-PhP), 136.5 (s, p-Ph), 
140.3 (d, 2JPC = 13.6 Hz, o-PhP). MS (ES
+) m/z: 399 (M+, 100%)   
3.11.9 Triazole Synthesis with Alternative Functionalised Phosphines 
General procedure: See section 3.11.4 
[1-(2-Fluoroethy),1H[1,2,3]triazole 4-ethylene] tris-4-methylphenyl phosphonium bromide (29) 
Yield 72 mg, 54%. 1H NMR (400 MHz, CDCl3); δ, 3.50 (s, 9H), 3.18 (m, 2H, CH2), 3.81 (m, 2H, CH2), 4.65 
(dt, 2H, 3JHF = 25.5 Hz, 
3JHH = 4.9 Hz, CH2), 4.81 (dt, 2H, 
2JHF = 46.6 Hz, 
3JHH = 4.8 Hz, CH2F), 7.48-7.69 
(12H, Ph), 8.52 (s, 1H, CH triazole). 31P{1H}  NMR (162 MHz, CDCl3); δ, 23.33 (s). 
19F NMR (377 MHz, 
CDCl3); δ, -223.59 (m). 
13C{1H} NMR (101 MHz, CDCl3), 18.9 (s, PCH2CH2) 20.0 (d, 
1JPC = 48.4 Hz, PCH2), 
21.7 (s, CH3), 50.4 (s, FCH2), 79.7 (s, FCH2CH2), 115.5 (d, 
1JPC = 88.9 Hz, Ph P-C), 126.0 (s, triazole-CH), 
128.5 (s, triazole-C),  131.3 (d, 3JPC = 13.9 Hz, m-Ph), 134.0 (d, 
2JPC = 10.7 Hz, o-Ph), 146.2 (s, p-Ph). 
Accurate MS (ES+) m/z: 446.2165 (M+, 100%), calc. mass: 446.2161. Elemental analysis (calc %): C 
(61.60), H (5.74), N (7.98) (actual %):  C (56.33), H (4.57), N (4.77) 
[1-(2-Fluoroethy),1H[1,2,3]triazole 4-ethylene] tris-4-methoxyphenyl phosphonium bromide (30) 
Yield 99 mg, 68%. 1H NMR (400 MHz, CDCl3); δ, 3.09-3.16 (2H, CH2), 3.76-3.81 (2H, CH2), 3.88 (s, 9H, 
Me), 4.63 (dt, 2H, 3JHF = 25.5 Hz, 
3JHH = 4.7 Hz, CH2), 4.79 (dt, 2H, 
2JHF = 46.7 Hz, 
3JHH = 4.6 Hz, CH2F), 
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7.55-7.66 (12H, Ph), 8.70 (s, 1H, CH triazole). 31P{1H} NMR (162 MHz, CDCl3); δ, 21.02 (s). 
19F NMR 
(377 MHz, CDCl3); δ, -223.36 (m). 
13C{1H} NMR (101 MHz, CDCl3), δ, ppm, 11.3 (d, 
1JPC = 59.1 Hz, 
PCH2), 14.0 (s, PCH2CH2), 50.5 (d, 
1JFC = 23.1 Hz, FCH2), 56.0 (s, OCH3), 73.5 (s, FCH2CH2), 110.3 (d, 
1JPC 
=  51.7 Hz, Ph P-C), 126.0 (s, triazole-CH), 128.6 (s, triazole-C),  135.0 (d, 3JPC = 13.4 Hz, m-Ph), 135.5 
(d, 2JPC = 11.3 Hz, o-Ph), 164.7 (s, p-Ph). Accurate MS (ES
+) m/z: 494. 2011 (M+, 100%), calc. mass: 
494.2009. Elemental analysis (calc %): C (56.45), H (5.26), N (7.32) (actual %):  C (54.01), H (4.88), N 
(3.41) 
[1-(2-Fluoroethyl),1H[1,2,3]triazole 4-ethylene] tris-4-terbutylphenyl phosphonium bromide 31 
Yield 92 mg, 56%. 1H NMR (400 MHz, CDCl3); δ, 1.39 (27H, CH3), 3.18 (m, 2H, CH2), 3.90 (m, 2H, CH2), 
4.68 (dt, 2H, 3JHF = 25.2 Hz, 
3JHH = 4.9 Hz, CH2), 4.84 (dt, 2H, 
2JHF = 46.7 Hz, 
3JHH = 4.9 Hz, CH2F), 7.69-
7.81 (12H, Ph), 8.78 (s, 1H, CH triazole). 31P{1H} NMR (162 MHz, CDCl3); δ, 23.77 (s). 
19F NMR (377 
MHz, CDCl3); δ, -223.36 (m). 
13C{1H} NMR (101 MHz, CDCl3), δ, ppm, 30.9 (s, CH3), 31.1 (d, 
1JPC =  23.6 
Hz, PCH2), 35.5 (s, PCH2CH2), 57.6 (s, FCH2), 87.3 (s, FCH2CH2), 109.9 (s, triazole-CH), 114.2 (s, triazole-
C), 125.3 (d, 1JPC = 40.2 Hz, Ph P-C), 127.6 (d, 
3JPC = 13.8 Hz, m-Ph), 133.5 (d, 
2JPC = 10.2 Hz, o-Ph), 
159.2 (s, p-Ph). Accurate MS (ES+) m/z: 573.3568 (M+, 100%), calc. mass: 573.3570. Elemental 
analysis (calc %): C (66.25), H (7.41), N (6.44) (actual %):  C (61.13), H (6.75), N (4.10) 
[1-(2-Fluoroethyl),1H[1,2,3]triazole 4-ethylene] tris-3,5-dimethylphenyl phosphonium bromide 32 
Yield 86 g, 60%. 1H NMR (400 MHz, CDCl3); δ, 3.44 (18H, CH3), 3.14 (m, 2H, CH2), 3.82 (m, 2H, CH2), 
4.69 (dt, 2H, 3JHF = 25.5 Hz, 
3JHH = 5.0 Hz, CH2), 4.84 (dt, 2H, 
2JHF = 46.7 Hz, 
3JHH = 4.9 Hz, CH2F), 7.30-
7.41 (12H, Ph), 8.72 (s, 1H, CH triazole). 31P{1H} NMR (162 MHz, CDCl3); δ, 23.77 (s). 
19F NMR (377 
MHz, CDCl3); δ, -223.36 (m). 
13C{1H} NMR (101 MHz, CDCl3), δ, ppm, 15.5 (d, 
1JPC = 44.3 Hz, PCH2), 
19.4 (s, PCH2CH2), 23.8 (s, CH3), 65.9 (s, FCH2), 77.4 (s, FCH2CH2), 117.4 (d, 
1JPC = 84.0 Hz, Ph P-C), 
126.0 (s, triazole-CH), 128.5 (s, triazole-C),  130.8 (d, 3JPC = 10.2 Hz, m-Ph),136.9 (s, p-Ph), 140.7 (d, 
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2JPC = 13.4 Hz, o-Ph). Accurate MS (ES
+) m/z: 488.2632 (M+, 100%), calc. mass: 488.2631. Elemental 
analysis (calc %): C (63.38), H (6.38), N (7.39) (actual %):  C (54.49), H (4.98), N (5.11) 
3.11.10 Diphenylphosphine Analogues 
(4-butanol)diphenyl(benzyl) phosphonium bromide (33) 
Lithium diphenylphosphine (Sigma Aldrich, 0.5 M (THF), 9.2 mmol) was added dropwise to 1-chloro-
4-pentyne (9.2 mmol) over a 20 minute period at 0oC. The reaction mixture was then left to stir at 
room temperature for 18 hours. All solvent was removed and the oily mixture redissolved in dry 
toluene before being washed with water (3 x 20 ml) and dried over magnesium sulfate. The solvent 
was the removed to give crude oil. This crude product (245 mg) and benzyl bromide (134 mg, 0.78 
mmol) were heated to reflux in toluene (3 ml) and after 20 minutes a white precipitate had formed. 
The mixture was left to heat for a further 2 hours and then cooled to RT and the white solid removed 
via filtration. Yield 0.26 g, 68%. 1H NMR (400 MHz, D2O); δ, 1.51 (m, 4H, CH2 CH2), 2.66 (m, 2H, CH2), 
3.42 (t, 2H, 3JHH = 6.7 Hz, CH2OH), 4.27 (d, 
2JPH = 15.4 Hz, CH2), 6.98 (m, 2H, Ph), 7.23-7.29 (3H, Ph), 
7.72-7.87 (10H, Ph). 31P{1H} NMR (162 MHz, D2O); δ, 27.81 (s). MS (ES
+) m/z: 349.1 (M+) 
General procedure of 34-3534: Triphenylphosphine (2.41 g, 9.19 mmol) was dissolved in dry THF (40 
ml) and to this lithium (0.65 g, 94 mmol) added. The mixture was stirred vigorously for 24 hours and 
then the resultant red solution filtered via cannular. t-Butylchloride (0.72 g, 7.8 mmol) was added to 
the filtrate and then this was added drop-wise over a 20 minute period to either 1-chloro-4-pentyne 
(0.94 g, 9.3 mmol) or 1-bromo-3-butyne (1.24g, 9.3 mmol) at 0oC. The solvent was removed under 
vacuum and then redissolved in dry toluene (20 ml) before being washed with water (3 x 20 ml) and 
dried over magnesium sulfate. The solvent was then removed to give a pale yellow oil.  
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(4-pentyne)diphenylphosphine 34  
Crude yield 1.61 g, 69%. 1H NMR (400 MHz, CDCl3); δ, 1.71 (m, 2H, CH2), 2.01 (t, 1H, 
4JHH = 2.6 Hz, 
ΞCH), 2.18-2.24 (2H, CH2), 2.35 (dt,2H, 
3JHH = 6.9 Hz, 
4JHH = 2.6 Hz, CH2), 7.29-7.53 (10H, Ph). 
31P{1H} 
NMR (162 MHz, CDCl3); δ, -17.05 (s). MS (ES
+) m/z: 253.1 (M+) 
(3-butyne)diphenylphosphine 35 
Crude yield 1.34 g, 61%. 1H NMR (400 MHz, CDCl3); δ, 1.92 (t, 1H, 
4JHH = 2.6 Hz, ΞCH), 2.34-2.39 (2H, 
CH2), 2.65 (m, 2H), 7.31-7.56 (10H, Ph). 
31P{1H} NMR (162 MHz, CDCl3); δ, -16.33 (s). MS (ES
+) m/z: 
239.2 (M+) 
General procedure of 36-37:  (3-butyne)diphenylphosphine (0.50 g, 1.68 mmol) was added to dry 
toluene (10 ml). To this, benzylybromide or 4-fluorobenzyl bromide (2.52 mmol) was added and the 
reaction mixture heated to reflux for 24 hours. Following this, the mixture was cooled to room 
temperature and the precipitation filtered off to give the product as a cream coloured solid. 
(3-Butyne)diphenyl(benzyl)phosphonium bromide 36 
Yield 0.65 g, 94%. 1H NMR (400 MHz, CDCl3); δ, 1.91 (t, 1H, 
4JHH =  2.7 Hz, ΞCH), 2.52 (dtd, 2H, 
3JPH =  
18.5 Hz, 3JHH = 7.0 Hz, 
4JHH = 2.7 Hz, CH2), 3.62 (dt, 2H, 
2JPH = 12.2 Hz, 
3JHH = 7.0 Hz, PCH2), 4.99 (d, 2H, 
2JPH =  14.9 Hz, CH2), 7.08-7.22 (5H, Ph), 7.63-7.95 (10H, Ph). 
31P{1H} NMR (162 MHz, CDCl3); δ, 27.65 
(s). MS (ES+) m/z: 329.1 (M+) 
(3-Butyne)diphenyl(4- fluorobenzyl)phophonium bromide 37 
Yield 0.67 g, 92%. 1H NMR (400 MHz, CDCl3); δ, 1.90 (t, 1H, 
4JHH =  2.7 Hz, ΞCH), 2.50 (dtd, 2H, 
3JPH =  
18.3 Hz, 3JHH = 7.0 Hz, 
4JHH = 2.7 Hz, CH2), 3.61 (dt, 2H, 
2JPH = 12.2 Hz, 
3JHH = 7.0 Hz, PCH2), 5.10 (d, 2H, 
2JPH =  14.6 Hz, CH2), 7.12-7.29 (4H, Ph), 7.67-7.98 (10H, Ph). 
31P{1H} NMR (162 MHz, CDCl3); δ, 27.79 
(d, 6JFP = 6.7 Hz). 
19F NMR (377 MHz, CDCl2); δ, -112.81 (m). 
19F{1H} NMR (377 MHz, CDCl2); -112.82 
(d, 6JFP = 6.7 Hz).  MS (ES
+) m/z: 247.1 (M+) 
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Modified rhodamine-B 3840 
Yield 0.84 g,  39%. 1H NMR (CDCl3); δ, 1.20 (t, 12H, 
3JHH =  6.74 Hz, CH3), 3.02 (t, 2H, 
3JHH = 8.3 Hz, CH2), 
3.37 (q, 8H, 3JHH = 7.1 Hz, NCH2), 3.55 (t, 2H, 
3JHH = 8.2 Hz, CH2), 6.28-6.47 (6H, Ph), 7.09 (m, 1H, Ph), 
7.46 (m, 2H, Ph), 7.94 (m, 1H, Ph), MS (ES+) m/z: 548.2 (M+) 
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4.0 THE RADIOCHEMISTRY OF NOVEL PHOSPHONIUM CATIONS 
This chapter describes the radiochemistry undertaken in order to make the 18F labelled 
phosphonium salts. Having discussed the design and the synthesis of the precursors required and 
reference compounds in chapter 2, it is already clear which tracers will be labelled. In order to help 
the understanding of which tracers are being discussed, the compounds have been renamed. The 
name includes the [18F] label followed by the number of carbon atoms between the phosphorus 
atom and triazole ring (e.g. C2, C3 or C4). If the phenyl groups have been functionalised, they will 
then have a label to help with recognising the group attached (e.g. Me for methyl, OMe for methoxy, 
tBu for tert-butyl and DiMe for 3,5-dimethyl). The structures and names are shown in Figure 4.1. 
 
Figure 4.1: Structures of all the proposed 
18
F labelled phosphonium cations discussed in this chapter, 
including new names 
The chapter will start by introducing the methods in radionuclide production and then will move on 
to discuss the proposed reaction conditions followed by the automated set-up used. The full 
reaction carried out will be described in representative terms for the [18F]C2 tracer, detailing the 
synthesis of [18F]fluoroethylazide, the copper catalysed alkyne azide cycloaddition (CuAAC) reaction 
step, purification and isolation by semi-preparative HPLC  and finally the confirmation of the pure 
tracer by QC HPLC.  
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Next, the other remaining analogues will be discussed including their synthesis and conditions, 
followed by any modifications that were made throughout this on-going radiochemistry work. Other 
important measurements, including the specific activity and lipophilicity of the tracers will also be 
discussed. 
The chapter will then conclude, describing a novel approach to synthesising more than one tracer in 
the same reaction vial. The separation of the tracers was made possible by different compound 
lipophilicities resulting in different retention times during HPLC purification. 
4.1 Radionuclide Production  
For a compound to be used for the purpose of PET imaging it must have a radionuclide incorporated 
into it. These radionuclides are man-made and depending on which one is going to be used for 
labelling, a cyclotron maybe required. A cyclotron (Figure 4.2) is a linear particle accelerator coiled 
into a spiral that accelerates charged particles using an alternating electric field. A perpendicular 
magnetic field causes the particles to re-encounter the accelerating voltage repeatedly, resulting in a 
high energy beam that is then directed onto a target. These will depend on the desired radionuclide 
and, in the case of this research for the production of 18F-, the target is [18O]H2O. 
 
Figure 4.2 Photograph of the inside of the cyclotron. Picture taken from www.wrha.mb.ca/healthinfo
1
 
Imanova, where this research was carried out, has state of the art equipment where the cyclotrons 
can be controlled via an online system which is available within the synthesis laboratory itself. This 
means that it is possible to control the amount of radioactivity delivered by varying the current (μA) 
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and time (mins) of the beam that is run. Aqueous [18F]fluoride is then delivered into the desired ‘hot’ 
cell, which is collected in a vial where it is then used to label compounds.  
   
 
The following steps of the synthesis and purification will depend on what tracer is being produced. 
4.2 Labelling of Phosphonium Salts 
As mentioned in both the introduction and the chemistry chapter, the synthesis of the new design of 
phosphonium cation features a CuAAC reaction between the phosphonium alkyne analogue and 
fluoroethylazide (Figure 4.4). 
 
Figure 4.4: General reaction scheme to synthesise labelled phosphonium cations 
4.2.1 Preparation for the Synthesis of [18F]Fluoroethylazide  
First, the methods of labelling the azide must be investigated. As 2-[18F]fluoroethylazide ([18F]FEA) is 
now a commonly used labelling agent in radiosynthesis which was developed by Glaser and Arstad in 
2007, the method is well described in literature (Figure 4.5).2,3,4 
 
Figure 4.5: Reaction scheme to synthesise [
18
F]FEA 
The reaction relies on the nucleophilic fluorination of 2-azidoethyl-4-toluenesulfonate. So in order to 
carry out the labelling step, the required starting material had to be synthesised. This involved a 
two-step synthesis from the starting compound, 2-bromoethanol which was then converted to 2-
azidoethanol via a similar method describe by Wu et al (Figure 4.6).5 
[18O]H
2
0                   
 
 18F
- 
(H2
18O) 
18
O (p,n) 
Figure 4.3: Nuclear equation of the formation of [
18
F]fluoride(aq) 
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Figure 4.6: Reaction scheme to synthesise 2-azidoethanol 
The reaction involved adding 2-bromoethanol to ice (approx. 100 g) and stirring for 10 min until the 
majority of the ice had melted. To this, sodium azide was added slowly over 10 min and the reaction 
mixture left to warm to room temperature and stirred form a further 6 hours. This was done to 
avoid rapid formation of the azidoethanol in case this resulted in a potential explosion. Once the 
reaction was underway safely a second batch of sodium azide was then added to ensure full 
functional group conversion and the mixture heated to 80 oC for 18 hours. The colourless oil was 
obtained with a yield of 67%. This was reacted on without any further purification. 
The next step then involved the conversion of the alcohol group to the tosylate leaving group (Figure 
4.7). A similar preparation as described by Sugai et al was followed which reacts the 2-azidoethanol 
with 4-toluenesulfonyl chloride in the presence of triethylamine in DCM at low temperatures.  
 
Figure 4.7: Reaction scheme to synthesise 2-azidoethyl-4-toluenesulfonate 
A colourless oil was isolated following a series of washings with HCl and brine (remove any 
unreacted 4-toluenesulfonyl chloride). Unfortunately the 1H NMR spectrum showed that there were 
still peaks present for unreacted tosyl groups and so the washing steps were repeated. With this 
making no difference to the proportion of the peaks, it was then thought that tosylazide was in fact 
the impurity. In order to remove the tosylazide (having formed from unreacted sodium azide from 
the previous step), flash column chromatography was required. This was carried out on silica gel 
using ethyl acetate and petroleum benzene (2:1) and gave the pure product as a colourless oil (72%). 
4.2.2 Preparation for the Synthesis of 18F Labelled Phosphonium Cations 
Initially the conditions used to form the reference compounds discussed in Chapter 3 were reviewed 
and as it was found that the best catalyst for this reaction was copper sulphate with the reducing 
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agent, L-ascorbic acid, these were considered. The use of sodium ascorbate instead of the acid 
analogue was also introduced as this tended to be used in literature for common conditions of the 
CuAAC reactions involving [18F]fluoroethylazide.6 
Another idea that was investigated was the introduction of a stabilising agent. These are often 
required due to the general thermodynamic instability of Cu(I), which can lead to oxidation (Cu(II)) 
and/ or disproportionation (Cu(0) or Cu(II)).7,8,9 Due to this, inert and anhydrous conditions are often 
required.10 This has not been an issue with the ‘cold’ chemistry, as the copper sulphate is reduced by 
the L-ascorbic acid in situ with the CuAAC reaction. During the ‘hot’ CuAAC reaction, the reaction 
mixture will be prepared prior to this step and could therefore be an issue with time.   
Previous research has shown that polytriazoles are able to stabilise the copper(I) oxidation state.10 
The most common one used in CuAAC reactions is tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine 
(TBTA).4  
 
Figure 4.8: Structure of TBTA 
TBTA (Figure 4.8) has been shown to accelerate the reaction and this is believed to be due to various 
reasons. The first being, that the basicity of the compound helps deprotonate the alkyne which aids 
in the facilitation of forming the copper(I) acetylide.11 Secondly, the multi-dendric structure allows 
encapsulation of the copper which protects it from oxidation and helps prevent polynuclear copper 
aggregates.12 Finally, due to labile coordination, fast ligand exchange can occur which is found to be 
beneficial for catalytic turnover.13 The latter point is also important when considering reaction 
conditions with radionuclides as the reaction times must be as short as possible to ensure that the 
yield and specific activity of the product do not affect the image quality.  
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For the above reasons, TBTA will be added to the CuAAC reaction mixture. Now that the proposed 
reaction conditions have been determined the next stage is to decide on how the radiolabelling 
method will be carried out. 
4.3 System Set-Up 
Radiochemistry can be performed either manually or on an automated platform and in some cases it 
may be a combination of the two. Manual synthesis ultimately results in a higher exposure to 
radiation which therefore tends to be less favourable. It may also introduce more variables than 
using an automated device and can consequently be less reliable. In terms of automation, there are 
many different platforms that are currently being used in both research and clinical production that 
are produced by various companies. A few examples of leading companies in this field are; GE, 
Siemens, Eckert and Ziegler and Synthra.  
The initial steps of the radiolabelling process for the work carried out here featured the preparation 
of the ‘naked’ fluoride followed by the radiolabelling of the azide. For the formation of the ‘naked’ 
fluoride, the aqueous [18F]fluoride was trapped on a cartridge (QMA). This is to purify [18F]fluoride 
from the aqueous solution and metal impurities and relies on a solid-phase extraction (SPE) 
method.14 The purified [18F]fluoride is then released with a eluent of K2,2,2 and K2CO3 before being 
dried via a series of azeotropic distillations. This step can be carried out manually with a heating 
block and nitrogen inlet but in this case, was implemented on an automated system produced by 
Advion called NanoTek® LF. The system also allows the addition of precursors and so the full 
synthesis of [18F]Fluoroethylazide could be achieved. A schematic of the different modules is shown 
in Figure 4.9 and indicates the different compartments. 
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Figure 4.9: System overview of Nano Tek® LF modes. Figure taken from Advion product notes at 
www.advion.com/products
15
 
The base module enables accurate delivery (>5 μL) of precursors, activity and reagent to the reactor 
module where the configuration allows multiple chemistry reactions to take place. The activity (18F) 
which has been prepared in the concentrator (allows rapid heating and cooling) is then transferred 
to the reactor module which is able to operate to pressures of 500 psi and temperatures of 200 oC to 
accommodate desired reaction conditions.  
The system is able to operate in three different modes; Discovery, Batch or Parallel. The mode of 
preference for this work is the Batch mode. This allows rapid conversion for large amounts of 
material in multiple step reactions either in the reactor alone or using vials. The 8-port valve systems 
enable all the different reagents, precursors and activity to be moved between vials via an 
automated control (Figure 4.10). 
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Figure 4.10: Schematic diagram of the system in Batch Mode for using one reactor and post reactor 
hydrolysis. Figure taken from Advion product notes at www.advion.com/products
15
 
The reason behind choosing the NanoTek® LF for this reaction is that, being a microfluidic system, it 
allows rapid reaction rates. It also offers a user friendly interface and therefore reduces learning 
time. 
Following the synthesis of the [18F] labelled fluoroethylazide on the NanoTek platform, the labelled 
azide was purified via distillation under helium flow into a reaction vial containing the CuAAC 
mixture where it would couple with the alkyne phosphonium precursor. For this to also be an 
automated process, a system for the distillation and the following reaction steps before injection 
into the HPLC had to be put in place. Firstly, the steps that were needed to be carried out must be 
determined, including the number of transfers between vials and how the transfers will work.  
In order to distil the [18F]FEA, there had to be a heating block and a controllable helium source. This 
was done by using a mass flow controller which can control the helium flow up to 100 ml/min. By 
using an a-valve tower set up, which consisted of three-way valves, the ability of venting vials and 
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moving liquids could be controlled. The final step was to be able to inject directly into a semi-
preparative HPLC and this could be achieved by using a 6-port/2-way HPLC valve. A schematic of the 
system is shown below in Figure 4.11. 
 
Figure 4.11: A schematic to show the valve tower set-up for the CuAAC reaction step 
As it can be seen from the diagram, the [18F]FEA will be delivered from the reactor into a vial which is 
placed in a heating block. To this, a helium line from the mass flow controller was added along with 
the distillation line. The other end of the distillation line was placed into the reaction vial which 
contained the pre-mix CuAAC mixture. Due to the flow of helium through the distillation line, stirring 
of the mixture could occur and all reagents kept under an inert atmosphere. Once the reaction was 
complete, by altering the positions of the valves, i.e. closing the vent on valve 7 and opening the 
route through valve 5 to the next vial, the total reaction mixture could be transferred. From here, 
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this was then loaded into the loop before being injected into the HPLC. By controlling valve 8 during 
the HPLC run, it was possible to selectively collect the desired peak. 
4.4 The Radiosynthesis of [18F]FEA and [18F]C2 
The aim of the radiochemistry was to successfully synthesise a library of 18F labelled phosphonium 
cations. The design of these compounds was discussed in depth in chapter 2 and involves using the 
well-known CuAAC reaction. The first tracer that was synthesised was the original design with the 
unfunctionalised phenyl rings and the shortest carbon chain length ([18F]C2) shown in Figure 4.12 
 
Figure 4.12: Structure of [
18
F]C2 
The first step of labelling the azide was carried out using modifications to the Glaser et al method on 
the Advion NanoTek® LF system described by a recent publication. 2,16 Aqueous [18F]fluoride (approx. 
2 ml) was delivered directly from the cyclotron and was passed through a resin cartridge (QMA) 
where the [18F]fluoride was trapped. It was then eluted using a mixture of Kryptofix-222 (5 mg, 14.3 
µmol), potassium carbonate (1 mg, 7.2 µmol, dissolved in 50 µl water), and acetonitrile (1 ml). All the 
solvent was then removed by heating at 120 oC under a stream of nitrogen. Afterwards, acetonitrile 
(0.5 ml) was added, and the distillation was continued. After cooling to room temperature, a 
solution of 2-azidoethyl-4-tosylate (2 µl, 10 µmol) in acetonitrile (0.5 ml) was added. The reaction 
mixture was then passed through the micro-reactor (100 µm x 1m, 0.2 ml/min) which was heated at 
80 oC. It was then released into a vial containing acetonitrile (0.2 ml). 
 [18F]fluoroethyl azide was distilled at 130oC under a flow of helium into the reaction vial containing a 
pre-made mixture of CuSO4.5H2O (56 μl, 0.4 mM), TBTA (10 mg, 0.019 µmol) and sodium ascorbate 
(40 mg, 0.202 µmol) in water (100 μL) and ethanol (50 μL) which had been mechanically shaken until 
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all the reagents had mixed. To this 3-butynyltriphenylphosphonium bromide (1 mg, 0.0025 µmol) in 
ethanol (50 μL) was also added prior to the distillation. Once all the labelled azide had distilled (this 
was tracked using radio-detectors (Figure 4.13) placed near to the necessary vials so the movement 
of activity could be followed) the reaction mixture was then left to stir under a flux of helium for 10 
minutes. 
 
Figure 4.13: A screen shot to show the tracking of the distillation 
 The total mixture was then transferred into another vial containing 1 ml of water to dilute the 
reaction mixture before being injected into the HPLC. 
4.4.1 Purification of [18F]C2 
The most common way to purify a labelled compound is to use semi-preparative (semi-prep) HPLC. 
This allows separation of the desired compound from other impurities (radioactive or unlabelled) by 
tracking the movement of the tracer and collecting the correct peak. Built in UV and acquired signals 
from external radio-detectors allow this to be possible. Like all HPLC purification, suitable conditions 
must be investigated prior to carrying out the actual reaction. This is usually done by running the 
reference compound, precursor and labelled synthon down the chosen column (often reverse phase 
C18) using different solvent systems until the compound elutes at a suitable time. 
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For the purification of [18F]C2, a Agilent Zorbax (SB-C18, 5 µM, 9.4 x 250 mm) column was chosen. In 
terms of the mobile phase, a solvent system that could elute the tracer and then be directly injected 
into cells was desirable. This would mean trying to avoid common HPLC solvents like acetonitrile and 
methanol. If these are used, reformulation methods are required to obtain the tracer in a 
biocompatible solution. If however, it is possible to isolate the desired tracer with ethanol and a 
buffer, reformulation steps may not be needed. This solvent mixture is allowed to be injected 
directly into cells and into live subjects as long as the ethanol concentration is below 10%. 
After trying different conditions with the reference compound of [18F]C2 a set of conditions were 
found that would elute the tracer using ethanol and a phosphate buffer (sodium dihygrogen 
phosphate, 50 mM at pH 5.5) in under 10 minutes. The UV Vis HPLC chromatogram (at 230 nm) is 
shown below in Figure 4.14. 
 
Figure 4.14: UV Vis semi-prep HPLC chromatogram of the reference compound for [
18
F]C2 
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The HPLC chromatogram shown above was achieved by using an increasing gradient of ethanol. The 
flow rate was set to 7 ml/min and the initial percentage of ethanol was 10% rising to 50% over 7 
minutes. As it can be seen, the reference compound was eluted at around 6.5 minutes, with the 
peak saturating the UV detector. Now that suitable conditions had been found using the reference 
compound, the expected eluting time for [18F]C2 was known.  
As well as the desired compound, unreacted [18F]FEA also needed to be taken into consideration. It 
had to be eluted at a different time to the triazole compound in order to allow separation. Therefore 
to check the retention time and the successful synthesis of [18F]FEA, it was prepared and injected 
into the HPLC before the CuAAC reaction was carried out. The radio-chromatogram from the HPLC 
run depicted below in Figure 4.15 showed the full conversion of [18F]fluoride to [18F]FEA. The 
retention time of the new labelling agent was found to be at around 4.8 minutes and should 
therefore allow enough time between the two possible labelled compounds to be isolated 
separately. It was also found that the retention time of the alkyne phosphonium precursor was a lot 
longer (around 12 minutes) and therefore would not contaminate the tracer. 
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Figure 4.15: Radioactivity semi-prep HPLC chromatogram of [
18
F]FEA 
Now that the synthesis of [18F]FEA had been confirmed, the next stage of the synthesis was 
attempted. The semi-prep HPLC radioactivity chromatogram of [18F]C2 is shown in Figure 4.16. 
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Figure 4.16: Radioactivity semi-prep HPLC chromatogram of [
18
F]C2 
It can be seen there was >99% conversion of [18F]FEA to [18F]C2 proving that the CuAAC conditions 
chosen were suitable to this reaction. Over the many runs carried out to synthesise this tracer, this 
was often not the case. The conversion from the azide to the triazole was often less efficient with 
percentage conversion usually ranging between 54 and 96%. Unfortunately there was no way of 
knowing what was causing the difference in reaction success as the system was automated and 
always set up in the same way. In terms of this research, it was not such an issue as long as there 
was enough of the tracer isolated to enable any further experiments planned to be carried out. 
The next stage in the confirmation of the synthesis of [18F]C2 was to run the sample through a 
analytical/quality control (QC) HPLC column. This uses a much more sensitive radio-detector and 
allows the determination of the radiochemical purity (RCP). Similarly to the use of the semi-prep 
HPLC for the isolation of the tracer, suitable conditions were determined prior to injection of [18F]C2.  
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After testing different solvents and gradients, the conditions that were used for the QC analysis of 
[18F]C2 were the following: The mobile phase consisted of acetonitrile (ACN) and ammonium 
formate (AMF). The 50 mM AMF solution was adjusted to pH 4 with formic acid. With a flow rate of 
2 ml/min, the first 6 minutes were run with an isocratic (constant mobile phase) elution of 30% ACN 
and 70% AMF and then the following 6 minutes a gradient was introduced, increasing the ACN 
contribution to 80%. The QC HPLC radioactivity trace for the isolated [18F]C2 is shown in Figure 4.17. 
 
Figure 4.17: QC HPLC radio-chromatogram of [
18
F]C2 
It can be seen from the HPLC trace shown in Figure 4.17 that the radiochemical purity (RCP) for 
[18F]C2 was found to be close to 100%. This proved that isolation using the semi-prep HPLC method 
was a sufficient way of purifying the tracer. 
In order to confirm that the peak seen in the QC HPLC trace related to that of the predicted labelled 
tracer, a spiked sample using the reference compound was run. This means that the UV peak seen 
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from the reference compound can be compared to the radio-peak of the labelled compound. As the 
UV and radio-detectors were in series, there was a short time delay seen on the radio-peak. This 
time depends on the length and size of the line connecting between the two detectors and on some 
occasions the flow rate of the mobile phase. In this case was time difference was found to be around 
0.11-0.14 minutes. 
 
Figure 4.18: QC HPLC UV chromatogram of [
18
F]C2 sample co-injected with reference compound 
It can be seen that the UV peak shown in Figure 4.18 correlated to the radio-peak shown in Figure 
4.17, and therefore confirmed the identity of the labelled tracer.  
The total reaction time for this synthesis was found to be less than one hour from dose delivery to 
isolation of the tracer. For 18F reactions, this is very quick and allows for sufficient time to carry out 
any quality control measures prior to injection without much radioactive decay. The radiochemical 
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yield was found to be a moderate 9% at end of synthesis (EOS) without being decay corrected. 
Reasons that were believed to have caused this lower yield, considering the high conversion yields 
seen for both the azide and triazole, were the loss of activity in the set up and during the fluoride 
drying. Activity can be lost during the transfer between vials and it was noted that a lot of activity 
remained in the concentrator. This could be due to an inefficient drying method that results in 
unreacted fluoride which then becomes stuck to the glass vial. The other reason was that the small 
size of the concentrator vial and the number of lines present sometimes meant the activity was lost 
via the vent or left behind post transfer. Due to the necessary use of this particular vial, this problem 
wouldn’t be easily solved and then time restrictions prevented looking for other solutions. 
This chapter has so far shown that the automated method designed to synthesise both [18F]FEA and 
[18F]C2 has been successful, and HPLC methods have been introduced so that tracer could be 
isolated with high RCP. The next stage of the research was to utilise the set-up and synthesise the 
other proposed 18F labelled phosphonium cations (Figure 4.19). 
 
Figure 4.19: Structures of the analogues of [
18
F]C2 
4.5 Radiosynthesis of the [18F]C2 Analogues 
One of the reasons behind choosing the CuAAC reaction with the labelling agent [18F]FEA was that it 
would hopefully offer an easy synthetic route into creating a library of different phosphonium 
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cations. The idea was to use different alkyne phosphonium starting materials in the reaction mixture 
but then carry out the reaction following exactly the same method. The only thing that would 
possibly have required alteration would be the HPLC conditions as the functionalisation of the 
tracers would alter the retention time along the column. 
The first two compounds to be synthesised were [18F]C3 and [18F]C4 as these were the closest 
related structures to [18F]C2 and therefore would require the least alteration to the system. This was 
done by following the same method as before but adding the different corresponding phosphonium 
bearing terminal alkyne to the CuAAC reaction mixture.  
Both [18F]C3 and [18F]C4 were successfully synthesised and isolated (same HPLC conditions), although 
conversions from the azide to the triazole were often found to be lower than that usually seen for 
[18F]C2 and more variable. As expected, the retention times of the tracers varied due to the increase 
in carbon chain length and increased lipophilicity (see section 4.7 for more details). The retention 
times for [18F]C3 and [18F]C4 were 7.38 and 8.23 minutes respectively.  
Again, the reaction set-up was used to synthesise the other analogues ([18F]C2Me, [18F]C2OMe, 
[18F]C2tBu and [18F]C2DiMe) by simply using the corresponding phosphonium alkyne as precursors 
for labelling.  All four tracers were successfully synthesised, although modifications to the semi-prep 
HPLC conditions had to be made in order to elute the tracers at suitable times. As anticipated, the 
range of functional groups on the phenyl rings significantly altered the retention times during the 
HPLC analysis thus suggesting a broad range of lipophilicities (see section 4.7) had been achieved. A 
summary of the conditions and retention times is shown in Table 4.1. 
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Tracer 
HPLC Conditions 
Ethanol % gradient 
Retention time 
(mins) 
[18F]C2Me 10-50% in 7 minutes 9.1 
[18F]C2OMe 10-50% in 7 minutes 8.4 
[18F]C2tBu 10-80% in 8 minutes 9.9 
[18F]C2DiMe 10-70% in 8 minutes 8.8 
 
Table 4.1: A table to show the semi-prep HPLC conditions and retention times for the methyl functionalised 
tracers 
Once isolated the QC HPLC conditions also had to be modified. This was done by introducing a 
gradient and increasing the percentage of ACN over the first 6 minutes of the run. This allowed all of 
the tracers to be eluted within 10 minutes and all four were confirmed with >99 percent 
radiochemical purity. 
The work so far has demonstrated that all seven of the proposed novel labelled phosphonium salts 
could be synthesised and isolated. This proves that the set-up can be used, with only slight 
modifications to create a library of different tracers. 
4.5.1 Modifications to the Reaction 
Over the three years that this research was carried out, various changes have been made and tested. 
The majority of the time was spent synthesising [18F]C2tBu as this was the first tracer carried through 
into in depth in vitro testing and in vivo studies (see Chapters 5 and 6). Therefore most of the 
modifications were carried out whilst repeatedly synthesising [18F]C2tBu. 
Micro-reactor 
One of the alterations that was attempted was the removal of the micro-reactor from the synthesis 
of [18F]FEA in order to try and reduce reaction times. Another incentive to remove the reactor was 
that on occasion it would get blocked and the pressure would build up leading to the shutdown of 
the program and therefore the failure of the run. Instead, following the addition of the 2-azidoethyl-
4-tosylate to the dried fluoride in the concentrator, this would be transferred through the loop 
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directly into the distillation vial. To ensure the production of [18F]FEA, this was heated to 80 degrees 
under a low flux of helium before the distillation took place. Having analysed this mixture prior to 
distillation, it was confirmed that removing the reactor still successfully synthesised [18F]FEA. 
When the next steps for carrying out the CuAAC reaction were run, the reaction was found to be 
unsuccessful and no [18F]C2tBu was prepared. The reason behind this was believed to be the 
concentration of acetonitrile now present in the reaction mixture after the distillation had taken 
place. This was now more than when previously using the micro-reactor as more acetonitrile was 
used to wash out the loop to ensure all activity was eluted. To try and rectify this problem, the 
amount of other solvents present in the reaction mixture were altered. In the CuAAC reaction 
mixture the amount of water was increased from 100 µl to 300 µl and the amount of ethanol also 
increased to 200 µl (100 µl to the reaction mixture and 100 µl to dissolve the starting phosphonium 
alkyne). To maintain the equal ratio of water to ethanol, the acetonitrile in the distillation vial used 
to trap the [18F]FEA prior to distillation was replaced by 100 µl of ethanol. 
This appeared to solve the problem and conversions from the azide to the triazole were found to be 
between 65-98%. This modification was used for approximately 6 months, with the synthesis giving 
similar radiochemical yields to those seen for [18F]C2. The average non-decay corrected value was 
found to be around 10% with a typical synthesis (ie. Cyclotron beam of 55 µA, 20 min) providing 
around 3 GBq of purified product. By removing the use of the reactor, the total synthesis time was 
reduced by 10 minutes. 
Unfortunately, following the yearly scheduled shut-down for maintenance of the cyclotron, the 
synthesis of [18F]C2tBu was no longer successful. The semi-prep HPLC traces showed only the azide, 
[18F]FEA and often another radioactive peak which would elute with the solvent front. It was unclear 
why this should be the case and so all starting materials were either replaced with fresh material or 
the purity confirmed by NMR analysis. The starting phosphonium alkyne (3-butynyl(tris-4-
tertbutylphenyl) phosphonium bromide) showed a small amount of degradation and so the synthesis 
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of this was repeated to ensure the purity of this compound was not affecting the reaction. Having 
carried out the reaction with the new starting material, this appeared to make no difference as the 
CuAAC reaction step was still failing. After repeating the reaction numerous times and having found 
no particular reason as to why the reaction was now failing after having worked well for so long, the 
micro-reactor was re-introduced. For some unknown reason, this appeared to solve the problem and 
the synthesis of [18F]C2tBu was successfully carried out again. The efficiency and reliability of the 
reaction however, seemed to have dropped as the radioactive yields were found to be lower and the 
conversion rates were often as low as 20%. Due to time restrictions by this point in the research and 
that the synthesis was still providing enough activity to carry out both the in vitro and in vivo work, 
an in depth investigation as to why these results have been seen has not yet been carried out.  
Reformulation 
With this tracer beginning to be regularly used in both in vitro and in vivo studies, it was important 
that the tracer was isolated in high radioactivity concentrations. Currently [18F]C2tBu was being 
eluted from the semi-prep HPLC in 80% ethanol. Although this is not a problem when carrying out 
cell assays as the activity will be diluted in the cell media, when going into live subjects the 
concentration of ethanol must be no greater than 10%. This would therefore, need to be diluted 
with saline 8 times which would greatly reduce the activity concentrations and often the small 
animals used for in vivo evaluation can restrict the volume to be injected and hence reducing the 
amount of activity further.  
A solution to this was to introduce a reformulation step. This relies on a solid phase extraction (SPE) 
cartridge to trap the tracer which can then be eluted with small volumes of ethanol and washed with 
saline. The SPE cartridge chosen for this series of compounds was the StrataTM X 33u Universal 
Sorbent.  
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To carry out the reformulation steps, the reaction was performed as normal but instead of collecting 
the HPLC peak directly, this was directed to a vial containing around 20 ml of water. This was then 
transferred through the StrataTM cartridge, trapping the tracer and sending the liquid to waste. 
Ethanol (0.5 ml) was then passed slowly through the cartridge (to elute the tracer) and collected in 
the dose vial and then followed by saline (4.5 ml). This means the tracer is now in a total of 5 ml with 
only 10% of ethanol, allowing it to be directly injected into live subjects. The efficiency of the 
reformulation was found to be above 90%. 
To maintain the fully automated synthesis of the tracers, the set-up had to be modified to allow 
these steps to be carried out. This was done by using the same valve tower as the one used in the 
CuAAC reaction steps. This time argon pressure was used to transfer volumes of liquid to the desired 
place using 3-way valves. A schematic of the valve-tower set-up is shown in Figure 4.20. 
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Figure 4.20: A schematic to show the valve tower set-up for the reformulation step 
This reformulation set-up was used for both [18F]C2tBu and [18F]C2DiMe prior to carrying out animal 
work. Unfortunately it was not as effective for [18F]C2DiMe as a non-radioactive impurity was being 
eluted from the HPLC at the same time and upon addition of the saline precipitated out of solution. 
Due to time constraints, instead of trying to alter the HPLC conditions to try and separate the 
compounds, a filter was used. The 5 ml of cloudy solution which was collected following the 
reformulation was taken-up into a syringe and slowly pushed through a filter cartridge (Agilent Tech, 
polypropylene filter with pore size 0.45 µm, diameter 30 mm). This gave a clear solution and QC 
HPLC demonstrated the purity of the filtered solution. Although this would not be a permanent 
solution to this problem, it allowed the animal work to be carried out on the day and therefore 
reduced the number of unnecessary rat fatalities.  
Ar 
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4.6 Determination of the Specific Activity 
The specific activity of the tracer is important when considering its use in in vivo studies. As stated in 
the introduction, this is currently defined as the radioactivity of a radionuclide divided by the mass 
(or molar amount) of the sum of all radioactive and stable nuclides (present in the same chemical 
and physical form) of the element present.17 In terms of a labelled tracer it is typically quoted as 
GBq/µmol and is the amount of activity divided by the total concentration of the tracer in both its 
radioactive and stable form (e.g. 19F and 18F compound). 
The most common method to measure this is to produce a standard curve using the reference 
compound. Different concentrations of the reference compound were made up and run on a QC 
HPLC and the area under the curve of the UV peak recorded. Once the points had been plotted, a 
line could be fitted and the equation determined. This equation could then be used to determine the 
amount of the compound (µg/ml) present in the radiolabelled sample. An accurate reading of the 
amount of activity present in the sample must also be determined. This has been done by accurately 
pipetting 100 µl of the final tracer solution into a vial and measuring it for radioactivity using an 
ISOMED 2000. 
Once the measurement of activity and the amount of compound present has been determined, 
these values can be used to calculate the specific activity in GBq/µmol. 
The specific activity of [18F]C2 was measured initially to confirm that the tracer was suitable for in 
vitro studies. First, the standard curve had to be recorded with concentrations between 100 and 
0.05 µg/ml. 
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Figure 4.21: Specific activity standard curve for [
18
F]C2 
Each concentration was run through the same QC column (4.6*250 mm Eclipse C18 column) under 
the same conditions, starting with the lowest concentration to avoid cross contamination. The area 
of the peak was recorded and plotted against the concentration (Figure 4.21).  
The next step was carried out following the synthesis of [18F]C2. After confirming the RCP of the 
sample, an accurate measure (100 µl) was pipetted into a separate vial and the activity recorded. 
Using a 100 µl loop size on the HPLC injector, the same amount of sample was run through a column. 
The area under the UV peak (same wavelength to the one used to run the standard curve) relating to 
the tracer was then recorded. The mAU*min value was then put back into the equation (x = y/0.418) 
and the concentration in µg/ml calculated. Using the molecular mass of the compound, the number 
of moles was determined and then the radioactivity measurement used to give the specific activity 
in GBq/µmol. 
The specific activities for a series of measurements for [18F]C2 were found to be 69.3 ± 30.1 
GBq/µmol at the time of QC. These measurements were found to be in a similar range to other 18F 
labelled tracers in literature and were deemed suitable to allow for in vivo analysis.18 The specific 
activity does however depend on the tracers and its in vivo target and therefore could still cause 
issues later in the tracer analysis.  
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With two of the other analogues going forward into in vitro and in vivo studies, the specific activity 
of both [18F]C2tBu and [18F]C2DiMe was also measured. Again, standard curves using the reference 
compounds were created and the same methods used as in [18F]C2, following the radiosynthesis of 
the tracers (Figure 4.22). 
 
Figure 4.22: Specific activity standard curve for [
18
F]C2tBu and [
18
F]C2DiMe 
As it can be seen, there was an increase in UV absorption (230 nm) between the functionalised 
analogues compared to basic C2 compound. This is due to the electron donating ability of the 
functional group increasing the aromaticity of the phenyl rings. 
The specific activities found for both [18F]C2tBu and [18F]C2DiMe were similar to that of [18F]C2, with 
averages being 49.6 ± 6.5 GBq/µmol and 68 ± 18.8 GBq/µmol respectively. As already mentioned, 
these values were suitable to take both tracers into the next stages of analysis. 
4.7 Lipophilicity Study 
Lipophilicity is an important factor that should be considered when designing a tracer that has to 
enter cells and pass through a lipophilic membrane. This section will give a brief introduction and 
discuss the methods to measure it followed by the results obtained.  
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4.7.1 Introduction to Lipophilicity 
Lipophilicity refers to the ability of a compound to dissolve in fats and non-polar solvents. When 
considering a biological system, these refer to lipids and water. The lipophilicity of a compound is 
quantified as a partition coefficient, log P and is calculated by finding the ratio of the concentration 
of the compound present in the organic layer (typically octanol) and the concentration present in an 
aqueous layer. This must be measured once the system has reached equilibrium.19  
Altering the lipophilicity of a compound will have an effect on the uptake and biodistribution in a 
system. When modelled in in vitro and in vivo environments the relationship between the uptake 
and lipophilicity in the brain is found to be different. In an in vitro model there a linear relationship 
between increasing lipophilicity and uptake as there is limited amount of non-specific binding 
observed. In an in vivo model there is found to be a parabolic relationship indicating there is an 
optimum value of lipophilicity and that increasing past this point will result in a decrease in the 
uptake.20 The reason behind this correlation is due to decreased plasma solubility, increased uptake 
by the kidneys and liver and increased non-specific binding. If the lipophilicity is too high the 
compound will preferably sit in the lipid membrane and prevent it from being distributed to target 
sites. 
Log P is the measurement of the lipophilicity of neutral compounds and so when considering a 
charged species this value will be inaccurate. Another way then to measure the lipophilicity is by 
calculating log D. Log D is a distribution coefficient which is dependent on the pH of the system and 
is related to log P through the ionisation constant, pKa. This measures the ratio between the 
equilibrium constants of all species (ionised and non-ionised) in octanol and then the same species 
in an aqueous buffered phase at a given temperature. The log D of a compound will vary according 
to the protogenic nature of the molecule. Log D at pH 7.4 is often quoted to give an indication of the 
lipophilicity of a drug at the pH of blood plasma. 
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pKa and Log P measurements are useful parameters for use in understanding the behaviour of drug 
molecules and are therefore very valuable tools in the pharmaceutical industry. Different ionic 
species of a molecule vary in physical chemical and biological properties and so it is important to be 
able to predict which ionic form of the molecule is present at the site of action. The Partition 
Coefficient is also a very useful parameter which may be used in combination with the pKa to predict 
the distribution (log D) of a drug compound in a biological system. 
It has been established in drug design that the partition coefficient of a proposed drug should be 
below log P = 5 and ideally between log P = 1 and log P = 3 and this is considered to be an optimum 
value to enter the bilayer. 21,22 
4.7.2 Measuring the Lipophilicity 
The most common way of measuring the log P/log D of a molecule is to use a shake-flask 
technique.23 This involves having a flask containing an organic solvent, usually octanol and an 
aqueous buffer solution.24 The drug is then placed in the mixture of the solvents and shaken 
vigorously. The mixture is left to reach equilibrium and the concentration of the compound in each 
phase measured. This is usually done using UV/Vis spectroscopy, gas chromatography or HPLC. The 
log of the ratio of these concentrations gives the partition coefficient, log P. 
         (
                                   
                                           
) 
Equation 4: The equation for the measurement of log P 
The shake-flask technique has many advantages and disadvantages over other methods of log P 
measurement. The main advantages are that the test is very accurate to a broad range of solutes, 
can measure compounds with a log P between -2 to 4 and is fairly quick and easy to carry out.25  
Disadvantages include the fact that the compound must be pure and be soluble in both the octanol 
and aqueous phases. It also requires high purity analytical grade octanol and the water should be 
distilled or double distilled in glass or quartz apparatus. This method can produce unreliable results 
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for ionisable compounds due to it being ionised differently at varying pHs. This means the compound 
would have different polarities depending on its surroundings which would alter its partition 
coefficient. This can be taken into account by calculating the log P value at a range of pH (log D) 
environments and then observing how the lipophilicity of the compound changes. 
Given that the compounds of interest in this research were triazole phosphonium cations, the log D 
was measured so that the lipophilicity value took into consideration its ionised form. This was done 
by using a buffer instead of water as the aqueous phase and in this case the pH adjusted to pH 7.4 as 
this is the physiological pH and is therefore the most relevant when relating lipophilicity to in vitro/in 
vivo testing. In terms of measuring the concentration in each phase, this can be done by simply using 
a Gamma counter as the counts released from the radio-tracers are quantitative. 
The measurements were carried out by following a method by Wilson et al whereby the aqueous 
layer is a 0.02 M phosphate buffer at a pH of 7.4.26 The paper discusses the positive and negative 
factors involved in measuring Log D with simple counting techniques compared to other quantitative 
techniques. One advantage is that it requires very small concentrations and so can eliminates 
artifacts such as molecular association. On the downside, many researchers have reported that 
measurements with radiotracers have large errors and this can be as much as 3 log units below 
other measured values.27 One of the proposed reasons behind these large errors is believed to be 
due to radioactive impurities present and it has been shown that if a radiotracer with a log D of 4 has 
a 0.1% impurity of a radioactive species with a log D of -1 the apparent log D will be 3.26 Wilson et al 
have investigated a method to try and remove this error whereby the radiotracer-containing organic 
phase is washed with the aqueous phase.26 
1-Octanol (10 ml) and phosphate buffer (10 ml) were pipetted into a 50 ml separatory funnel along 
with 40 µl of radiotracer. After hand shaking for about 3 min, the bottom aqueous layer was 
discarded. Three aliquots (2.0 ml) of octanol phase containing the washed radiotracer were pipetted 
into three 12 ml test tubes containing 2.0 ml of phosphate buffer. The test tubes were stoppered, 
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mechanically shaken for 10 min, and centrifuged (5 min, 1000 g). From each tube, approximately 0.2 
ml (x 3) of buffer was transferred into a test tube for counting. The remaining buffer was discarded 
and approximately 0.2 ml (x 3) of octanol phase was also transferred into a separate test tube. The 
samples are then placed into a carrier tray and transferred to an automatic Gamma counter (Perkin 
Elmer Wizard TM 1470) for reading. 
For each tracer, an n of 3 was run and then for each n, the readings on the gamma counter were 
recorded in triplicate. From this data the log D value was calculated using the following equation: 
              [
(                 )
(                )
] 
Equation 4.1: The equation used to calculate log D 
Measuring of the log D value was carried out using this method on all seven novel tracers 
synthesised and the results are summarised in Table 4.2. 
Tracer 
Average Log D 
n=3 (± SD) 
[18F]C2 -0.342 ± 0.003 
[18F]C3 -0.079 ± 0.008 
[18F]C4 0.062 ± 0.010 
[18F]C2Me 1.312 ± 0.055 
[18F]C2OMe 0.678 ± 0.032 
[18F]C2tBu 2.033 ± 0.187 
[18F]C2DiMe 1.827 ± 0.039 
 
Table 4.2: This table shows the log D (pH 7.4) for all seven new tracers 
It can be seen in the table above that upon increasing the number of carbons between the 
phosphorus and the triazole moiety, the log D of the tracer, as expected also increased. The log D 
values for these first three triazoles ([18F]C2/C3/C4) however, were found to be very low with two of 
them having negative readings. It was believed that the triazole moiety must be reducing the 
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lipophilicity. For example, when the groups between [18F]FBnTP and [18F]C2 were compared, it 
demonstrated why the new tracers may have such low log D values. 
 
Figure 4.23: Different functional groups between [
18
F]FBnTP and [
18
F]C2 with predicted log P values from 
ChemDraw Pro 12.0 
Figure 4.23 shows that the log P values provided by ChemDraw Pro 12.0 for the fluorophenyl and 
fluoroethyl triazole groups are 2.19 and 0.17 respectively. As these are only computerised 
predictions based on a three fragment method the values may vary but due to the simple nature of 
the fragments they will be accurate enough to provide a basis into understanding the large change in 
lipophilicities seen. 
With the addition of the functional groups to the three phenyl rings attached to the phosphorus 
atom, the lipophilicity of the overall tracer was increased. In order to get an idea of the effects these 
groups would have on the log D values, the log P of the individual groups was found, again using the 
software ChemDraw Pro 12.0 (Figure 4.24). 
 
Figure 4.24: The different functionalised phenyl rings used to modify the triphenyl phosphine core of the 
[
18
F]C2 analogues 
The values for the different functionalised phenyl rings suggested that there would be a broad range 
of lipophilicities seen for the four tracers and predicted that the methoxy analogue ([18F]C2OMe) 
would lead to the lowest log D value and the tertbutyl analogue ([18F]C2tBu) would produce the 
highest. When this was related back to the figures shown in Table 4.2 it was seen that the results 
were as anticipated and that tracers with a range of log D from 0.68 to 2.03 had been produced, 
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with the order of these tracers in terms of log D directly correlating to the numbers discussed in 
Figure 4.24. 
When taking into account the original design of [18F]C2 and the analogues with increasing carbon 
chain lengths [18F]C3 and [18F]C4, the range of lipophilicities achieved was very broad. By using the 
same synthetic method and set-up, seven different tracers with log D values varying between -0.34 
and 2.03 were achieved.  
4.8 Multiple Probe Synthesis 
With the success of synthesising seven different tracers using the same reaction conditions, it was 
postulated as to whether more than one tracer could be synthesised at the same time within the 
same radiochemical experiment. This would have many advantages over single tracer synthesis as 
not only would it save time and money, it would also allow tracers to be directly compared to each 
other on the same day. This was particularly appealing when considering the amount of cell assays 
being carried out of [18F]C2tBu and [18F]C2DiMe (see Chapter 5). Both tracers could be tested on the 
same batch of cells, eliminating any variability that might have observed between cell passages. The 
two factors that would determine whether this would be possible would be the reaction kinetics of 
the different reactions taking place and also the possibility of separating the tracers via HPLC.  
4.8.1 Two-Probe-One-Pot-Synthesis 
As both [18F]C2tBu and [18F]C2DiMe were the two main tracers undergoing further research, the 
synthesis of the two tracers from the same batch was initially attempted. Equal amounts of both 
starting phosphonium salts bearing the terminal alkyne (0.5 mg) were added into the CuAAC 
reaction mixture and the reaction proceeded as normal. As the semi-prep HPLC conditions and the 
retention times the tracers were already known from carrying out the individual syntheses, similar 
conditions could be used. It was predicted that [18F]C2DiMe would be eluted first given its lower 
lipophilicity, followed by [18F]C2tBu. The mobile phase on the HPLC was therefore set at the same 
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conditions used to elute [18F]C2DiMe (10% to 70% ethanol over 8 min) and once that had been 
collected the ethanol percentage was increased to 80% in order to elute [18F]C2tBu.  
The HPLC radio-chromatogram (Figure 4.25) shows that the synthesis of both [18F]C2tBu and 
[18F]C2DiMe in the same reaction vial was possible and that the HPLC conditions used were suitable 
enough to separate the two peaks. The HPLC also suggests that the reaction kinetics of both 
reactions were comparable as equal amounts of both tracers were synthesised. 
 
Figure 4.25: Semi-prep HPLC radio-chromatogram of the crude mixture from the 2-probe-1-pot synthesis 
The peaks for the two tracers at 9.05 and 12.79 minutes allowed enough time between them to aid 
isolation. The method of collection was manual and so the dose line was transferred by hand 
between vials to collect the different peaks. If time had permitted, this would have been set-up to 
be carried out on the automated system. By introducing another 3-way valve, the HPLC collection 
could be directed to different vials or sent to waste (Figure 4.26). 
Chapter 4 
 
133 
 
 
Figure 4.26: A schematic to show the proposed valve tower set-up for the isolation of two tracers 
As with any tracer, it needs to be radio-chemically pure. Although it has been proven that both 
tracers can be made, the purity of both the samples were tested to confirm that the method of 
separation was also successful. QC HPLC of the samples showed that they both had >99% RCY 
confirming that a viable method to synthesise and isolate two different tracers had been created.  
This method to synthesise [18F]C2tBu and [18F]C2DiMe was carried out on many occasion (>10) with 
the same positive result. Each time, the tracers were isolated in close to equal doses with very high 
RCP. 
4.8.2 Three-Probe-One-Pot-Synthesis 
The success of the two-probe-one-pot-synthesis provided a basis to attempt to produce three 
tracers. This would allow for rapid/comparable lipophilicity measurements and save both user’s time 
as well as [18O]H2O required for irradiation. 
An attempt to synthesise not only the [18F]C2tBu and [18F]C2DiMe tracers but also [18F]C2Me was 
carried out. This time all three starting phosphonium alkynes were placed into the CuAAC reaction 
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mixture (approx. 0.35 mg) and the reaction followed as normal. Starting with the HPLC mobile phase 
condition of the least lipophilic tracer ([18F]C2Me) and then increasing the concentration of ethanol 
allowed the isolation of the three individual tracers. 
 
Figure 4.27: Radioactivity semi-prep HPLC trace of the crude mixture from the 3-probe-1-pot synthesis 
It can be seen from Figure 4.27 that all three tracers (including some unreacted [18F]FEA) were 
present in the crude reaction mixture. Isolation of the three tracers was done manually by 
transferring the dose line by hand between collection vials. In between the collections the line was 
placed into a waste vial to ensure complete flush of the line and avoid cross contamination.  
Although the proportions of each tracer were found to be slightly less compared to the two-probe 
synthesis, all three were collected with sufficient activity needed to carry out any further assays.  
The confirmation of high radiochemical purity (> 98%) of each tracer was demonstrated via QC HPLC 
analysis. 
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This work has shown that three different functionalised 18F labelled phosphonium cations can be 
synthesised in one reaction vial from one 18F labelled precursor. The comparable reaction rates for 
each reaction and then differences in lipophilicity allowed the separation via semi-prep HPLC, to give 
all three tracers with >98 RCP. 
4.9 Synthesis of [11C]Methyltriphenylphosphonium Iodide 
There were numerous reasons why the synthesis of a cabon-11 phosphonium cation was carried out. 
First, it would be beneficial to obtain some comparison data to the 18F analogues and observe 
whether the cellular uptake would be similar. It would also allow for the understanding of the 
chemistry and set-up of 11C labelling, in particular, methylation. Finally, was the synthesis of any of 
the 18F labelled phosphonium tracers to fail, the synthesis of an 11C tracer could be carried out 
quickly and on different equipment, which would result in the cells that would be used in in vitro 
studies still being utilised. 
Due to time restrictions, the simplest known 11C phosphonium cation was chosen. This was 
[11C]methyltriphenylphosphonium iodide ([11C]MeTPP) (Figure 4.28). This compound was originally 
synthesised by Fukuda in 1986 as an agent for evaluation the membrane potential in the heart.28 
Studies have then gone on the show the ability of this tracer to act as a cancer imaging agent.29 
 
Figure 4.28: Structure of [
11
C]MeTPP 
The synthesis of [11C]MeTPP was carried out via the methylation of triphenylphosphine with 
[11C]methyl iodide. Prior to the radiolabelling, the reference compound was used to determine the 
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conditions required for HPLC purification and QC analysis. Once this was done the synthesis of 
[11C]MeTPP was performed using a similar synthesis as that described by Fukuda.28 
Initially the synthesis of 11C-Carbon dioxide was carried out using a Siemens Eclipse cyclotron. Once 
this was successfully delivered to the hot cell, the [11C]CO2 was converted into [
11C]CH3I using an 
automated set-up on a Synthra methyl iodide production system. The steps carried out involved the 
catalytic reduction (H2/Ni) of [
11C]CO2 which gave the [
11C]CH4 intermediate followed by gas phase 
iodination with iodine. Once the synthesis of [11C]CH3I was completed it could then be reacted with 
the triphenylphosphine. 
The precursor triphenylphosphine (30 mg, 0.074 mmol) dissolved in dry toluene (500 µl) was placed 
in a 3 ml glass vial. The [11C]CH3I was passed through the solution containing the precursor at room 
temperature using a helium stream. After delivery of [11C]CH3I, the sealed vessel was heated to 
140°C for 5 min. The reaction mixture was then diluted with approximately 0.5 ml of mobile phase 
and injected onto the semi-prep HPLC column (Agilant Zorbax-SB-C18, 5 µM, 9.4 x 250 mm). HPLC 
purification was performed at a 7 ml/min flow rate with a mobile phase consisting of 35% 
acetonitrile (95% in water) and 65% ammonium formate (50 mM) adjusted to pH 4. The product 
fraction eluting at approximately 5 min corresponding to [11C]MeTPP was collected in a vial 
containing 20 ml of water. A reformulation step was then preformed to elute the tracer in a 
biocompatible solution mixture. The resulting solution was therefore loaded onto a Sep-Pak classic 
C-18 (Waters) and washed with 10 ml of water. [11C]MeTPP was eluted from the cartridge using 1 ml 
of EtOH followed by 4 ml of 0.9% Saline solution and collected into a sterile vial. 
In order to confirm the purity of the tracer, the quality control was performed on a 4.6*250 mm 
Eclipse C18 column with the UV detection at wavelength λ = 254 nm using acetonitrile and a solution 
of AMF (50 mM, pH 4) (34:66) as mobile phase at a flow rate of 2 ml/min. Identity of the 
radiolabelled product was confirmed by co-injection with the unlabelled MeTPP reference standard 
at a retention time of approximately 3.8 minutes. 
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This method allowed for the successful synthesis of [11C]MeTPP with high radiochemical purity and 
with yields suitable to carry out the in vitro assays. No further analysis/characterisation was 
performed on this tracer as only a few simple uptake assays would be carried out. 
4.10 Summary 
A fully automated set-up was designed and implemented to synthesise a library of novel 18F labelled 
phosphonium cations. The Advion NanoTek® LF micro-fluidic system was used to synthesise the well-
known 18F precursor, [18F]fluoroethylazide. Using a valve tower and a mass flow controller, the next 
step which involved a CuAAC reaction was successfully carried out.  
Initially the synthesis of [18F]C2 was carried out and suitable HPLC conditions found to isolate the 
tracer. QC HPLC was then used to confirm the purity. The total synthesis time was less than one hour 
from dose delivery and RCY of around 9% (NDC) and RCP of >99% were achieved.  
Using the same reaction conditions, a further six analogues were synthesised and HPLC conditions 
altered for each to allow for suitable retention times. This demonstrated that the set-up could be 
used to produce a range of 18F labelled triazoles, just by adjusting the alkyne precursor. 
Various modifications to the set-up throughout this research were carried out which involved the 
introduction of a reformulation step. This was also implemented as an automated process which 
enabled the tracer to be isolated in 10% ethanol and was therefore suitable for intravenous 
administration to subjects. Other adjustments also included the removal of the micro-reactor which 
initially resulted in a successful reaction but then later failed due to unknown reasons. Even though 
there were many problems with the reactions following this (reduced conversions and yields), 
enough activity was made to continue the analytical and biological work. 
The specific activity of three of the tracers ([18F]C2, [18F]C2tBu and [18F]C2DiMe) advanced into in 
vivo studies (see Chapter 6), were determined using analytical HPLC. All three tracers were found to 
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have a specific activity ranging between 49 to 70 GBq/µmol which was comparable to many other 18F 
labelled tracers in the literature. 
The lipophilicity measurements for all seven new tracers were carried out using the ‘shake-flask’ 
method by measuring the radioactivity partition between octanol and aqueous buffer. The 
lipophilicity of a tracer is an important parameter when considering the uptake into cells and can 
affect the metabolic pathways and tissue uptake in live subjects. The goal was to design a range of 
tracers with different lipophilicities and observe each tracer’s cellular uptake and for selected 
tracers, progress into in vivo biodistribution studies. The log D measurements ranging from -0.34 and 
2.03 demonstrated that a wide range of lipophilicities were achieved. 
Finally, the research went on to investigate the possibility of synthesising two different tracers in 
one reaction vial. This was proven possible with the synthesis of both [18F]C2tBu and [18F]C2DiMe in 
equal amounts. The differences in lipophilicity made it possible to isolate both tracers in >99 RCP via 
semi-prep HPLC. Given the success of this reaction, an attempt to produce three tracers was carried 
out. Thankfully there was no competition in reaction rates between the three reactions taking place 
and [18F]C2Me, [18F]C2tBu and [18F]C2DiMe were all formed and again isolated successfully.  
4.11 Experimental 
The fully automated synthesis of [18F] labelled phosphonium salts was carried out using the Advion 
NanoTek® platform followed by an in-house developed automated system consisting of a  set of 
valves , a mass flow controller, reactor and a 6-port/2-way HPLC valve. 18O enriched water, >98% 18O 
atom was purchased from Rotem. All other reagents were from Sigma-Aldrich Chemical Co. Semi-
preparative purification of the radiolabelled phosphonium salt was carried out on a HPLC system 
consisting of a Gilson 121 p-p and Gilson 151 UV detector controlled by the Dionex Chromaleon 
software and QC HPLC was performed on a QC Agilent 1100 series (quaternary pump with diode 
array UV detector). NMR spectra were recorded on a Bruker AV 400 MHz spectrometer. ESI mass 
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spectra were recorded on a Micromass LCT Premier spectrometer by either John Barton or Lisa 
Haigh. 
2-Azidoethanol 
Carried out with modifications to a procedure described by Wu et al.5  2-Bromoethanol (5.00 g, 40 
mmol) was added to ice (approx. 100 g) and stirred for 10 min. To this, sodium azide (4.90 g, 60 
mmol) was added slowly over 10 min. The reaction mixture was left to warm to room temperature 
and stirred for 6 hours. Sodium azide (2.90 g, 45 mmol) was added and then the mixture heated to 
80 oC for 18 hours before being cooled to room temperature. The mixture was then extracted with 
diethyl ether (5 x 30 ml) and the organic phase dried over magnesium sulphate. After filtration and 
removal of the solvent, 2-azidoethanol was obtained as a colourless liquid (2.33 g, 67%).  1H NMR 
(CDCl3), δ, 4.46 (t, 
3JHH = 5.2 Hz, 2H, CH2), 4.79 (t, 
3JHH = 5.1 Hz, 2H, CH2) 
2-Azidoethyl-4-tosylate 
Carried out with modifications to a procedure described by Sagai et al.30 2-azidoethanol (2.00 g, 23 
mmol, 1 eq), triethylamine (4.65 g, 46 mmol, 2 eq) in dichloromethane (25 ml) were cooled to 0oC. 
To this 4-toluenesulfonyl chloride (5.47 g, 28.7 mmol, 1.2 eq) was added slowly over 20 min. before 
being stirred at room temperature for 3 hours. The mixture was then washed with HCl (3 M, 3 x 30 
ml) and then brine (3 x 30 ml) before being dried over magnesium sulphate and placed under 
vacuum to remove the solvent. Purification to remove tosyl azide was carried out using flash column 
chromatography on silica gel (2:1 ethyl acetate, petroleum benzene) to give a colourless oil (4.04 g, 
72%).  1H NMR (CDCl3), δ, 2.47 (s, 3H, CH3), 4.50 (t, 
3JHH = 5.1 Hz, 2H, CH2), 4.17 (t, 
3JHH = 5.1 Hz, 2H, 
CH2), 7.39 (d, 
3JHH = 8.1 Hz, 2H, Ar), 7.77 - 7.88 (2H, Ar). MS(CI
+): 242 (M+1) (68), 228 (40), 199 (50), 
155(100). 
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[18F]fluoroethylazide2,16 
Method followed as described by Glaser et al.2 Aqueous [18F]fluoride (approx. 2 ml) was passed 
through a resin cartridge (QMA) where the [18F]fluoride was trapped. It was then eluted using a 
mixture of Kryptofix-222 (5 mg, 14.3 µmol), potassium carbonate (1 mg, 7.2 µmol, dissolved in 50 µl 
water), and acetonitrile (1 ml). The solvent was removed by heating at 120 oC under a stream of 
nitrogen (100 ml/min). Afterwards, acetonitrile (0.5 ml) was added, and the distillation was 
continued (80 oC). After cooling to room temperature, a solution of 2-azidoethyl-4-tosylate (2 µl, 10 
µmol) in acetonitrile (0.5 ml) was added. The reaction mixture was transferred into the micro-
reactor at 80 oC before being released into a vial containing acetonitrile (0.2 ml) or ethanol (0.1 ml). 
CuAAC general reaction conditions for [18F]C2, [18F]C3 and [18F]C4 
The [18F]fluoroethyl azide was distilled directly (in acetonitrile only) into a vial containing a pre-made 
mixture of CuSO4.5H2O (56 μL, 0.4 mM), TBTA (10 mg) and sodium ascorbate (40 mg) in water (100 
μL) and ethanol (50 μL) which had been shaken until all reagents had mixed. To this the 
corresponding phosphonium alkyne (1 mg) in ethanol (50 μL) was added.  Following the distillation 
of [18f]fluoroethyl azide into this vial it was left to mix under helium at room temperature for 10 
minutes. The entire mixture was then transferred into a vial containing water (1 ml), before being 
injected into the semi-preparative HPLC (Eclipse C18 250 x 10 mm). 
Flow rate 7 ml/min, with the mobile phase starting from 10% ethanol and 90% 50 mM dihydrogen 
sodium phosphate buffer (pH=5.5) to 50% ethanol over 7 minutes before becoming isocratic. The 
radioactive peak for unreacted [18F]fluoroethyl azide was found to be at approximately 5 minutes 
and the peaks for [18F]C2, [18F]C4 and [18F]C4 seen were 6.46, 7.38 and 8.23 minutes respectively. All 
three tracers was found to be >99% radiochemically and >95% chemically pure as determined by 
analytical HPLC (4.6 x 250 mm Eclipse C18 column; isocratic 0–6 min 70% 50mM AMF, pH 4/30% 
acetonitrile; gradient 6–15 min: 20% 50 mM AMF, pH 4 /80% acetonitrile, flow rate: 2.0 ml/min). The 
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retention time for [18F]C2, [18F]C3 and [18F]C4 were found to be 6.56, 7.24 and 9.31 minutes 
respectively.   
CuAAC general reaction conditions for functionalised tracers 
The [18F]fluoroethyl azide was distilled directly (in acetonitrile and ethanol (0.1 ml)) into a vial 
containing a pre-made mixture of CuSO4.5H2O (56 μL, 0.4 mM), TBTA (10 mg) and sodium ascorbate 
(40 mg) in water (300 μL) and ethanol (100 μL) which had been shaken until all reagents had mixed. 
To this the corresponding phosphonium alkyne (1 mg) in ethanol (100 μL) was added.  Following the 
distillation of [18f]fluoroethyl azide into this vial it was left to mix under helium at room temperature 
for 10 minutes. The entire mixture was then transferred into a vial containing water (1 ml), before 
being injected into the semi-preparative HPLC (Eclipse C18 250 x 10 mm). 
[18F]C2Me and [18F]C2OMe 
Flow rate 7 ml/min, with the mobile phase starting from 10% ethanol and 90% 50 mM dihydrogen 
sodium phosphate buffer (pH = 5.5) to 50% ethanol over 7 minutes before becoming isocratic. 
Retention times for [18F]C2Me and [18F]C2OMe were 9.06 and 8.40 minutes respectively. 
[18F]C2tBu 
Flow rate 7 ml/min, with the mobile phase starting from 10% ethanol and 90% 50 mM dihydrogen 
sodium phosphate buffer (pH = 5.5) to 80% ethanol over 8 minutes before becoming isocratic. 
Retention time was found to be 9.89 minutes. Reformulation steps, following collection of HPLC 
peak, involved dilution with water (approx. 20 ml) and trapping of tracer on SPE cartridge (StrataTM X 
33u Universal Sorbent). [18F]C2tBu was then eluted with ethanol (0.5 ml) and saline (4.5 ml). 
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[18F]C2DiMe 
Flow rate 7 ml/min, with the mobile phase starting from 10% ethanol and 90% 50 mM dihydrogen 
sodium phosphate buffer (pH = 5.5) to 70% ethanol over 8 minutes before becoming isocratic. 
Retention time was found to be 8.84 minutes. See [18F]C2tBu for reformulation steps. 
[11C]MeTPP 
11C-Carbon dioxide was produced by the 14N(p,α)11C nuclear reaction using a nitrogen gas target 
(containing 1% oxygen) pressurized to 300-350 psi and bombarded with 11 MeV protons using the 
Siemens Eclipse cyclotron. Subsequently, [11C]CO2 was converted into [
11C]MeI by catalytic reduction 
(H2/Ni) which gave the [11C]CH4 intermediate followed by gas phase iodination with iodine. 
Triphenylphosphine (30 mg, 0.074 mmol) dissolved in dry toluene (500 µl) was placed in a 3 ml glass 
vial. The [11C]CH3I was passed through the solution containing the precursor at room temperature 
using a helium stream. After delivery of 11C-CH3I, the sealed vessel was heated to 140°C for 5 min. 
The reaction mixture was then diluted with approximately 0.5 ml of mobile phase and injected onto 
the semi-prep HPLC column (Agilant Zorbax-SB-C18, 5 µM, 9.4 x 250 mm). HPLC purification was 
performed at a 7 ml/min flow rate with a mobile phase consisting of 35% acetonitrile (95% in water) 
and 65% ammonium formate (50 mM) adjusted to pH 4. The product fraction eluting at 
approximately 5 min corresponding to [11C]MeTPP was collected in a vial containing 20 ml of water. 
The resulting solution was loaded onto a Sep-Pak classic C-18 (Waters) and washed with 10 ml of 
water. [11C]MeTPP was eluted from the cartridge using 1 ml of EtOH followed by 4 ml of 0.9% Saline 
solution and collected into a sterile vial. Quality control was performed on a 4.6 x 250 mm Eclipse 
C18 column – UV detection at wavelength λ = 254 nm using acetonitrile and a solution of ammonium 
formate (50 mM pH 4) (34:66) as mobile phase at a flow rate of 2 ml/min. Identity of the 
radiolabelled product was confirmed by co-injection with the unlabelled MeTPP reference standard. 
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5.0 IN VITRO ANALYSIS OF NEW 18F LABELLED PHOSPHONIUM 
CATIONS 
Having successfully synthesised and radiolabelled a library of novel phosphonium cations, the next 
stage was to investigate their suitability to act as imaging agents of apoptosis in cells. In vitro analysis 
of a select few tracers was carried out to determine whether there was a need for further 
investigation. 
Initially, the first stages were to confirm suitable membrane transport into cell and then following 
this, determine whether the accumulation could be altered by inducing apoptosis or altering the 
mitochondrial membrane potential. 
5.1 Introduction to Cells Assays 
When carrying out cell work, the first detail that had to be decided was which cell line to use. The 
cell line of choice depends heavily on what tracer you are trying to test, the targets of the tracer and 
the assays you plan to carry out. For this work, the uptake of the tracer into the cell and inducing 
apoptosis was the main focus. First, to allow for good uptake, a cancerous cell line was chosen as 
they are known to have an increased membrane potential which should facilitate uptake and 
secondly, the cell line must respond to the induction of apoptosis. For these reasons and because 
they are relativity easy to grow, could be translated into xenograph models and have been used in 
other studies with apoptosis targeting probes, 38C13 cells were chosen.1 
38C13 cells are a naïve murine B-lymphoma cell line and were kindly donated by Professor Kristaan 
Thieleman, Vrije Universiteit Brussel, Brussels. 38C13 are a suspension cell line and like all cells 
required passaging after a certain time to fresh media to ensure continued cell growth and good 
viability. To determine at which time point the cells are in an optimum environment for the 
experiment, the point at which they are at a log phase of growth and high viability, a growth study 
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was carried out. This involved calculating the number of both living (viable) and dead cells at certain 
time intervals. 
There are a number of methods that can be used to determine this information. One is to measure 
the cell density spectrophotometrically where the absorbance of the sample is measured in a 
spectrophotometer and then correlated to either the dry weight or the number of cells per volume. 
However this form of determination does not allow an assessment of cell viability. 
Another method that can used to determine both measurements is to count the cells manually 
though a microscope (Nikon Eclipse T5100). The device used for determining the number of cells per 
unit volume of the suspension is called a counting chamber and the most widely used type of 
chamber is called a hemocytometer (Figure 5.1), as it was originally designed for performing blood 
cell counts.  
 
Figure 5.1: Picture and diagram showing components of a hemocytometer. Picture taken from 
http://upload.wikimedia.org and diagram from www.ruf.rice.edu 
2,3
 
Instantly after passaging, the cells (1 ml/well) were placed into a 12-well plate and placed back into 
the humid incubator (370C, 5% CO2). Three wells formed the replicates for each time point and the 
initial cell count (t = 0) was taken at this point. Cells were agitated to disperse aggregates, producing 
a uniform cell suspension before being stained with Trypan-blue. Trypan-blue is a diazo dye that is 
commonly used to selectively colour dead cells and allows the distinction between live and dead 
cells under a microscope.  
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Figure 5.2: diagram to illustrate the counting quadrants in a hemocytometer 
Under a light microscope, the cells (both live and dead) were then counted in the four outer 
quadrants (see Figure 5.2 for illustration) giving the number of cells/mm2 for each one. The average 
of the four readings was calculated and then these numbers used to calculate the cells/ ml and the 
viability.  
In order to calculate the number of cells/ml, the depth of the plate must be take into account 
(0.1mm), the conversion to cm3 (1000 mm3 in 1 cm3 = 1ml) and also the dilution factor involved (x2 
in this case). Therefore, the average number of viable (live) cells in the square was multiplied by 
20,000 to obtain the number of cells per ml. To calculate the viability, both the live and dead cells 
must be counted and then the percentage of live ones to the total number of cells calculated.  
At each time point the samples were measured in triplicate and then the average calculated. The 
two graphs below (see Figure 5.3) show the measurements taken over a period of 96 hours at 
various intervals. 
1mm 
1mm 
Chapter 5 
 
148 
 
0 2 0 4 0 6 0 8 0 1 0 0
0
1 0 0 0 0 0 0
2 0 0 0 0 0 0
3 0 0 0 0 0 0
4 0 0 0 0 0 0
5 0 0 0 0 0 0
6 0 0 0 0 0 0
T im e  f r o m  p a s s a g e  ( h r s )
v
ia
b
le
 c
e
ll
s
/
m
l
0 2 0 4 0 6 0 8 0 1 0 0
0
2 0
4 0
6 0
8 0
1 0 0
T im e  f r o m  p a s s a g e  ( h r s )
%
 v
ia
b
il
it
y
 
Figure 5.3: Cell growth and percentage viability of 38C13 lymphoma cells 
The growth curve above showed the expected shape for a suspension cell closed system study. 
There is an initial lag phase where the growth is slow before an exponential increase in growth rate. 
The cell growth will continue in this phase until one or more of the following factors interfere. These 
are, nutrients becoming limited, oxygen levels become depleted and metabolic byproduct 
accumulation to toxic levels. At a point, around 50 hours in this case, the number of cells becomes 
stationary before lysis sets in and the cells begin to die. It can also be seen that the cells are at their 
highest viability at around 50 hours also. This information showed that the most efficient time to 
carry out cell assays with 38C13 cells was around 48-50 hours after cell passage. 
In order to maintain good cell growth and viability the cell line required the addition of 2-
mercaptoethanol (βME). This is often added to the cell cultures during growth as it is believed to 
exert several effects on murine lymphocytes in culture that might explain its ability to enhance 
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survival and growth of these cells.4 The uptake of the essential amino acid cystine and consequently 
the maintenance of intracellular glutathione levels are enhanced by βME.5 Furthermore, βME (even 
in the disulfide form) causes lymphocytes to release thiols into the culture medium. These effects 
might protect the cells from oxidative damage by acting as an inhibitor/scavenger of reactive oxygen 
species, regulate gene expression and activating enzymes.6,7,8 
 
Figure 5.4: Structure of βME 
A study conducted by Pruett et al was carried out to assess the importance of the antioxidant and 
protein synthesis effects of βME as mentioned.9 It was found that βME increased cystine uptake at 
all concentrations that enhanced growth and survival, but four nonthiol antioxidants that enhanced 
growth and/or survival did not substantially affect cystine uptake or decreased it and also did not 
affect the release of cystine or its products. This demonstrates that antioxidant protection is 
necessary and sufficient for lymphocyte survival. Also that cystine uptake in untreated lymphocytes 
is sufficient to support the protein synthesis needed for survival and limited growth. However, it was 
also noted that concentrations of βME that stimulated maximal growth more than doubled protein 
synthesis as measured at 8 hr. Therefore the portion of the effects of βME not accounted for by 
antioxidant action could be accounted for by enhanced protein synthesis. 
5.2 Uptake Analysis of [18F]C2  
The first assays that were carried out were to observe the uptake of the tracers and [18F]C2 was the 
first to be tested. To determine the accumulation in the 38C13 cell line, different methods of 
measuring could be carried out.  
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Figure 5.5: Chemical structure of [
18
F]C2 
The 38C13 B-cell lymphoma cells were passaged in fresh media in the absence of 2-mercaptoethanol 
and plated in 12-well plates. The plates were then left in an incubator for 48 hours before being used 
in the study. On the assay day, plates were treated with [18F]C2 for 5, 15, 30, 60 or 90 minutes at 
370C (all in triplicate).  
The first method tested to calculate the uptake was via a Brandel Harvester. This is a cell harvester 
which allows the isolation of cell from the media. Unfortunately, the results for this method showed 
that there were no radioactivity counts on the filter paper above the background signal. 
This method of isolating the cells can sometimes lead to the break-down of the cell membrane 
which could result in nothing being trapped by the filter. This would therefore give results that 
would suggest that the tracer has not been retained by the cell.  
To confirm the results seen from this assay, a different method of isolating the cells was tested. The 
cells were treated with the tracer and incubated (30, 60 and 90 minutes). After this time the cells 
(suspended in the media) were transferred into eppendorf tubes and centrifuged (2000 rpm, 5 
minutes). The media was then carefully removed and the cell pellet left behind. Cold buffer was then 
added and the cells resuspended. Again, the cell pellet was isolated via centrifugation and this was 
repeated two times. Finally the cells were resuspended in media and placed in an automated gamma 
counter (Perkin Elmer WizardTM 1470). The activity found in each cell sample could then be related 
back to the administered dose and a % uptake calculated. 
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Figure 5.6: Uptake of [
18
F]C2 in 38C13 cells (n = 3) 
The results shown in Figure 5.6 confirm very little accumulation of [18F]C2 in 38C13 cells and due to 
such a small signal the variability in the results was high. The reason behind the lack of uptake was 
believed to be due to the low lipophilicity of the tracer. The log D was found to be below 0 at -0.341 
(see section 4.7.2). This result was possibly to be expected as the tracer must be lipophilic enough to 
pass through the bilayer and hence the reason why a library of phosphonium cations were prepared. 
5.3 Uptake Analysis of [18F]C2tBu  
In order to try and ensure a good cellular accumulation of a tracer, [18F]C2tBu was chosen to be 
taken into in vitro testing. Initially, the uptake of [18F]C2tBu (structure shown in Figure 5.7) was 
investigated to prove cell uptake and to confirm an optimum incubation time point. 
 
Figure 5.7: Chemical structure of [
18
F]C2tBu 
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The 38C13 cells were prepared in the same way as mentioned for the [18F]C2 assay and incubated 
with the tracer on the day of study at 37 oC for various time periods (5, 15, 30, 60, 90 minutes). The 
graph below (Figure 5.8) showed that upon increasing the incubation time there is a small increase 
in uptake but after 30 minutes the uptake appears to stabilise. 
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Figure 5.8: Uptake of [
18
F]C2tBu in control 38C13 cells 
When this is considered as a percentage uptake of the administered dose 30 minutes post tracer 
addition, the accumulation in the cells was very high. The percentage of tracer that had accumulated 
in the cells was found to be around 40.77 ± 2.24 % of the administered dose. Having carried out a 
literature search the highest uptake seen from similar phosphonium salts is that of [18F]fluorobenzyl 
triphenylphosphonium bromide and is found to be around 17 % of the administered dose.10 
Although this cannot be a direct comparison due to difference in cell lines it suggests very good 
uptake of [18F]C2tBu which should lead to a promising signal drop upon inducing apoptosis.  
5.3.1 Cisplatin Response  
The next study that was carried out was to observe if the uptake could be altered upon the 
treatment with an anti-cancer drug. The anti-cancer drug chosen for this study was cis-
diamminedichloroplatinum(II) or Cisplatin as it is commercially known (Figure 5.9). It is a 
chemotherapy drug commonly used for a range of different forms of cancer. These include 
sarcomas, carcinomas and lymphomas.  
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Figure 5.9: Chemical structure of Cisplatin 
The wide scope of cancer treatments and usage is one of the main reasons behind choosing Cisplatin 
along with its mode of mechanism. Although there is still a lot to be understood about the 
mechanism, it is known however that the primary target of Cisplatin is DNA.11 The reactivity of the 
platinum centre and its ability to undergo hydrolysis is found to be affected by the concentration of 
chloride in the surrounding environment.12 Due to the low concentration of chloride ions compared 
to that found in the blood, Cisplatin is hydrolysed once in the cells. Here, chloride ions are displaced 
to allow the formation of the aquated species which are found to be the reacted forms of the 
drug.12,13 The most predominant one is found to be cis-[Pt(NH3)2(H2O)Cl)]
+ which undergoes reactions 
with a range of molecules present inside the cell, for example; DNA, RNA and proteins (Figure 
5.10).14  
 
Figure 5.10: The major aducts that form between cisplatin and DNA 
Eventually, the reactions will cause the cell to undergo apoptosis causing the cell to die. During the 
stages of apoptosis though, there will be a loss of the mitochondrial membrane potential which will 
be attempted to be observed by measuring the accumulation of the tracer at certain times post 
Cisplatin treatment.  
For the cell assay, 38C13 cells were placed in 12-well plates but this time they were treated with 
Cisplatin (100 µM) at 3 time points (2-4, 20-24 and 44-48 hours) prior to tracer incubation. A control 
with no Cisplatin was also measured. 
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Following exactly the same method as described to determine the uptake of the tracers, the uptake 
response to Cisplatin was measured (Figure 5.11). 
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Figure 5.11: Uptake of [
18
F]C2tBu in 38C13 cells post treatment with Cisplatin (n = 4) 
The tracer was incubated with the control and Cisplatin treated cells for various time periods. It was 
seen from the graph shown in Figure 5.11 that this length of time made little difference to the 
uptake. What can be observed was that the uptake of the tracer was affected by the length of time 
of Cisplatin treatment. After 2-4 hours little change was observed as a percentage of the control but 
after 20-24 hours and 44-48 hours there was a large decrease (around 55% and 90% respectively). 
As Cisplatin induces apoptosis which would eventually lead to lysis of the cells, the decrease 
observed could effectively be due to the fact that there was a huge decrease in cell viability. If there 
were no living cells with intact membranes the probe would not become trapped and would be 
washed away during pellet isolation. In order to ensure the change in uptake was due to the change 
in membrane potential and not due to cell loss, analysis of the protein concentration was carried out 
to calculate the proportion of viable cells. Once the percentage of viable cells was known, the uptake 
(as the percentage of the control) could be modified to allow analysis of suggested decrease due to 
initiation of apoptosis rather than cell death. 
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5.3.2 Protein Correction Assay 
The method of choice used to calculate the proteins in the cell samples is the BCA protein assay. This 
method is based on the original Lowry method optimised in the early 1950s.15 The Thermo Scientific 
Pierce BCA Protein Assay Kit was used to carry out this assay. 
The BCA Protein Assay used combines the well-known reduction of Cu2+ to Cu+ by protein in an 
alkaline medium with the highly sensitive and selective colorimetric detection of the copper cation 
(Cu+) by bicinchoninic acid (Figure 5.12).16 
 
Figure 5.12: Structure of bicinchonic acid 
The first step is the chelation of copper with protein to form a light blue complex. In this reaction, 
known as the biuret reaction, peptides containing three or more amino acid residues form a 
coloured chelate complex with copper ions in an alkaline environment containing sodium potassium 
tartrate. 
In the second step of the colour development reaction, bicinchoninic acid (BCA) reacts with the 
reduced copper cation that was formed in step one. The intense purple-coloured reaction product 
results from the chelation of two molecules of BCA with one Cu ion. The BCA/copper complex is 
water-soluble and exhibits a strong linear absorbance at 562 nm with increasing protein 
concentrations. The BCA reagent is approximately 100 times more sensitive than the pale blue 
colour of the first reaction. 
The reaction that leads to BCA colour formation is strongly influenced by four amino acid residues 
(cysteine, tyrosine, and tryptophan) in the amino acid sequence of the protein. However, unlike the 
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Coomassie dye-binding methods, the universal peptide backbone also contributes to colour 
formation, helping to minimize variability caused by protein compositional differences.17 
Before making up the cell samples, reference samples had to be made up in order to obtain a 
calibration curve. The standards were made up following a protocol of serial dilutions for different 
concentration (0 to 2000 µg/ml) of BSA (bovine serum albumin). The BCA assay was carried out on 
these samples and the absorption at 562 nm plotted against the BSA concentration. The resultant 
absorbance values for the cell samples were then related back to the calibration graph and the 
concentration of protein for that sample found. Once this was carried out for all of the samples, the 
gamma readings for the uptake of the probe could be adjusted so that the concentration of viable 
cells was taken into account. 
Due to the results found in the initial study which showed very little decrease at 2-4 hours and then 
a large drop at 20-24 hours, it was decided that a more valuable time point to try and observe early 
stages of apoptosis would be at around 12 hours. Also, since the incubation time point of the tracer 
makes little difference due to rapid cell uptake, the assay was carried out with only the 30 minute 
incubation time period.  
The 38C13 cells were therefore treated with Cisplatin at 12-14 and 20-24 hours prior to incubation. A 
control with no Cisplatin was also prepared in the same well plate and triplicates for each were set 
up. Once the cell pellets for each sample were isolated and unbound tracer removed, they were 
suspended in buffer before the activity measure in the gamma counter. For carrying out the protein 
assay, 96 well plated were used and each sample was tested with an n = 3 giving 9 readings for each 
data point. 
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Figure 5.13: Uptake of [
18
F]C2tBu in 38C13 cells post Cisplatin treatment as a % of control with and without protein 
correction 
The results (Figure 5.13) have shown that when cell viability was taken into consideration there was 
a slight increase in uptake as a percentage of the control. However an uptake decrease of around 
60% (12-14 hours) and 70% (20-24 hours) was still observed. This result suggested that the uptake of 
[18F]C2tBu could be modified by inducing apoptosis using the common anti-cancer drug, Cisplatin.   
5.3.3 Fluorescence Automated Cell Sorting (FACS) Analysis 
The next experiment was to try and characterise the induced apoptosis in the 38C13 cells and relate 
this to the tracer uptake. A common method used to characterise the level of cellular apoptosis 
observes the activation of caspase-3 (known to be activated in the early stages of apoptosis) in 
conjunction with the loss of integrity of the plasma membrane.1 The method used to quantify these 
signals was Fluorescence-activated cell sorting (FACS). 
FACS is a specialised type of flow cytometry. It provides a method for sorting a heterogeneous 
mixture of biological cells into two or more containers, one cell at a time, based upon the specific 
light scattering and fluorescent characteristics of each cell. It is a useful scientific instrument, as it 
provides fast, objective and quantitative recording of fluorescent signals from individual cells as well 
as physical separation of cells of particular interest.  
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This technique was used recently by Aboagye et al in a very similar study when looking at apoptosis 
using 18F labelled caspase 3/7.1,18 They characterised anti-cancer drug-induced apoptosis via caspase-
3 activation in conjunction with the loss of integrity of the plasma membrane using vital dyes and 
compared this to the cell binding of their labelled caspase. The idea was to use the same method to 
observe the effect of cisplatin on apoptosis/cell death and relate this back to the cellular uptake of 
the phosphonium salt.  
The two fluorescent markers that were used are propidium iodide (PI) and a fluorescent inhibitor of 
caspase-3/7 (FLICA). The 38C13 were treated with cisplatin at the same time frames as used in the 
uptake study and then the dyes introduced. Depending on the stage the cell is in will determine 
which dye, if any, is taken up. As PI depends on the membrane being compromised, this will show up 
in cells that are either in late stages of apoptosis or are dead. FLICA on the other hand will be 
present during early and late stages of apoptosis as this is when there will be caspase present. 
The method starts by introducing the cell suspension into the centre of a narrow, rapidly flowing 
stream of liquid. The flow is arranged so that there is a large separation between cells relative to 
their diameter. A vibrating mechanism causes the stream of cells to break into individual droplets 
(Figure 5.14). The system is adjusted so that there is a low probability of more than one cell per 
droplet.  
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Figure 5.14: Diagram illustrating the components of a flow cytometer. Picture taken from www.Invitrogen.com
19
 
Just before the stream breaks into droplets, the flow passes through a fluorescence measuring 
station where the fluorescent character of interest of each cell is measured. An electrical charging 
ring is placed just at the point where the stream breaks into droplets.  
A charge is placed on the ring, based on the immediately-prior fluorescence intensity measurement, 
and the opposite charge is trapped on the droplet as it breaks from the stream. The charged droplets 
then fall through an electrostatic deflection system that diverts droplets into containers based upon 
their charge.  
Initially, the reading is carried out on the cells without the fluorescent dyes added and relies on two 
parameters (Figure 5.15). The first is forward scattering (FSC) and is where the light is scattered in a 
forward direction along the same axis as the laser. The intensity of this signal has been related to cell 
size and refractive index (cell permeability). Cells and the suspending medium show a different 
refractive index otherwise cells would not scatter incident light. This difference is partially 
maintained by an intact membrane functioning as a permeability barrier to water and solutes. Cells 
with a damaged membrane produce smaller forward scatter signals due to a lower refractive index. 
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The side scatter (SSC) is a measurement of mostly refracted and reflected light that occurs at any 
interface within the cell where there is a change in refractive index. The scattered light is detected in 
the direction approximately perpendicular to the laser beam axis by a collection lens and is then 
redirected by a beam splitter to the appropriate detector. Side-scattered light is proportional to cell 
granularity or internal complexity.  
 
Figure 5.15: Diagram to show FSC and SSC and the translation of these to quantitative data sets. Modified from 
Invitrogen.com
19
 
When FSC and SSC are plotted against each other, regions can be gated to isolate a subset of cells on 
the plot. This allows the ability to look at parameters for only that subset of cells. The charts plotted 
below shown in Figure 5.16 have been analysed and the area of interest gated and labelled P1. This 
area shows the population of cells that are classed as viable. These have a high FSC indicating they 
have an intact membrane and low SSC due to little cell granularity. Subcellular debris and clumps can 
be distinguished from the single cells as they are found to have a very low FSC and dead cells also 
due to them having low FSC but high SSC.  
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Figure 5.16: Flow cytometry data upon treatment with Cisplatin at 24 and 48 hours 
In the control it can be seen that there is a large population of viable cells (shown in green) and that 
upon treatment of Cisplatin this number decreases with increasing treatment time. By 48 hours 
there is seen to be literally no viable population. 
As mentioned early, fluorescent biomarkers can be added and then the cells sorted depending on 
whether the markers are present in that particular cell. The two makers that were used for this study 
were PI and FLICA. By combining these two markers different stages of cell death can be 
determined.  
Again the cells were treated with Cisplatin at both 24 and 48 hours and compared against a control 
set of cells. The results are shown below (Figure 5.17) and in the control data the area shown in red 
is the viable population which are negative for both PI and FLICA. The x-axis shows increasing FLICA 
presence and the y-axis increasing PI. 
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Figure 5.17: FACS analysis data upon treatment with Cisplatin at 24 and 48 hours 
From the control data, it can be seen that there are two populations present. The red one being the 
viable population and the black region showing cells naturally undergoing necrosis (PI positive and 
FLICA negative). Once treated with Cisplatin for 24 hours there is a shift in these regions resulting in 
three more distinct areas. These are shown more clearly in Figure 5.18, where the areas have been 
gated and colour adjusted. 
 
Figure 5.18: FACS analysis data with gating upon treatment with Cisplatin at 24 hours 
 A viable population still remains and cells undergoing necrosis still present (dark blue and yellow 
regions respectively). There is also a region of positive FLICA suggesting cells currently in early stages 
of apoptosis (purple). Above this is an area whereby the cells show signs of both PI and FLICA 
present which indicates late stages of apoptosis (green). The final region shows cells with a very high 
presence of PI and also FLICA which is taken to be cells that are non-viable (light blue).  
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At 48 hours, it can be seen that most of the cells are dead with a small proportion in late stage 
apoptosis. 
As this is a quantitative technique, this data can be displayed as a graph showing percentage cell 
population in each region (Figure 5.19). The regions have been renamed depending on what the 
regions stand for in order for the data to be more easily understood.  
 
Figure 5.19: Quantitative analysis of FACS data in 38C13 cells undergoing treatment-induced apoptosis 
By analysing the data shown in Figure 5.19 (which also includes a 2 hour time point) it was clear that 
the early stages of apoptosis were only present in the cells that were treated with Cisplatin for 24 
hours. After 2 hours the Cisplatin appeared to have not had enough time to initiate apoptosis and by 
48 hours most of the cells are non-viable.  
This data confirmed why little uptake of [18F]C2tBu in the 38C13 cell was seen after being treated 
with Cisplatin for 48 hours and why there was no difference seen between the control and the cells 
treated for 2 hours (see section 5.3.1).  It does however show that there are both early and late 
stages of apoptosis occurring 24 hours post treatment which could be owing to the signal drop seen 
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in the cellular uptake assays at this time. Unfortunately the number of non-viable cells could also be 
responsible for the drop in signal which would mean the drop in accumulation could be due to the 
total loss of the plasma membrane integrity.  
What has been determined was that upon inducing apoptosis into a cancer cell line, a decrease in 
accumulation of the tracer was seen. If these results could be translated into tumour models, 
determination as to whether a drug has induced apoptosis should be possible with this tracer. 
5.3.4 Uncoupling the Mitochondrial Membrane Potential 
Unlike Cisplatin that causes apoptosis, there are compounds that can alter the membrane potential 
whilst still maintaining the function of the cell. One compound that has been used in literature to do 
this is carbonyl cyanide m-chlorophenylhydrazone (CCCP) shown in Figure 5.20. CCCP is an uncoupler 
of oxidative phosphorylation and can lead to the destruction of living cells.20 With intact 
mitochondria, CCCP enters in the protonated form, discharging the pH gradient, and then promptly 
leaves as the anion, destroying the membrane potential.21,22 The process can be repeated, which 
means that a tiny amount of CCCP can catalyse the movement of huge numbers of protons, and 
short-circuit the respiratory chain.  
 
Figure 5.20: Structure of carbonyl cyanide m-chlorophenyl hydrazone (CCCP) 
Unlike Cisplatin used in the previous study, it has been shown that CCCP can interrupt the 
membrane potential without causing initial cell death (concentration dependent).23 To confirm this, 
a cell assay whereby a cell count and viability were measurement in cells treated with various 
concentrations of CCCP (incubation time with CCCP for 30 minutes where n = 3) was carried out. 
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Figure 5.21: A graph to show viable cells/ml and percentage in 38C13 viability against CCCP concentration 
The data in Figure 5.21 showed that upon treatment with CCCP the number of viable cells actually 
increases slightly and the percentage cell viability was only compromised by a small percentage (< 15 
%). This means that if there was a decrease in the uptake of the tracer, this was not due to decrease 
in cell count. 
The cell assay to observe the effects of CCCP was carried out with a similar method to that used for 
the Cisplatin treatment. Cells were placed into 12-well plates, 48 hours prior to the assay and then 
various concentrations (1, 5, 50 and 100 µM) of CCCP (dissolved in minimum amounts of DMSO and 
then diluted with buffer) were added at either 30 or 10 minutes before tracer addition (data shown 
in Figure 5.22). 
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Figure 5.22: Uptake of [
18
F]C2tBu post treatment with CCCP 
First, it could be seen that the incubation time of CCCP has only a small effect (5.8-20.2%) on the 
uptake of the tracer at all concentrations. The general trend also showed that upon increasing the 
concentration a decrease in uptake was observed. The result seen from the 5 µM data suggested 
that a dilution error had occurred and this would hopefully be corrected on repeat of the study.  
These preliminary data imply that the uptake of the tracer was dependent on the mitochondrial 
membrane potential and therefore has the potential to be a biomarker in processes whereby the 
membrane potential is compromised (for example, apoptosis).  
As this data was only carried out with an n = 1, repeats were needed to be carried out to confirm the 
result. A second cell batch was seeded and after an appropriate number of passages the cells were 
used to repeat the CCCP assay.  
In order to see if an even higher concentration of CCCP could push the percentage decrease further, 
1000 µM was introduced. The various treatment concentrations tested were now 1, 10, 100 and 
1000 µM. This time, due to no significant differences seen between the 10 min and 30 min 
incubation time, only the 30 minute incubation time was considered.  
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Figure 5.23: Uptake of [
18
F]C2tBu 30 minute post CCCP treatment (n = 4) 
The uptake experiment was repeated with an n of 4 and the results in Figure 5.23 show a very 
consistent set of data. This time there was no significant decrease in the uptake of [18F]C2tBu seen 
post the CCCP treatment up to 100 µM. There is a trend of increased uptake at 100 µM but this was 
not significant.  It was also unclear as to whether the drop of around 60% upon treatment with 1000 
µM CCCP could be classed as a true value. Concentrations of CCCP administered to cells above 100 
µM had not been tested in literature and so it was uncertain as to what effect this would have on 
the cell and its metabolism. A BCA protein assay was carried out on these samples and the data 
protein corrected (see Figure 5.24). Post correction, the decrease in uptake seen at 1000 µM is 
reversed. 
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Figure 5.24: Uptake of [
18
F]C2tBu 30 minute post CCCP treatment (n = 4) 
Figure 5.24 shows the uptake of [18F]C2tBu after correction for protein concentration compared with 
the original uptake data. For the lower concentrations (1 and 10 µM) there was no longer an 
increase in uptake seen compared to the control. Instead a small decrease of accumulation (10-13%) 
was observed but not as significant as seen in the data when this assay was first carried out (35-
50%). The protein correction for this data did show that the drop seen after treatment with 1000 µM 
was due to the decrease in protein present, implying that the CCCP has caused cell death.  
Given that CCCP did not alter the uptake of [18F]C2tBu, further experiments were carried out in order 
to ascertain whether this was due to the tracer not being sensitive to changes in mitochondrial 
membrane potential or whether the CCCP treatment was ineffective in this cell line. The first idea 
was to take a well-known phosphonium cation and compare the uptake and response to CCCP 
treatment with that of the [18F]C2tBu. The compound chosen to carry out this comparison was 
methyltriphenylphosphonium iodide ([11C]MeTPP). The main reason behind this decision was that 
the starting materials and reference compound were easily obtainable and the labelling step used 
the well know methyl iodide method. [11C]MeTPP had also been reported to show a response to 
CCCP.24 
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5.4 Testing with Other Imaging Agents 
5.4.1 [11C]Methyltriphenylphosphonium Iodide 
 [11C]Methyltriphenylphosphonium iodide ([11C]MeTPP shown in Figure 5.25) was successfully 
synthesised from carbon-11 methyl iodide and triphenyl phosphine in dry toluene.25 
 
Figure 5.25: Structure of [
11
C]MeTPP 
First, the uptake of this compound was measured in 38C13 cells after varying incubation times. As 
this is a literature compound an idea of the expected uptake is known. Cheng et al described in 
literature a mass spectrometry method which was used to determine the uptake of a library of 
phosphonium cations.26 A rat glioma (brain) C6 cell line was used and the ability of the cations to 
accumulate in cells measured using MALDI-MS-TOF. They found that the accumulation after 90 
minutes of incubation was around 1%. This is found to be low when compared to something like 4-
ﬂuorophenyltriphenyl phosphonium (FTPP) which has an uptake of closer to 9%.26 Even though it is a 
completely different cell type being used in this assay, this data suggests that low uptake into the 
38C13 cell line will be observed. 
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Figure 5.26: Uptake of [
11
C]MeTPP in 38C13 cells (n = 3) 
As shown Figure 5.26, the accumulation appeared to increase with a linear trend. The shorter half-
life of carbon-11 meant that longer incubation times were not possible as the signal to noise ratio 
would become too high. As expected, the overall accumulation in the cells was low with uptake 
reaching around 2% after 80 minutes of incubation. This value was low when compared to the 
uptake seen for [18F]C2tBu which was found to be around 40%. This could be due to the differences 
in lipophilicity of the two probes. 
The next step was to see how the uptake of [11C]MeTPP was affected when the cells were treated 
with varying concentrations of CCCP. As discussed previously, 38C13 cells were placed into 12-well 
plates 48 hours prior to the cell assay. [11C]MeTPP was then added to all wells and incubated for 30 
minutes. After this time, CCCP (dissolved in DMSO so that the total percentage of DMSO is less than 
1%) was added and then incubated for a further 30 minutes. Once the cells had been isolated the 
activity was measured. 
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Figure 5.27: Uptake of [
11
C]MeTPP post treatment with CCCP (n = 4) 
Figure 5.27 showed the average results for the percentage uptake against the control (no CCCP 
added). As seen with the results obtained for [18F]C2tBu, CCCP did not significantly alter the cellular 
uptake of [11C]MeTPP. There was a small decrease after treatment with 1 and 10 µM (12% and 
22.5% respectively). After treatment with 100 µM however, an increase compared to the control 
was seen. 
In order to see if cell concentration and viability were affecting the results, a protein correction assay 
was carried out (Figure 5.28).  
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Figure 5.28: Uptake of [
11
C]MeTPP in 38C13 post CCCP treatment (n = 1) 
A drop in accumulation post protein correction was seen for 1 and 10 µM, albeit not to the extent 
expected and reported in the literature.24 Meanwhile 100 µM showed a small increase on the non-
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corrected value and 1000 µM showed a very large increase. The result seen for the 1000 µM 
treatment suggested that upon increasing the concentration above 100 µM, the accumulation of the 
probes was enhanced. This could possibly be due to either the accuracy of the protein correction 
assay as very low concentrations of protein were found and therefore the variance in the readings 
became greater or that the cells were being put under some form of oxidative stress which would be 
increasing the membrane potential.  
CCCP has previously been reported to significantly alter the mitochondrial membrane potential, 
reducing [11C]MeTPP uptake in a cellular assay.27,24 However, this data supports a blunted response 
of 38C13 cells to CCCP. To confirm this, the cell lines response was investigated further using an 
alternative imaging technique. The main reasons for doing this were to reduce the exposure to 
radiation, save synthesis time and reduce the amount of expensive resources used. 
5.4.2 Testing with Rhodamine-123  
One of the most common labels used in mitochondrial imaging is rhodamine-123 (RH-123). It has 
been proven to be selectively taken-up into the mitochondria, dependent on the membrane 
potential.28 Like the phosphonium cations used in this project, RH-123 is also classed as a delocalised 
lipophilic cation due to the ability of the positive charge on the xanthene to delocalise through the 
conjugated backbone. It is part of the rhodamine family which all act as fluorescent dyes (Figure 
5.29).  
 
Figure 5.29: Structure of Rhodamine-123 
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In order to use RH-123 to show the effect of CCCP on the mitochondrial membrane potential, a 
fluorescence assay had to be devised. Two methods were considered, the first one was to use FACS 
analysis and the second to use a similar set up to the protein correction assay and use the FLUOSTAR 
OPIMA plate reader and the fluorescence signal in each well. The availability and high throughput 
nature of the second method meant that this was tested first. 
Initially the assay needed to be optimised.  The suitability of the equipment was investigated as to 
whether it had the correct wavelengths to support the emission and excitation profiles of RH-123 
had to be carried out. The machine however, did not have the correct filters for the exact 
wavelengths (Ex/Em = 503/527 nm) but it did however have some close (Ex/Em = 490/520 nm) 
which could capture enough of the signal to provide the data required. In order to test this, different 
concentrations of RH-123 (1, 20, 50, 100 nM) were made up in DMSO (the concentrations are stated 
as if 10 µL of the RH-123 solution was added to the 1 mL of cells) and then placed into a black 96 
well plate and the absorbance measured on the plate reader. These concentrations were chosen as 
they have already been proven to show no cytotoxicity of effect on the cell metabolism.29 The results 
showed that a signal was present but in the concentrations used, the signal saturated or was close to 
saturation.  
As the concentration of RH-123 following the incubation in the cells would be different these 
concentrations were still used. 38C13 cells were placed into 12-well plates 48 hours prior to the cell 
assay. On the day of the assay, various concentrations of RH-123 were added (10 µL) to the cells and 
placed back in the incubator for either 10 or 30 minutes. The isolation of the cell pellet was carried 
out in exactly the same way as described for the previous experiments and aliquots were taken and 
placed into 96-well plates. These aliquots were either added as 10, 50 or 100 µL and then one set 
was diluted so that the total volume was 100 µL.  
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Figure 5.30: 38C13 uptake of various concentrations of RH-123 as a function of fluorescence intensity at 2 incubation 
times with varying dilution factors 
As it can be seen from the graph shown in Figure 5.30, the signal was now within the detection 
range of the equipment. The 10 minute results with no dilution (green) at lower concentrations 
produced a very low signal and were therefore not used. The 30 minute incubation with no dilution 
(red) also produced inconsistent results as the 10 µL aliquot amount seemed to produce a similar 
signal regardless of the concentration added. Due to signal strength it was therefore decided that 
the 100 nM RH-123 would be incubated with the cells for 30 minutes and then 100 µL (blue) of the 
final cell mixture (after isolation and washing) would be placed into each of the 96-wells. 
Now that the conditions for the assay had been optimised, the next stage was to investigate the 
response of RH-123 following treatment of the 38C13 cells with CCCP. The upper concentration of 
CCCP (1000 µM) would no longer be tested due to uncertain effects on the cells but lower 
concentrations were added (20 and 50 µM). The assay was carried out via the same method as used 
for the radiotracers. 10 µL of CCCP (various concentrations) and 100 nM RH-123 (both in DMSO) 
were added to the cells and then incubated for 30 minutes. Once the cell pellets had been isolated 
and washed, the pellet was resuspended into buffer and then 100 µL placed in triplicates into 96-
well plates.  
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The cells with no CCCP added act as the control and then the measurement of the signal from the 
cells treated with the CCCP compared to this as a percentage. Each concentration was carried out as 
an n = 3 and then each was triplicated for the fluorescence measurement (Figure 5.31). 
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Figure 5.31: Uptake of RH-123 in 38C13 cells post treatment with CCCP (n = 3) 
The results again showed a lack of response to uptake after treatment with CCCP as all 
concentrations appeared to give a similar uptake of RH-123 as the control, supporting that cells that 
were not responding to the treatment of CCCP rather than it being the tracer’s lack of dependency 
on the mitochondrial membrane potential alteration. 
In order to confirm that this response was still seen when the number of cells and the viability were 
taken into consideration, a protein correction assay was carried out. Using the BCA assay method as 
before, the protein concentration of each sample was determined and the signals amended for 
these values.  
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Figure 5.32: Uptake of RH-123 post treatment with CCCP (n = 3) 
The results of the uptake of RH-123 following protein correction are shown in Figure 5.32 and were 
compared to the results seen without the correction. It was seen that there was a significant 
difference in the values. When taking the protein concentration into account there was a large drop 
in uptake as a percentage of control for all CCCP concentrations. The accumulation in the cells 
dropped by 27% following treatment with 1 µM CCCP and then by 65% and 71% for 10 and 20 µM 
respectively. The uptake remained constant at 50 µM and then increased slightly for 100 µM treated 
cells.  
Although these results look sensible and comparable to that seen in the literature.10 However, on 
closer inspection of the values for the protein assay it can be seen that there was twice as much 
protein present following treatment of 100 µM CCCP than that of the control. CCCP was a coloured 
compound and from observing the cells after treatment appeared to stain the cells. Could the colour 
be interfering with the protein assay as this relied on the absorbance of light at a certain 
wavelength? If this was the case, could Rhodamine-123, a fluorescent dye also be influencing the 
results seen following protein correction? 
One way to conclude if these concerns were true was to perform a protein assay and add both CCCP 
and RH-123 to a standard bovine serum albumin protein sample. A protein sample known to lie 
within the range of the protein collaboration curve was placed in a 96-well plate and then 10 µL of 
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varying concentrations of CCCP added. RH-123 (100 nM) was added to one set of the CCCP treated 
protein. After 30 minutes of incubation time to allow for the BCA assay to develop, the plate was 
placed in the plate reader (results are shown in Figure 5.33).   
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Figure 5.33: Protein assay to test the influence of CCCP and RH-123 on the outcome of the protein concentration result 
The results showed that the addition of CCCP and RH-123, did not interfere with the protein assay. A 
small increase was seen when both high concentrations of CCCP and RH-123 was added but this was 
not significant enough to result in doubling the protein concentration signal. Having proven that 
there was no interference in the protein assay from either of the compounds that are added the 
answer to why the protein concentration increases with the addition of CCCP was still unknown. 
5.5 Was Phenol Red the Problem? 
Finally the only other difference that can be seen between the first set of data (n = 1 CCCP 
treatment, Figure 5.22) and the various resulted repeats was the presence of phenol red in the 
media. Phenol red (Figure 5.34) is a pH indicator and is often used in cellular biology.  
 
Figure 5.34: Chemical structure of phenol red 
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In many cell cultures this should make little or no difference to the cells. However phenol red has 
been suggested to have an effect on cell lines which have a sensitivity towards oestrogen.30 This is 
because phenol red is a weak mimic of the hormone which plays an important role in growth and 
terminal differentiation of mammary glands.31 Węsierska-Gądek et al reported that phenol red 
‘reduced the therapeutic effect of the drug (roscovitine) on MCF-7 (human breast cancer) cells. Its 
anti-apoptotic and proliferation-enhancing action reduced the levels of cell cycle arrest and 
apoptosis’.31 Although this produced a good rationale behind the results, upon repeating the data no 
difference in data was seen.  
Having carried out an extensive investigation as to why there was a little or no change in the uptake 
of [18F]C2tBu and [11C]MeTPP seen 38C13 cells following the treatment with the membrane 
uncoupler CCCP, a definitive answer is still unknown.  The cellular response to CCCP may be blunted, 
however further investigations into the cellular mechanisms were considered outside the scope of 
this thesis.  
The consistent decrease seen in the uptake of [18F]C2tBu in 38C13 cells after Cisplatin treatment and 
the correlation of this will the appropriate cellular biology by FACS analysis support the on-going 
investigation of this tracer.    
5.6 The in vitro Testing of Other Analogues 
The next stage was to test some of the other analogues that had been synthesised and investigate 
their differences and suitability to act as an imaging tracer.  
5.6.1 Uptake of [18F]C2Me and [18F]C2DiMe 
Having measured the uptake of both [18F]C2 and [18F]C2tBu in 38C13 cells, it was discovered that 
very different accumulation percentages were seen (0.2% and 40% respectively). Given that the two 
tracers that were initially tested had either the highest or the lowest lipophilicities measured, it was 
decided that the uptake of two other tracers would be measured. The two that were chosen were, 
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[18F]C2Me and [18F]C2DiMe (Figure 5.35) which were found to have a log D of 1.312 and 1.827 
respectively.  
 
Figure 5.35: Structures of [
18
F]C2Me and [
18
F]C2DiMe 
Three time points were chosen for the incubation period and each reading carried out in triplicate 
with an independent n = 3. The results of both uptake assays are shown in Figure 5.36. 
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Figure 5.36: Uptake of [
18
F]C2Me and [
18
F]C2DiMe in 38C13 cells (n= 3) 
It could be seen that a higher uptake was observed for the di-methyl derivative, which was expected 
due to the increase in lipophilicity. 
These results however, left the question as to why [18F]C2tBu had a much higher accumulation in 
38C13 cell over other analogues in the series, including one with a fairly similar log D value. The fact 
that these experiments were carried out on a different cell batch was addressed by utilising the two-
probe-one-pot-synthesis. Both [18F]C2tBu and [18F]C2DiMe could be synthesised on the same day 
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and therefore directly compared on the same batch and passage of cells. This did not alter the 
results and a 10 fold increase of the accumulation of [18F]C2tBu was seen over [18F]C2DiMe. With the 
elimination of the cells as being a factor in affecting the results, the tracer must be the cause. 
One theory that was considered was whether the bulky tert-butyl groups were binding directly to 
the plasma membrane. Alternatively, were the bulky groups aiding the transport across the 
membrane (passively or actively) and potentially into the mitochondria? If the data measured from 
the Cisplatin assay were reconsidered, it made the second theory more likely. This would be 
because, if [18F]C2tBu was adhering to the membrane, after inducing apoptosis the drop in signal 
would be less likely as this would remain unchanged. If the tracer was in fact inside the cell or the 
mitochondria, when inducing apoptosis and therefore reducing the membrane potential and making 
the membrane become more permeable the drop in accumulation seen would be expected. 
One future experiment that could be carried out to see the effect of the tert-butyl groups have 
would be to modify the [11C]Methyltriphenylphosphonium iodide tracer. By functionalising the 
phenyl rings on the methyl C-11 tracer with additional tert-butyl groups and repeating the uptake 
study, the effect may be seen. If the uptake was greatly increased it would confirm that the groups 
are responsible for the significant difference in uptake.  
5.6.2 Direct comparison of [18F]C2tBu and [18F]C2DiMe in Cisplatin treated 38C13cells 
The uptake of both [18F]C2tBu and [18F]C2DiMe following treatment with Cisplatin was investigated. 
Even though the initial uptake of the tracers was so different, would the drop seen following 24 hour 
treatment with 100 µM Cisplatin be similar? Both tracers were synthesised using the one-pot 
method, so that the results could be directly compared using the same cells and the protein 
correction assay. Again, each result was carried out in triplicate with an independent n of 3. The 
results found are shown in Figure 5.37. 
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Figure 5.37: The uptake of [
18
F]C2tBu and [
18
F]C2DiMe  in 38C13 cells post Cisplatin with protein correction (n = 3) 
As it can be seen in Figure 5.37, both tracers respond to the induction of apoptosis as a drop in 
accumulation was seen post Cisplatin treatment. Although there was a lower accumulation seen for 
[18F]C2DiMe, the percentage drop seen from the control post Cisplatin treatment were consistent to 
that seen for [18F]C2tBu. These results showed that although both tracers have very different initial 
accumulation in the cells they could both be used to illustrate the initiation of apoptosis following 
Cisplatin treatment by providing a large drop in signal. 
5.7 Dose Dependent Uptake 
In order to understand why there was such a difference in uptake between [18F]C2tBu and 
[18F]C2DiMe in 38C13 cells and whether the uptake might be facilitated, a dilution study was carried 
out. The uptake of both [18F]C2tBu and [18F]C2DiMe in three different dilution concentrations (non, 
1:10 and 1:100) were measured to check for a mass-dose effect.  
Both tracers were synthesised in the same reaction vial and were obtained in very similar quantities 
(MBq/ml). From previous specific activity measurements, it is known that both tracers have similar 
values and therefore should allow for a close comparison. 
Chapter 5 
 
182 
 
N
o
n
1 :
1 0
1 :
1 0
0
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
D ilu t io n  fa c t o r
N
o
rm
a
li
s
e
d
 u
p
ta
k
e
[
1 8
F ]C 2 t B u
[
1 8
F ]C 2 D iM e
 
Figure 5.38: The uptake of [
18
F]C2tBu and [
18
F]C2DiMe in 38C13 cells expressed as a normalised uptake (% control) 
The data in Figure 5.38 suggested that there was a trend on the uptake of both tracers with respect 
to mass dose concentrations.  The uptake for [18F]C2DiMe appeared to have a greater dependency 
than [18F]C2tBu with nearly twice the amount of activity enters the cell with a 1:100 dilution. The 
fact that a dose dependency is seen for the tracer uptake, may suggest either active/facilitated 
uptake or to membrane potential dependent uptake.  
5.8 The Testing of Other Cell Lines 
To further the understanding of the uptake of the tracers and due to the blunted response of 38C13 
cells to CCCP, two different cell lines were then investigated and the results compared to the 38C13 
cells.  
5.8.1 Ramos Cells 
For a more translational approach a human cell line was investigated. Ramos cells are a B lymphoma 
from a white Caucasian male and are also suspension cells. They were chosen to be a human cell line 
comparison to the 38C13 cells. Initially the cell count and viability percentage was measured for the 
cells (Sigma-Aldrich, UK).  
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Figure 5.39: Cell growth and percentage viability of Ramos human lymphoma cells 
It can be seen from the graphs shown in Figure 5.39, that the Ramos cells appeared more sensitive 
to the environmental conditions. For cell growth there was a very narrow window whereby it 
reached the maximum before rapidly decreasing. Extra care was needed to maintain the right length 
of time in between passages to avoid huge loss of cell population. The viability of the cell was also 
found to decrease dramatically at this point. The optimum time from passaging to use of the cells 
was around 50 hours and so as with the 38C13, passaging would be carried out every 2 days and the 
cells were plated 48-50 hours prior to cell assays. 
The first assay measured the uptake of [18F]C2tBu. The accumulation after a 30 minute incubation 
time period was 57.93 ± 5.36 % of administered dose. Similar to the 38C13 cell line, this is a lot 
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higher than other similar tracers in the literature and enables a very good signal prior to initiating 
apoptosis. 
The Ramos cells, like the 38C13 ones were also used to look at the response of [18F]C2tBu uptake 
following Cisplatin treatment. The cells were therefore treated with 100 µM of Cisplatin at around 
12-14 and 20-24 hours prior to ligand addition. The accumulation was calculated as the percentage 
of the control.  
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Figure 5.40: Uptake of [
18
F]C2tBu in Ramos cells post Cisplatin treatment (n = 3) 
It can be seen from the results shown in Figure 5.40 that upon treatment with the Cisplatin for two 
different time periods there is only a very small decrease in accumulation (< 20%). This is very low 
and not consistient with the results seen with the 38C13 cell line. Following these results it was 
found that Ramos cells are resistant to Cisplatin and therefore this agent does not cause an 
induction of apoptosis.32 Goulelet et al looked into a range of haematological cancer cells and their 
resistance to varying anticancer drugs. They found that the percentage of cell proliferation of Ramos 
cells within 48 hrs of being treated with Cisplatin was 90%, indicating that no apoptosis has taken 
place.32  
Although this means that it is not possible to look at the effect on the accumulation of [18F]C2tBu 
when inducing apoptosis in this cell line, it does however give us an interesting result. It shows that 
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uptake of this probe into cells is not affected by the drug resistance. It has been reported that some 
simpler phosphonium cations are substrates for multidrug resistant transport protein, P-
gylcoprotein.33 Gros et al showed that there was a reduced accumulation of lipophilic cations and in 
particular, tetraphenylphosphonium (TPP+) in cells that were transfected with the mdr1 and mdr3 
gene. 34  This can therefore lead to false results and misreading of apoptosis activity.  
The fact is that with this compound there is still an accumulation of the probe in the resistant cells 
which remains stable following anticancer treatment. This has a huge advantage over other 
apoptosis imaging agents as the cancer can be detected via a high uptake signal and then the 
response to treatment confirmed via a permanent drop in signal.   
Other apoptosis imaging agents such as caspase inhibitors and Annexin V rely on the event of 
apoptosis to cause a signal. In addition, these events also have a framed time period in which the 
signal can be detected and so can often be missed.  
5.8.2 CHO-K1 Cells 
CHO-K1 cells are a Chinese hamster ovarian cell line that is commonly used in biological and medical 
research. One of the reasons they are so widely used is that they do not express any epidermal 
growth factor receptors and can be used to express recombinant proteins.35,36  The CHO-K1 version 
is very similar to the original CHO cells but contains slightly less DMA.  
This cell line was chosen to repeat some of the studies with CCCP and Cisplatin as they were easily 
obtainable and are an adherent version of cell line which allowed for quicker assays.37 By not having 
to isolate and wash the pellet via centrifugation, the assay time was greatly reduced. Once the tracer 
had been incubated, the media could be removed leaving the cells on the bottom of the well ready 
to be washed with buffer. Once washed and ready, they were scraped from the surface and 
transferred into a tube to be counted. 
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The initial assay was to measure the uptake of both [18F]C2tBu and [18F]C2DiMe after different 
incubation times. Given that both tracers were able to be produced on the same day at the same 
time, a direct comparison between the assays could be made.  
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Figure 5.41: Uptake of [
18
F]C2tBu and [
18
F]C2DiMe in CHO-K1 cells (n = 3) 
The data in Figure 5.41 showed the uptake of both [18F]C2tBu and [18F]C2DiMe in CHO-K1 cells after 
four incubation times and it can be seen that a higher uptake is seen for the  [18F]C2tBu tracer 
overall. This was expected as [18F]C2tBu has a higher lipophilicity. What was of most interest is that 
whilst the uptake of [18F]C2DiMe remained similar to that seen in the 38C13 cells (see Figure 5.36), 
the uptake of [18F]C2tBu dramatically reduced (ca. around 40% for 38C13 and 60% for Ramos). The 
accumulation of [18F]C2tBu was now similar to what would be expected when comparing the tracer 
to similar lipophilic phosphonium cations in literature. 
As both 38C13 and Ramos cells are cancerous lymphoma cell lines compared to the CHO-K1, the 
uptake of this type of tracer would be expected to be higher due to the increase in membrane 
potential. However, this increase would be expected to be seen for all the tracers, not just for 
[18F]C2tBu. The difference in uptake seen here between [18F]C2tBu and [18F]C2DiMe in CHO-K1 cells 
was what would be expected for two tracers with only slightly different lipophilicities.  
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In order to examine whether a response could be seen in CHO-K1 cells with CCCP, the uptake assay 
was carried out for both [18F]C2tBu and [18F]C2DiMe. The cells were treated with 4 different 
concentrations of CCCP and incubated with the tracer for 30 minutes and then the data corrected 
for protein concentration.  
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Figure 5.42: The uptake of [
18
F]C2tBu and [
18
F]C2 in CHO-K1 cells post CCCP treatment with protein correction (n = 3) 
The results shown in Figure 5.42 show that a small drop in accumulation compared to the control 
could be seen at the lower concentration of CCCP and that this was greater for the [18F]C2DiMe 
tracer. The results seen at the higher concentrations again showed an unexpected result. For 
[18F]C2DiMe there was a small increase in the uptake above the control level whereas the [18F]C2tBu 
showed a large increase, with accumulation up at 300%. Given that these results have been modified 
to take into consideration the protein concentration the results imply that there were two to three  
times the amount of [18F]C2tBu entering the cell following treatment with CCCP at 50 and 100 µM 
concentrations. If the CCCP at these concentrations was indeed putting the cell under oxidative 
stress and causing an increase in oxidative phosphorylation and therefore an increase in the 
membrane potential, [18F]C2tBu appeared to respond well to this change. However, there has been 
no precedence for this published in the literature and a drop in membrane potential is always seen 
with concentrations up to 100 µM.38,39 Another explanation would be that at higher concentration of 
CCCP the membrane may become more permeable due to toxic effects, and due to the high 
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lipophilic nature of the tracers (and in particularly, [18F]C2tBu) they may enter the cell more easily 
and become trapped in the membrane bilayer or the cytoplasm. 
5.9 Discussion Summary and Future Work 
This work has proven that a range of phosphonium cations with varying lipophilicities have been 
tested and have shown different uptake into 38C13 cells. [18F]C2, [18F]C2Me and [18F]C2DiMe show a 
consistent and steady trend between uptake and the measured log D values. Independent of the 
initial uptake into these cells, the signal can be depleted upon treatment with Cisplatin for both 
[18F]C2tBu and [18F]C2DiMe with similar effect. The uptake of [18F]C2tBu was also tested in Ramos 
cells which showed high uptake and although the cells were found to be resistant to Cisplatin, it 
demonstrated that this tracer could be used to image drug resistant cell lines and give an early signal 
indication of failed drug treatment. Due to time restraints, further research into the use of this 
tracer in multi-drug resistant cell lines could not be carried out but could lead to an interesting 
investigation and should be carried out. 
To help confirm these results, the most relevant research would be to investigate the uptake in the 
isolated mitochondria. To gain an understanding as to whether the uptake seen for these tracers in 
the cell is accumulating in the mitochondria or whether they are being either trapped in the 
membrane of the cytoplasm, assays using isolate the mitochondria should be performed. This would 
allow for confirmation of where [18F]C2tBu is accumulating to give such a high uptake in 38C13 cells. 
If both the uptake of [18F]C2tBu and [18F]C2DiMe were similar in isolated mitochondria it would 
suggest that the tert-butyl groups on [18F]C2tBu were facilitating the uptake into the cells and that 
the tracer then becomes trapped outside of the mitochondria. In 2009 Lanza and Nair published an 
article discussing the functional assessment of isolated mitochondria in vitro.40 This paper describes 
a method that can be carried out to successfully isolate the mitochondria in a way that maintains the 
integrity. Tests on the mitochondria were then carried out to calculate both the yield and integrity. 
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Although the paper uses skeletal muscle as the source of mitochondria, it was believed that this 
method could be translated to other tissues and cell cultures. 
Using both cardiac and liver tissue, known to have high concentrations of mitochondria could 
provide a sample necessary to give a high enough ATP signal to confirm mitochondrial integrity and 
observe the uptake of the tracers. Were the uptake found to be similar for both [18F]C2tBu and 
[18F]C2DiMe it would confirm that the uptake of the tracers are not just dependent on the 
mitochondrial membrane potential.  
Finally, following this research, an independent and adjacent study was published by Yuan et al that 
could help to explain these findings.41 Their research involved attaching an 18F labelled fluorescent 
probe to a phosphonium cation to image the mitochondria. Initially, three different 19F fluorescence 
probes were attached to the phosphonium salt and studies were carried out to see their localisation 
in the mitochondria and to determine whether it was dependent on the mitochondrial membrane 
potential.  It was found that all three tracers were localised in the mitochondria and the uptake was 
compared to that of either rhodamine-123 or TetraMethylRhodamineEster (TMRE), both known to 
accumulate in the mitochondria. The cells were then treated with FCCP, which similarly to CCCP is a 
membrane uncoupler, to see the dependency on the membrane potential. Both RH-123 and TMRE, 
as expected, show a drop in the fluorescence signal whereas the fluorescent labelled phosphonium 
cations show no change. Yuan et al suggest that the uptake is therefore independent of the 
membrane potential and that they must be binding to an unknown target expressed by the 
mitochondria.41  
This makes the work already started in section 3.10.10 more vital as gaining fluorescent visualisation 
of the tracer in the mitochondria could help confirm this hypothesis. It would also be interesting to 
observe what dependency on the membrane potential there would be by attaching the rhodamine 
probe to the phosphonium salt. If for example, binding is occurring with the current phosphonium 
tracers and the binding site remains unchanged after the addition of the rhodamine, the uptake 
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should remain constant following CCCP/FCCP treatment. If no binding is occurring and the tracer is 
accumulated in the mitochondria, then a dependency on the membrane potential would still be 
expected. 
5.10 Methodology 
This section will describe the different methods that were carried out during this research. 
5.10.1 Cell Cultures 
Both the 38C13 and Ramos cells were cultured in RPMI-1640 media (RPMI1640, 10% foetal bovine 
serum, 2 mM l-glutamine, 100 UI/ml penicillin, 100 µg/ml streptomycin) with the addition of 50µM 
2-mercaptoethanol. 2-Mercaptoethanol was removed the passage before the experiment, to 
prevent interference. Cell lines were maintained in a humid environment at 370C with 5% CO2(g) and 
were passaged by adding 2:1 (v/v) pre-warmed fresh media: cell suspension every 2-3 days. 
CHO-K1 cells were cultured in Ham’s F12 media (10% foetal bovine serum, 2mM l-glutamine, 100 
UI/ml penicillin, 100 µg/ml streptomycin). Cell lines were maintained in a humid environment at 
370C with 5% CO2(g) and were passaged once cells reached 80% confluency. Trypsin (0.05 M) added 
to dissociated cells from surface and then cells diluted in ratios of 1:6. 
5.10.2 In vitro Radioligand Uptake Assays  
In preparation for the radioligand uptake assays, the 38C13 and Ramos cells were passaged in fresh 
media in the absence of 2-mercaptoethanol and plated in triplicate (n = 1) in 12-well plates 48 hours 
prior to assay. Each plate resulted in an n = 1 for the assay. For untreated cells, the tracers 
(approximately 0.1 MBq in 10 µL) were added to the cells and incubated, for treated cells they were 
either left treated with 100µM Cisplatin for 2, 12, 24 and 48 hours or varying concentrations of CCCP 
(1-1000 µM) for 10-30 minutes. Centrifugation was used to isolate the cells, which were washed 
three times in ice-cold PBS prior to being resuspended and the associated activity measured by 
automated gamma counter (Perkin Elmer WizardTM 1470). 
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CHO-K1 cells were passaged in fresh media 48 hours prior to assay and plated in triplicate in 12-well 
plates in a 1:6 cell to media ratio. Cells were either left untreated or treated with CCCP in the same 
way as 38C13 cells. To isolate the cells, they were scraped from the surface before being 
resuspended in buffer and counted. 
5.10.3 Protein Correction Assay 
The protein correction assay was carried out in accordance to the protocol provided in the Pierce™ 
BCA Protein Assay Kit. 
5.10.4 FACS Analysis 
The cell staining and FACs analysis conditions were carried out according to the Vybrant® FAM 
caspase-3 and -7 assay kit (Molecular Probes, Invitrogen Detection Technologies, product 
information MP35118).  
5.10.4 Rhodamine Assay 
Rhodamine-123 was purchased from Sigma Aldrich and used without further modification. Solutions 
were made up in the minimum amount of DMSO and the concentration adjusted with buffer. 
Untreated cells with RH-123 were used as a baseline of fluorescence. A BMG LABTECH- FLUOstar 
OPTIMA was used to read the plates (Ex/Em = 490/520 nm). 
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6.0 IN VIVO ANALYSIS AND DATA COMPARISON  
Having successfully synthesised and radiolabelled a small library of phosphonium cations with 
fluorine-18, [18F]C2tBu and [18F]C2DiMe shown in Figure 6.1, went on to undergo a series of in vitro 
assays. Following the differing results seen for the accumulation assay between the two tracers and 
the equally positive response to the induction of apoptosis with Cisplatin, further analysis on these 
tracers was required. 
 
Figure 6.1: The structures of [
18
F]C2tBu and [
18
F]C2DiMe 
This chapter details the next stages of the tracer characterisation, which involved carrying out in vivo 
studies. Understanding the metabolic pathway and knowing where the tracer accumulates in the 
body can help determine the success or failure of that tracer. It also allows the comparison to other 
tracers already developed in literature and enables determination as to whether the new tracer has 
advantages over those reported.  
In the first instance, the in vivo evaluation of [18F]C2tBu was performed on a series of healthy rats 
and consisted of metabolic stability, biodistribution and dynamic PET/CT scanning studies used to 
determine the tracer’s biological behaviour in a live subject. 
The same studies were then carried out with [18F]C2DiMe and the data obtained will be discussed 
and analysed before a comparison between the two tracer’s results made.  
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6.1 In Vivo Evaluation of [18F]C2tBu 
When carrying out the in vitro cell assays, [18F]C2tBu was found to have the highest accumulation in 
the different cell lines. This was therefore chosen as the first tracer to be taken into forward onto in 
vivo studies as it suggested there may be a higher uptake in the organs of interest leading to a better 
signal-to-noise ratio.  
With similar phosphonium lipophilic cations already being researched and discussed in literature, a 
prediction of the outcome of these studies could be anticipated. When considering three literature 
tracers (see Figure 6.2) with varying lipophilicities, the outcome of the biodistribution studies are 
very similar. 
 
Figure 6.2: Structures and log P values of current 
18
F labelled phosphonium cations in literature
1,2
 
They all have high accumulation in the myocardium and this is also found to be in high ratio when 
compared to the lungs.3,2,1 The % of injected dose per gram for the heart in mice was found to be > 
10% for A, > 20% for B and up to 35% seen for C.3,2,1 
In terms of the metabolism of the tracers, again, similar results are seen for all three. The kidney 
uptake was found to be much greater than the activity measured in the liver. This suggests that the 
clearance of tracers from the body was predominantly via the renal tract than from the hepatobiliary 
tract.4 An important factor that has to be considered is the clearance from the liver due to its close 
proximity to the heart. It is believed that the greater the lipophilicity of a tracer, the slower the 
clearance, which could therefore lead to poor visualisation of the heart due to spill-over of the signal 
from the liver.1 This was found to be the issue with A (believed to have a higher lipophilicity due to 
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the additional phenyl ring) as it was seen that after 25 minutes the time activity curves revealed that 
the ratio of myocardium to liver was 1.4 There was still however good contrast between the heart 
and lungs (heart to lung ratio > 6). With this in mind, Dong-Yeon et al went on to develop and 
investigate tracer B and C in order to try and combat this issue. They found that by 
reducing/optimising the lipophilicity, they could still observe high and retained uptake into the heart 
whilst increasing the washout in other organs.1,2 
This was something that could be an issue with taking [18F]C2tBu into in vivo models (and hence why 
these can be justifiably carried out prior to man) as the measured lipophilicity of the tracer was 
believed to be similar to that reported for A. As with any new tracer though, trying to predict the 
profile of the pathway is deemed impossible as many other factors can cause a different effect.  
6.1.1 Metabolite Study of [18F]C2tBu 
Determining whether a new tracer is going to be stable in live subjects is an important stage in tracer 
development and the outcome could result in the failure of that particular compound, especially 
when one of the metabolic pathway leads to defluorination. One way of investigating this is to carry 
out a metabolic stability study which allows the observation of the percentage of parent tracer 
compound still present in the plasma after various time frames and gives an indication of tracer 
clearance, which will have a direct effect upon dosimetry. A metabolite analysis was carried out on 
[18F]C2tBu using healthy Sprague Dawley (SD) rats and was performed using the following 
procedure.  
The rat was anaesthetised and maintained under terminal isoflurane anaesthesia. A tail vein was 
cannulated for radiotracer administration and a tail artery was cannulated for blood sampling 
respectively. Intravenous administration of approximately 10 MBq [18F]C2tBu was carried out. 
Arterial blood samples were taken at 5, 10, 20, 40 and 60 min. At the end of the experimental 
period, the rat was killed by exsanguination. 
Chapter 6 
 
197 
 
 Blood samples were collected and processed to obtain plasma. Plasma proteins were precipitated 
with 1:1 ACN and the extract was obtained by centrifugation. An aliquot of the extract and the 
protein pellet were measured for radioactivity for the determination of extraction efficiency.  
The extract was diluted with ammonium formate prior to injection for HPLC analysis. Aliquots of the 
resulting solution were measured for radioactivity to determine the HPLC recovery. In total, 30 
sample fractions were collected over a 10 min run and placed in an automated gamma counter to 
determine the radioactivity in each fraction. 
First, to confirm that the method being used was viable, the extraction efficiency was measured. To 
determine the extraction efficiency, the activity remaining in the protein pellet was compared to the 
activity in the extract. By adjusting the activity of the accurate measure of the extract to give the 
total activity, this could then be compared to the pellet and a percentage of extraction found. For 
[18F]C2tBu, this was always found to be greater than 90 %, meaning that the majority of the activity 
in the plasma was recovered. 
The second measurement that was determined was the HPLC recovery of the total activity injected. 
Using an accurate measurement of an aliquot of the injected sample and comparing this to the total 
activity of all HPLC fractions, the percentage loss of activity on the column was calculated. The 
activity lost for [18F]C2tBu during the HPLC run was found to be less than 10%. 
A radio-chromatogram was reconstructed from the activity data collected from the HPLC fractions 
and the percentage of unchanged tracer was calculated. An example of a reconstructed radio-
chromatogram for [18F]C2tBu is shown below in Figure 6.3 and illustrates the parent compound with 
a retention time around 8.5 minutes and radio-metabolite(s) peak with a retention time around 2.5 
minutes. 
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Figure 6.3: Reconstructed radio-chromatogram for a plasma sample taken 5 minutes after the injection of [
18
F]C2tBu 
There were different ways in which to determine this measurement which took into consideration 
factors like background noise (baseline correction) and gamma counter well cross-talk. These were 
all analysed and then the method that gave the most represented result used. 
The first method was to divide the sum of the fractions corresponding to the parent compound by 
the total activity of all fractions (no baseline correction). The second method was then to take into 
consideration a baseline correction. Small fluctuations in the baseline, especially seen when low 
levels of activity are present in the plasma can have an effect on the results and so by calculating the 
average activity seen before the solvent front is eluted (the first 1.66 minutes), the background noise 
could be taken into account. The average baseline activity found from the first five fractions could 
then be deducted from each reading and then the calculation carried out using the first method. 
The final method involved only using the data seen from the parent and the metabolites formed 
(manual method). The sum of the parent was divided by the sum of the parent and any metabolites. 
The results from these three methods are shown below in Figure 6.4. 
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Figure 6.4: The percentage of [
18
F]C2tBu present in the plasma after varying incubation times, calculated by three 
different methods from the reconstructed chromatograms (n=3) 
Having analysed all the data, the method that appeared to produce the most closely related trends 
to those observed in the chromatograms was the manual method. This method eliminated all 
background interference, thereby allowing a more accurate determination of the parent peak and 
metabolites.  
The metabolite profile seen for [18F]C2tBu is depicted below in Figure 6.5 and shows the slow 
metabolism of the tracer.  
0 1 0 2 0 3 0 4 0 5 0 6 0
0
2 0
4 0
6 0
8 0
1 0 0
T im e  o f  s a m p le  t a k e n  ( m in )
%
 o
f 
p
a
re
n
t 
c
o
m
p
o
u
n
d
 
Figure 6.5: Metabolism profile of [
18
F]C2tBu (n=3) 
Following 60 minutes of incubation, there was still over 60% of the parent compound circulating in 
the plasma of the subject suggesting that the tracer is relatively stable over the course of the 
scanning session. 
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6.1.2 Biodistribution Study of [18F]C2tBu 
Biodistribution studies using PET radiolabelled compounds, allow the accumulation of radioactivity 
within a live subject to be determined, thereby giving an indication of how a radiolabelled tracer 
passes though the body and in which tissues the activity accumulates. In addition, this study helps to 
develop understanding of the method of metabolism and route of clearance of the tracer. Finally, 
biodistribution studies can give an indication of whether the activity accumulates in a tissue 
expressing the biological target of interest and the initial suitability of the tracer kinetics for a PET 
imaging application.  
In a similar manner to the metabolite study, SD healthy male rats were used. Prior to the 
experiments, the weight of each rat was measured and noted. The total amount of activity injected 
into the rat need to be known. This was calculated by measuring the pre-dose (decay corrected) and 
then subtracting the post-dose and the waste dose (both decay corrected). 
The radioactivity associated with each tissue sample was determined by gamma counting. Care was 
taken to order the samples to reduce the amount of cross talk of radiation between tissues of high 
and low activity. The weight of each tissue sample was recorded and the radioactivity associated 
with the tissue samples decay corrected to the time of injection.  
The percentage injected dose per gram (%ID/g) and the standardised uptake values (SUV) are the 
most common measures used to illustrate PET biodistribution data. The SUV data for [18F]C2tBu is 
shown below (table 6.1) and analyse the movement of the tracer over time. 
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Table 6.1: SUV average (± SEM) data for [
18
F]C2tBu of all organ tissues measured (decay corrected) 
The purpose of this tracer was to image apoptosis by targeting the mitochondrial membrane 
potential and potentially be used for cardiac imaging like other similar tracers in literature. 
Therefore the following tissues were of interest; red bone marrow, spleen, thyroid and the heart. All 
these tissue have a high cell proliferative capacity or a high energy demand and would therefore be 
expected to see a higher and retained accumulation of the [18F]C2tBu tracer. The other tissues of 
interest were ones that would allow the determination of the metabolic route of excretion and 
clearance. For ease of understanding the data, the tissues of interest have been summarised below 
in Figure 6.6. 
Blood 0.710 ± 0.07 0.277 ± 0.10 0.290 ± 0.05 0.230 ± 0.03
Plasma 0.337 ± 0.01 0.137 ± 0.02 0.103 ± 0.03 0.083 ± 0.01
Bladder content 0.387 ± 0.14 0.533 ± 0.17 0.533 ± 0.14 1.130 ± 0.09
Bladder wall 0.173 ± 0.03 0.137 ± 0.01 0.160 ± 0.02 0.145 ± 0.01
Pancreas 0.234 ± 0.03 0.273 ± 0.05 0.240 ± 0.04 0.310 ± 0.06
Stomach wall 0.517 ± 0.26 0.783 ± 0.23 0.697 ± 0.12 0.740 ± 0.08
Stomach content 0.137 ± 0.13 0.021 ± 0.01 0.017 ± 0.01 0.007 ± 0.00
Small intestine wall 1.523 ± 0.55 3.257 ± 1.20 4.073 ± 0.40 2.323 ± 0.39
Small intestine content 9.160 ± 4.14 70.953 ± 19.39 98.030 ± 4.44 30.860 ± 3.12
Upper large intestine wall 0.633 ± 0.09 0.643 ± 0.16 0.367 ± 0.17 0.667 ± 0.08
Upper large intestine content 0.030 ± 0.00 0.043 ± 0.01 0.757 ± 0.59 1.933 ± 1.74
Colon wall 0.387 ± 0.07 0.530 ± 0.15 0.343 ± 0.08 0.403 ± 0.03
Colon content 0.010 ± 0.00 0.010 ± 0.01 0.017 ± 0.01 0.020 ± 0.01
Red bone marrow 1.490 ± 0.10 1.517 ± 0.31 1.277 ± 0.29 1.522 ± 0.05
Bone surface 0.180 ± 0.01 0.143 ± 0.03 0.173 ± 0.04 0.173 ± 0.03
Muscle 0.137 ± 0.01 0.113 ± 0.02 0.127 ± 0.03 0.133 ± 0.01
Spleen 9.130 ± 1.00 9.577 ± 1.38 7.950 ± 1.84 8.490 ± 0.54
Liver 14.090 ± 0.53 8.537 ± 0.68 6.277 ± 1.48 4.123 ± 0.06
Testes 0.017 ± 0.00 0.020 ± 0.00 0.023 ± 0.00 0.023 ± 0.00
Adrenals 10.253 ± 1.41 10.273 ± 0.56 6.470 ± 1.57 14.470 ± 3.16
Kidney 5.963 ± 0.74 5.873 ± 0.81 5.177 ± 0.97 6.520 ± 0.55
Lung 3.107 ± 1.19 2.277 ± 0.33 1.993 ± 0.38 2.090 ± 0.35
Heart 0.660 ± 0.13 0.510 ± 0.08 0.453 ± 0.08 0.553 ± 0.06
Oesophagus wall 0.233 ± 0.09 0.230 ± 0.05 0.157 ± 0.03 0.267 ± 0.07
Skin 0.127 ± 0.02 0.127 ± 0.02 0.120 ± 0.02 0.140 ± 0.01
Thymus 0.170 ± 0.04 0.147 ± 0.03 0.157 ± 0.04 0.163 ± 0.03
Thyroid 4.507 ± 0.35 3.787 ± 0.97 3.207 ± 0.49 4.180 ± 0.84
Brain 0.023 ± 0.00 0.023 ± 0.00 0.017 ± 0.00 0.023 ± 0.00
Organ
5 min 60 min30 min15 min
SUV (n=3)
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Figure 6.6: The SUV profile (n=3) of [
18
F]C2tBu for tissues of interest over four time points 
By interpreting the data shown in Figure 6.6 it can be seen that the metabolism of [18F]C2tBu and 
excretion of radioactivity were predominantly via the hepatobiliary route via the gastrointestinal 
tract. This is supported by the high peak uptake in liver (SUV value = 14), the tissue clearance and 
the significant uptake in the small intestine content (SUV values ranging from 9-98 over 60min) 
(Figure 6.7). 
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Figure 6.7: The SUV profile (n=3) of [
18
F]C2tBu for the small intestine contents over four time points 
The time course of activity in the liver supports the release of the metabolites into the 
gastrointestinal track for excretion. The uptake in the kidneys, which was found to be relatively 
stable, shows little clearance of activity over the time course of the experiment which was also 
confirmed by the lack of uptake in the urine (SUV 0.39-1.13 over the course of 60min). This supports 
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the predominant hepatobiliary route. It is also known that lipophilic compounds are not eliminated 
efficiently by the kidneys and so suggests that the parent compound has become trapped.5 The 
uptake in the lungs after 5 minutes was also found to be high which could be a concern but the 
washout over time suggests that the tracer was not actually accumulating there but was due to the 
activity in the circulating blood. 
Most tissues with a high proliferative capacity showed high and stable accumulation (bone marrow 
SUV 1.277–1.522 and thyroid SUV 4.507-3.207 over the experimental period). However, despite a 
stable accumulation, the uptake in the heart was surprisingly low (SUV 0.453-0.660 over the 
experimental period). Given that all other lipophilic phosphonium cations discussed earlier from the 
literature produce good cardiac uptake, [18F]C2tBu was expected to be similar. This limits the use of 
this tracer as a cardiac imaging agent but does open the investigation as to why this tracer behaves 
so differently to other similar tracers in literature. To determine whether any of the other tracers in 
this series behave in the same way, [18F]C2DiMe was tested and will be discussed later in this 
chapter.  
6.1.3 Effective Dose Calculation of [18F]C2tBu 
From the biodistribution data, an effective dose calculation was determined. The ICRP (International 
commission of radiological protection) reports that the effective dose is ‘a value estimated by 
applying risk-based weighting factors to individual organ doses, to estimate a uniform whole-body 
dose that in theory gives the same risk as the non-uniform dose pattern that actually occurred.’6 
Percentage injected dose (%ID) was determined for each tissue sample without sample decay 
correction. The average of the data at each time point was found and modified for the average mass 
of the rats. This was then converted into an integral value based on the % ID (hr)/g and then using 
both a human scaled ID factor and average human organ mass, the human scaled ID (hr) was 
calculated. 
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Using the software, OLINDA - Organ Level INternal Dose Assessment Code (Version 1.1, copyright 
Vanderbilt University, 2007), the effective dose was determined. Table 6.2 below shows the 
dosimetry calculations for the individual organ doses and the whole body effective dose. The total 
effective dose of [18F]C2tBu was estimated to be 21 µSv/MBq of injected activity.  
Target Organ Alpha Beta Photon Total 
EDE 
Cont. 
ED 
Cont. 
Adrenals 0.00E+00 6.21E-02 1.82E-02 8.03E-02 4.82E-03 2.01E-04 
Brain 0.00E+00 1.08E-04 2.01E-03 2.12E-03 0.00E+00 5.30E-06 
Breasts 0.00E+00 2.25E-03 5.19E-03 7.44E-03 1.12E-03 3.72E-04 
Gallbladder Wall 0.00E+00 2.25E-03 1.99E-02 2.22E-02 0.00E+00 0.00E+00 
LLI Wall 0.00E+00 4.58E-03 1.54E-02 2.00E-02 0.00E+00 2.39E-03 
Small Intestine 0.00E+00 1.00E-01 2.79E-02 1.28E-01 7.70E-03 3.21E-04 
Stomach Wall 0.00E+00 1.10E-02 1.14E-02 2.24E-02 0.00E+00 2.69E-03 
ULI Wall 0.00E+00 6.02E-03 2.93E-02 3.53E-02 0.00E+00 8.83E-05 
Heart Wall 0.00E+00 3.22E-03 7.82E-03 1.10E-02 0.00E+00 0.00E+00 
Kidneys 0.00E+00 3.02E-02 2.00E-02 5.02E-02 3.01E-03 1.26E-04 
Liver 0.00E+00 2.49E-02 2.26E-02 4.76E-02 2.85E-03 2.38E-03 
Lungs 0.00E+00 1.03E-02 8.00E-03 1.83E-02 2.20E-03 2.20E-03 
Muscle 0.00E+00 6.41E-04 7.06E-03 7.71E-03 0.00E+00 1.93E-05 
Ovaries 0.00E+00 2.25E-03 2.02E-02 2.24E-02 5.61E-03 4.49E-03 
Pancreas 0.00E+00 1.47E-03 1.32E-02 1.47E-02 0.00E+00 3.67E-05 
Red Marrow 0.00E+00 5.09E-03 9.51E-03 1.46E-02 1.75E-03 1.75E-03 
Osteogenic Cells 0.00E+00 1.08E-02 7.63E-03 1.84E-02 5.51E-04 1.84E-04 
Skin 0.00E+00 2.25E-03 4.08E-03 6.33E-03 0.00E+00 6.33E-05 
Spleen 0.00E+00 4.10E-02 2.13E-02 6.23E-02 3.74E-03 1.56E-03 
Testes 0.00E+00 2.25E-03 5.21E-03 7.46E-03 0.00E+00 0.00E+00 
Thymus 0.00E+00 6.63E-04 5.12E-03 5.78E-03 0.00E+00 1.45E-05 
Thyroid 0.00E+00 1.94E-02 7.04E-03 2.65E-02 7.94E-04 1.32E-03 
Urinary Bladder 
Wall 
0.00E+00 4.63E-03 9.39E-03 1.40E-02 0.00E+00 7.01E-04 
Uterus 0.00E+00 2.25E-03 1.86E-02 2.09E-02 0.00E+00 5.21E-05 
Total Body 0.00E+00 4.73E-03 7.77E-03 1.25E-02 0.00E+00 0.00E+00 
Effective Dose Equivalent (EDE) (mSv/MBq) 
  
3.41E-02 
 
Effective Dose (ED) (mSv/MBq) 
    
2.10E-02 
 
Table 6.2: Organ effective doses (ED, mSv/MBq injected) for the ‘adult male’ hermaphrodite phantom derived by 
OLINDA for [
18
F]C2tBu 
An effective dose of 21 µSv/MBq for an 18F labelled tracer was found to be a suitable value for taking 
the tracer into humans. Other examples in literature of successful 18F labelled tracers are found to 
have effective doses varying between 18.5 and 22 µSv/MBq with the common tracer [18F]FDG being 
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19 µSv/MBq, confirming that this was an appropriate value to allow further study.7,8 If the limit for 
radiation exposure as part of clinical trial is considered which is usually 10 mSv/scan and the usual 
injected dose of the tracer is approximately 250 MBq, the effective dose for [18F]C2tBu indicates that 
up to two scans can be carried out on one patient.  
6.2 In Vivo Evaluation of [18F]C2DiMe 
Following the unexpected low cardiac uptake seen for the biodistribution study of [18F]C2tBu, 
[18F]C2DiMe was also taken into in vivo studies. Recapping on the in vitro results, [18F]C2DiMe was 
found to have a lot lower uptake (10 fold) in the 38C13 cells compared with [18F]C2tBu but upon 
treatment with Cisplatin, showed a better response to the induction of apoptosis. The log D value 
was also found to be lower than that of [18F]C2tBu which could potentially help in reducing the 
uptake in the liver. 
6.2.1 Metabolite Study of [18F]C2DiMe 
[18F]C2tBu was metabolically stable and underwent minimal defluorination in vivo, with > 60 % of the 
parent tracer being present after 60 minute post injection. The metabolic stability of [18F]C2DiMe in 
live subjects was determined in a similar manner. 
The percentage of parent tracer was determined by analysing the reconstructed radio-
chromatograms and using the manual calculation method.  An n of 2 was obtained for this tracer 
due to a rat fatality. The data obtained is shown in Figure 6.8 below. 
 
Chapter 6 
 
206 
 
0 1 0 2 0 3 0 4 0 5 0 6 0
0
2 0
4 0
6 0
8 0
1 0 0
T im e  ( m in )
%
 o
f 
p
a
re
n
t 
c
o
m
p
o
u
n
d
 
Figure 6.8: Metabolism profile of [
18
F]C2DiMe (n=2) 
Figure 6.8 showed that [18F]C2DiMe underwent a more rapid metabolism over the first 20 minutes 
before slowing down to give the parent compound present in around 40 % post 60 minute injection. 
6.2.2 Biodistribution Study of [18F]C2DiMe 
The next stage was to determine the route of [18F]C2DiMe metabolism in a live subject over time. A 
biodistribution study was carried out for [18F]C2tBu with consistent methodology to that used 
previously. To facilitate the interpretation of the data, SUV data is summarised below (Table 6.3). 
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Table 6.3: SUV (± SEM) average data for [
18
F]C2DiMe of all organ tissues measured (decay corrected) 
To help compare the data more easily, the tissues of interest (those involved in excretion or have a 
high proliferative capacity) have been grouped together and shown as SUV results over time (Figure 
6.9). 
Blood 0.346 ± 0.17 0.163 ± 0.02 0.143 ± 0.02 0.056 ± 0.02
Plasma 0.191 ± 0.11 0.056 ± 0.01 0.072 ± 0.02 0.017 ± 0.01
Bladder content 0.058 ± 0.05 3.181 ± 2.35 5.228 ± 3.29 20.806 ± 7.02
Bladder wall 0.997 ± 0.24 0.636 ± 0.11 0.801 ± 0.26 1.066 ± 0.06
Pancreas 0.560 ± 0.12 0.503 ± 0.06 0.610 ± 0.06 0.468 ± 0.09
Stomach wall 2.880 ± 0.41 2.015 ± 0.66 2.465 ± 0.20 2.427 ± 0.41
Stomach content 0.238 ± 0.23 1.328 ± 0.92 3.589 ± 2.93 0.311 ± 0.31
Small intestine wall 4.969 ± 0.85 8.082 ± 2.20 10.803 ± 3.59 3.355 ± 1.14
Small intestine content 7.936 ± 1.14 68.045 ± 60.77 300.883 ± 19.56 58.281 ± 25.67
Upper large intestine wall 3.061 ± 0.34 2.613 ± 0.24 2.220 ± 0.13 1.563 ± 0.29
Upper large intestine content 0.508 ± 0.07 0.743 ± 0.10 1.921 ± 0.55 6.352 ± 5.16
Colon wall 2.549 ± 0.43 2.602 ± 0.18 2.612 ± 0.18 1.724 ± 0.35
Colon content 0.285 ± 0.03 0.246 ± 0.05 0.394 ± 0.06 0.227 ± 0.08
Red bone marrow 2.162 ± 0.42 2.274 ± 0.05 2.285 ± 0.03 1.792 ± 0.79
Bone surface 0.553 ± 0.07 0.438 ± 0.04 0.557 ± 0.13 0.608 ± 0.20
Muscle 0.296 ± 0.04 0.217 ± 0.02 0.237 ± 0.06 0.222 ± 0.06
Spleen 6.666 ± 1.87 6.044 ± 0.36 7.279 ± 0.55 4.231 ± 0.83
Liver 3.909 ± 0.69 2.254 ± 0.30 1.527 ± 0.30 0.463 ± 0.12
Testes 0.043 ± 0.00 0.036 ± 0.01 0.037 ± 0.00 0.029 ± 0.00
Adrenals 12.502 ± 4.52 11.319 ± 1.31 21.157 ± 6.47 14.295 ± 4.25
Kidney 20.772 ± 1.63 17.758 ± 0.28 21.687 ± 1.37 18.647 ± 4.57
Lung 2.360 ± 0.15 2.967 ± 1.42 1.425 ± 0.25 1.374 ± 0.36
Heart 5.406 ± 0.61 4.601 ± 0.32 5.167 ± 0.56 4.736 ± 1.05
Oesophagus wall 0.868 ± 0.13 0.554 ± 0.08 0.781 ± 0.06 0.776 ± 0.19
Skin 0.578 ± 0.08 0.380 ± 0.03 0.443 ± 0.02 0.495 ± 0.09
Thymus 0.694 ± 0.09 0.558 ± 0.02 0.622 ± 0.04 0.606 ± 0.15
Thyroid 21.508 ± 4.81 1 4.212 ± 4.21 24.305 ± 1.77 21.749 ± 6.62
Brain 0.075 ± 0.01 0.066 ± 0.00 0.061 ± 0.01 0.048 ± 0.01
Organ
SUV (n=3)
5 min 15 min 30 min 60 min
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Figure 6.9: The SUV profile (n=3) of [
18
F]C2DiMe for tissues of interest over four time points 
First, when the organs responsible for the metabolism were analysed, it was found that a much 
greater uptake was seen in the kidneys over the liver, suggesting a renal excretory route over a 
hepatobiliary one. This was supported by the activity increase found in the urine over time (SUV 
0.058-20.806). The initial uptake was seen in the liver post 5 minute injection was rapidly washed 
out within the hour.   
In terms of the tissues with high cell proliferative capacity (bone marrow, spleen, adrenals, heart and 
thyroid), all were found to have high and retained accumulation.  
The data obtained for the tracer [18F]C2DiMe was much more in line with what was expected for this 
series of phosphonium cations. Like other similar tracers (discussed earlier in 6.1), excretion via the 
renal track, a lower uptake in the liver seen and then a high and stable accumulation in the 
myocardium. The uptake in the heart also showed a good ratio to the liver and the lung also 
suggesting it to be a highly suitable cardiac imaging agent. 
6.2.3 Effective Dose Calculation of [18F]C2DiMe 
This was calculated using the same method (OLINDA) as for [18F]C2tBu and the data is presented in 
Table 6.4.  
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Target Organ Alpha Beta Photon Total EDE Cont. ED Cont. 
Adrenals 0.00E+00 7.40E-02 1.95E-02 9.34E-02 5.61E-03 2.34E-04 
Brain 0.00E+00 2.94E-04 2.17E-03 2.46E-03 0.00E+00 6.15E-06 
Breasts 0.00E+00 8.89E-04 3.60E-03 4.49E-03 6.74E-04 2.25E-04 
Gallbladder Wall 0.00E+00 8.89E-04 1.81E-02 1.90E-02 0.00E+00 0.00E+00 
LLI Wall 0.00E+00 7.88E-03 2.11E-02 2.90E-02 0.00E+00 3.47E-03 
Small Intestine 0.00E+00 1.53E-01 3.77E-02 1.91E-01 1.14E-02 4.77E-04 
Stomach Wall 0.00E+00 2.29E-02 1.64E-02 3.93E-02 0.00E+00 4.71E-03 
ULI Wall 0.00E+00 1.08E-02 4.06E-02 5.14E-02 3.09E-03 1.29E-04 
Heart Wall 0.00E+00 2.38E-02 1.12E-02 3.50E-02 0.00E+00 0.00E+00 
Kidneys 0.00E+00 9.37E-02 3.85E-02 1.32E-01 7.93E-03 3.30E-03 
Liver 0.00E+00 4.87E-03 1.08E-02 1.56E-02 0.00E+00 7.81E-04 
Lungs 0.00E+00 8.11E-03 6.33E-03 1.44E-02 1.73E-03 1.73E-03 
Muscle 0.00E+00 1.19E-03 7.27E-03 8.46E-03 0.00E+00 2.11E-05 
Ovaries 0.00E+00 8.89E-04 2.74E-02 2.83E-02 7.08E-03 5.66E-03 
Pancreas 0.00E+00 2.80E-03 1.42E-02 1.70E-02 0.00E+00 4.24E-05 
Red Marrow 0.00E+00 5.45E-03 1.12E-02 1.66E-02 2.00E-03 2.00E-03 
Osteogenic Cells 0.00E+00 1.79E-02 7.92E-03 2.58E-02 7.75E-04 2.58E-04 
Skin 0.00E+00 8.89E-04 3.64E-03 4.52E-03 0.00E+00 4.52E-05 
Spleen 0.00E+00 2.75E-02 1.95E-02 4.70E-02 0.00E+00 1.18E-04 
Testes 0.00E+00 8.89E-04 4.68E-03 5.57E-03 0.00E+00 0.00E+00 
Thymus 0.00E+00 3.32E-03 4.96E-03 8.27E-03 0.00E+00 2.07E-05 
Thyroid 0.00E+00 8.78E-02 1.58E-02 1.04E-01 3.11E-03 5.18E-03 
Urinary Bladder 
Wall 
0.00E+00 3.72E-02 2.40E-02 6.13E-02 3.68E-03 3.06E-03 
Uterus 0.00E+00 8.89E-04 2.59E-02 2.68E-02 0.00E+00 6.70E-05 
Total Body 0.00E+00 4.34E-03 7.99E-03 1.23E-02 0.00E+00 0.00E+00 
Effective Dose Equivalent (mSv/MBq) 
  
4.71E-02 
 
Effective Dose (mSv/MBq) 
    
3.15E-02 
Table 6.4: Organ effective doses (ED, mSv/MBq injected) for the ‘adult male’ hermaphrodite phantom derived by 
OLINDA for [
18
F]C2DiMe 
The total effective dose of [18F]C2DiMe was estimated to be 31.5 µSv/MBq of injected activity. 
Although this is higher than the values usually seen for 18F labelled tracers, it still enables a scan to 
be carried out with sufficient injected dose (approx. 315 MBq). 
6.3 [18F]C2tBu and [18F]C2DiMe Comparison Summary 
Having successfully carried out in vivo studies on two of the 18F labelled phosphonium cations; this 
section looks to compare the results. What was found was that even though the structural 
differences between the tracers are small (functional groups on the phenyl rings), the pathway of 
the tracers differ significantly.  
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6.3.1 Metabolite Profile Comparison 
The determination of the metabolite profile was carried out on both [18F]C2tBu and [18F]C2DiMe and 
the results are shown below (Figure 6.10). 
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Figure 6.10: A comparison of the metabolite profiles of [
18
F]C2tBu and [
18
F]C2DiMe 
It can be seen that [18F]C2DiMe had a faster rate of metabolism within the live subject when 
compared to [18F]C2tBu. This suggests that the tert-butyl groups may be less easily metabolised than 
single methyl groups. The main difference in rate is seen between 5 and 10 minutes where very little 
metabolism has taken place on [18F]C2tBu, unlike [18F]C2DiMe which sees a 20% decrease in the 
amount of parent compound present in the plasma.  
When reviewing the normal methods of drug metabolism in the body, there are two phases that 
usually take place. Phase I involves the P450 monooxygenase system which results in catabolic 
reactions usually leading to more chemically reactive products.9,5 The reaction often introduces a 
more reactive group such as a hydroxyl and then phase II involves a conjugation reaction which 
usually leads to inactive products.5 Both phases look to decrease the lipid solubility of the compound 
to aid renal clearance.10  
Given the structure of these tracers, they must undergo a phase I functionalisation as there are no 
active groups to conjugate. The most likely reaction to occur on the methyl groups would be the 
oxidation to the alcohol. Although there are many different cytochrome P450 enzymes present in 
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the body that can catalyse a wide range of oxidative reactions, an example in literature suggests that 
the rate seen for t-butylbenzene oxidation was much lower than that observed for both n-butyl and 
propyl derivatives (product formation rate of 2.7, 310 and 635 respectively).11 Although this study 
was not applied to shorter carbon chains and was only one variant of a P450 enzyme it could imply 
that t-butyl groups are metabolised at a much slower rate and could therefore account for the 
slower rate seen for [18F]C2tBu over [18F]C2DiMe in this study. Another characteristic that should be 
considered is the position of the methyl moieties. p-Hydroxylation is also a common mechanism in 
phase I metabolism by cytochrome P450 enzymes and would also explain the increased rate of 
metabolism seen for [18F]C2DiMe.12,13,14 
6.3.2 Dynamic Scan Data  
The dynamic PET/CT study of [18F]C2tBu and [18F]C2DiMe were performed in a healthy SD male rat. 
The scan was carried out on a Siemens Inveon PET/CT scanner. Having already discussed the data 
from the ex vivo cut and count experiment for both tracers, this section will look to compare the 
pathways using the in vivo data analysed from the scans carried out. 
 The data was reconstructed to an image using filter-back projection (FBP) algorithms in Inveon 
Acquisition Workshop (IAW) and the data corrected for the injected dose. Initially from the images, 
regions of interest (ROI) must be defined and this was done using ITK-SNAP. This software allows for 
3D navigation and manual segmentation in three orthogonal planes at once. Using this, semi-
automated definition of the volumes of interest (VOI) can be performed. Depending on which organ 
is trying to be segmented will depend on whether the CT or PET image will be used. The heart for 
example will use the PET image whereas the lungs are easier to locate using the CT image. To give an 
idea as to how this segmentation occurs an example using the heart from the [18F]C2DiMe will be 
used.  
First, the heart must be located on the image which is a sum for all SUV0-60 (Figure 6.11). A voxel size 
must also be selected in order for the program to know the size of each area it is analysing.  
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Figure 6.11: Screen shot of a PET/CT overlay for [18F]C2DiMe highlighting the myocardium 
Once the heart it located and all three planes are in the right position, the segmentation can begin. 
These steps are depicted in Figure 6.12. Firstly, the intensity region filter must be set so that the 
software knows whether or not to include that voxel in the VOI (A). Once that is set, the VOI tool can 
be placed in the image to initialise the active contour (B). An automatic evaluation on the area is 
then performed and the build-up of the area with the voxels that are within the threshold 
highlighted (C). Finally, the VOI is rendered and used to evaluate the data from that particular organ.   
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Figure 6.12: Screen shots to show the steps involved in segmentation of a ROI. The build-up on the myocardium tissue is 
shown for [
18
F]C2DiMe  
This method was performed on all ROI in the field of view and for all scanned animals. From this data 
a mean VOI volume can be found with the standard deviations (SD) and the data can be visualised in 
an image of the VOIs overlaid with the CT skeleton (Figure 6.13). Although the mean and SD values 
are not used for calculating the uptake in these organs as each rat will be done individually, it allows 
the analyst to see the range of values found between each rat and could potentially highlight areas 
that may be more difficult to assess. 
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From the results shown in the table, it was seen that the most consistent measurements were taken 
for the bone marrow, liver and myocardium. 
In order to gain an overall qualitative view on the extent of the differences in uptake in various 
tissues, the PET/CT image is shown In Figure 6.14. The image is a sum of the SUV value for each data 
point between 30-60 minutes post injection. 
VOI name 
Mean ±SD VOI 
volume (mm3) 
Thyroid 24.2 ± 7.16 
Bone Marrow 56.0 ± 3.98 
Lungs 3600 ± 1810 
Spleen 449 ± 214 
Liver 6700 ± 198 
Myocardium 891 ± 128 
Heart Chamber 46.3 ± 10.6 
Figure 6.13: The average VOI for different organs shown in the table and then depicted in the image with the CT overlay 
image  
Chapter 6 
 
215 
 
 
Figure 6.14: Dynamic PET/CT scan (SUV30-60) static images for [
18
F]C2tBu and [
18
F]C2DiMe 
The most obvious feature that differs between the two tracers is again the uptake into the 
myocardium. In the image for [18F]C2tBu shown at the top, there is no sign of any uptake into the 
heart whereas for [18F]C2DiMe there is a good uptake. The uptake into the liver also differs 
dramatically. For [18F]C2tBu, this is the main feature in the image and the fact that it contains a high 
amount of activity makes it difficult to observe other organs. For [18F]C2DiMe, the uptake in the liver 
is found to be a lot lower and so will cause minimum spill over effect when trying to image the heart. 
As for the thyroid, uptake can be seen for both tracers although it appears to be higher for 
[18F]C2DiMe. 
For visualising the kinetics of the tracer in these different regions, the data was plotted as time 
activity curves (TACs). TACs allow for the activity in each ROI to be visualised over time. The VOI are 
used and the activity accounted for in that area summed at a given time. TACs were produced for 
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both the [18F]C2tBu and [18F]C2DiMe data and the average plotted on the same graph to allow for a 
direct comparison (Figure 6.15). 
 
Figure 6.15: Time activity curves for [
18
F]C2tBu and [
18
F]C2DiMe  
The TACs for both tracers were in agreement with the results obtained from the ex-vivo 
biodistribution study with the highest uptake in the liver for [18F]C2tBu and the highest uptake in the 
myocardium for [18F]C2DiMe. It is also clear from the TACs that both tracers have identical profiles 
for both the lung and heart chamber (blood) uptake but the accumulation in both the thyroid and 
bone marrow is higher for [18F]C2DiMe. 
To confirm these observations and to calculate if the differences seen in the uptake values between 
the two tracers are significant, a summary of the mean and standard deviation of the SUV30-60 for 
each ROI was imputed into a table (Table 6.5). 
 
 
 [
18
F]C2tBu 
 [
18
F]C2DiMe 
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Tissue [18F]C2tBu (n=3) [18F]C2DiMe (n=3) 
Thyroid* 1.11 ± 0.33 3.55 ± 1.46 
Bone Marrow* 0.99 ± 0.04 1.88 ± 0.52 
Lung 0.80 ± 0.22 0.62 ± 0.14 
Liver* 8.26 ± 2.36 1.64 ± 0.83 
Spleen 3.82 ± 1.07 n.m 
Myocardium* 0.65 ± 0.06 2.74 ± 0.96 
Heart Chamber 0.48 ± 0.05 0.76 ± 0.37 
 
Table 6.5: A table to summarise the mean and standard deviation of the SUV30-60 for each ROI for both [
18
F]C2tBu and 
[
18
F]C2DiMe. n.m: not measured because outside of the field of view. * indicates statistical significance between the two 
data series determined by an unpaired t-test (95% confidence) 
The data shows that four tissues were found to have a statistically significant difference between the 
two tracers uptake. The uptake was significantly higher for the thyroid, bone marrow and 
myocardium for [18F]C2DiMe but significantly higher for [18F]C2tBu in the liver. The spleen was out of 
the field of view for [18F]C2DiMe and so no comparison could be made. 
6.4 Results Discussion and Future Work 
Having presented the data obtained from the in vivo analyses of [18F]C2tBu and [18F]C2DiMe, this 
section will look to try and explain some of the results seen and discuss any future investigations 
that could be carried out. 
Firstly, confirmation that both tracers were metabolically relatively stable was carried out by 
determining the amount of parent compound in the plasma over time. For [18F]C2tBu, over 60% of 
the parent tracer was in circulation after 60 minutes and for [18F]C2DiMe it was found to be slightly 
lower at around 40%. Minimum defluorination was also confirmed by the lack of uptake seen in the 
bone which would have been caused by [18F]fluoride. Along with the difference seen in metabolism 
rates, the route of excretion was also found to be very different for the two tracers. [18F]C2tBu was 
metabolised predominately by the liver and excreted via the hepatobiliary system and 
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gastrointestinal tract, whereas, [18F]C2DiMe was excreted via a renal route. The reason behind the 
different mechanism is still to be determined but the higher lipophilicity of [18F]C2tBu may explain 
higher liver uptake.  
This difference in excretion pathways between the two tracers has also meant that a difference 
effective dose was seen. The ED of [18F]C2tBu was estimated at 21 µSv/MBq and [18F]C2DiMe was 
31.5 µSv/MBq. The major organ ED contribution differences found for [18F]C2DIMe compared to 
[18F]C2tBu were an increase in kidney and bladder uptake along with a drop in uptake by the liver 
and spleen. There was also increased stomach and colon uptake, and an increase in ovary dose 
which was due to the gamma dose from increase in the local organs. This has therefore led to a 
much higher full body effective dose. 
Following on from the in vitro cellular research discussed in chapter 5, the in vivo data could also 
help in determining the mode of mechanism into the cell. Along with the mitochondrial membrane 
potential found across the inner membrane of active mitochondria, there is a resting potential 
across all outer cell membrane. This is present due to the ion channels which selectively transport 
ions across the plasma membrane and as a result creates a negative potential within the cell.15 By 
considering the resting potential of various cell types, a comparison between the two tracers could 
be made to help determine whether they respond differently to a membrane potential.  
Red blood cells, for example, contain no active mitochondria and therefore by considering these 
cells it was possible to rule out any role being played by the mitochondrial membrane potential.16 
Although the resting membrane potential is low at approximately 8 mV it should still induce a small 
uptake with this type of tracers, given their positive charge.17 For determining the uptake into the 
red blood cells the uptake of the tracers in the heart chamber could be compared. Having already 
seen from the comparison of the TACs, both [18F]C2tBu and [18F]C2DiMe have exactly the same 
profile suggesting very similar accumulation. This suggests that both tracers are affected by the 
membrane potential to the same extent. 
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When looking into the resting membrane potentials of cells it was found that varying cell types can 
have very different values. The most interesting find was that both skeletal and cardiac muscle have 
the same resting membrane potential at around 80-90 mV.15 If the resting potential was in fact a 
contributor to the uptake of these tracers, it would be assumed that similar accumulation would be 
seen in both skeletal and cardiac muscle. However, by examining the scan images for both [18F]C2tBu 
and [18F]C2DiMe little activity is seen in the skeletal muscle (Figure 6.16). 
 
Figure 6.16: Dynamic PET/CT scan (SUV30-60) static images for [
18
F]C2DiMe. White arrow indicates little activity in the 
skeletal muscles 
The image shown in Figure 6.16 shows that there is a very different uptake seen for the cardiac 
tissue and the skeletal muscle for [18F]C2DiMe. The lack of skeletal muscle uptake suggests that the 
resting membrane potential does not affect the uptake of tracer.  
The most interesting result presented in this work on the two tracers was the fact that they had 
completely different uptake into the myocardium tissue. [18F]C2DiMe allowed for very good cardiac 
imaging whereas the heart could not be observed with [18F]C2tBu. There was also significantly more 
activity seen in the thyroid and bone marrow for [18F]C2DiMe. One possible reason behind these 
results that had to be considered was whether the activity seen in these three tissues belonged to a 
metabolite rather than the parent compound. The metabolism of [18F]C2DiMe may have led to the 
production of a different labelled species that had a higher affinity for these tissues. The different 
mode of metabolic pathway between [18F]C2tBu and [18F]C2DiMe could easily lead to different 
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metabolites being formed. It is also known that [18F]C2DiMe was metabolised at a higher rate to 
[18F]C2tBu resulting in a higher concentration of the metabolite being in circulation. By examining 
the TACs for [18F]C2DiMe, there was little indication as to whether this was occurring. As the tracer 
metabolises the amount of metabolite activity in a tissue to be expected to rise over time. 
 
Figure 6.17: Time activity curve for [
18
F]C2tBu and [
18
F]C2DiMe in the myocardium 
The TACs shown in Figure 6.17 strongly indicates that uptake in the myocardium for [18F]C2DiMe is 
not related to the metabolite. 
There are two methods however, that could be carried out in order to confirm the parent tracer 
accumulation in the myocardium. The first would be to directly analyse the activity found in the 
heart of a live subject. The distribution study would be carried out as normal but following 
exsanguination of the subject the heart would be removed and the myocardium tissue isolated. This 
would then be homogenised in order to break down the tissue and to try and extract as much as the 
activity present as possible. HPLC analysis on the sample would then be ran to confirm whether the 
activity belonged to that of the parent compound or was actually a labelled metabolite. 
The other experiment would be to look at the uptake in an isolated perfused heart model. Due to 
the pioneering work of Langendorff in the late 1800s, isolated hearts have been used for over a 
century to investigate the fundamental physiology of the heart.18 It wasn’t till more recently 
 [18F]C2tBu 
 [18F]C2DiMe 
 
Chapter 6 
 
221 
 
however, that the method has been used for the study of PET tracers.19 By cannulating a rat heart 
and maintaining its contractions with various suitable buffers which are applied retrogradely down 
the aorta, a tracers can be introduced.20 Southworth et al at King’s College London have devised a 
set-up whereby the radioactivity can be monitored during an uptake study in an isolated perfused 
rat heart.21 Three radio-detectors are positions around the heart; one to record the activity entering 
the heart, another to measure the counts in the heart tissue and the last to record the wash out of 
tracer. By introducing both tracers to the heart via this method the direct uptake into the 
myocardium of [18F]C2tBu and [18F]C2DiMe could be measured and compared.  
6.5 Methodology 
All research carried out in the chapter was performed at Imanova, Hammersmith Hospital, London. 
Help with the animal work was performed by Lisa Wells and Sac-Pham Tang, the dosimetry analysis 
by Nick Keat and the dynamic scan data by Christopher Coello. 
6.5.1 Animals 
Male Sprague-Dawley rats were housed 2 or 3 per cage in a temperature (22 ± 20C) and humidity (55 
± 10%) controlled room with a 12 h light/ 12 h dark cycle. Rats were acclimated for a minimum of 
seven days prior to use. All animal studies were ethically reviewed and carried out in accordance 
with Animals (Scientific Procedures) Act 1986 and the GSK Policy on the Care, Welfare and 
Treatment of Animals. 
6.5.2 Metabolite Study 
The rats were anesthetised (Isoflurane: 3-4.5% induction, 2.5-3.5% maintenance at 1.5 L/min 
medical oxygen) under non-recovery anaesthesia and cannulae surgically placed in the tail vein in an 
aseptic manner. The rat’s body temperature was maintained during the procedure with a heating 
mat regulated by rectal probe feedback. The rats were maintained under terminal anaesthesia for 
the duration of the procedure. The rats received an intravenous administration of ca. 10 MBq of 
[18F]C2tBu or [18F]C2DiMe. Post administration, blood samples were collected into tubes (5, 10, 20, 
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40 and 60 min) with anticoagulant and processed to plasma (centrifuge spin: 7500 x g, 5mins at 
+4oC). Plasma was extracted with 1:1 ACN and the extract was obtained by centrifugation (12000 x g, 
5 min at +4°C). To the extract, 0.1 mL of 100 ammonium formate (50 mM, pH 4) was added and the 
resultant solution was mixed and 0.5 mL injected into the HPLC column. Aliquots of the resulting 
solution were measured for radioactivity to determine the HPLC recovery. The HPLC system 
consisted of a pump, degasser, UV-Vis/Diode Array Detector and fraction collector. The HPLC 
conditions were determined prior to the experiment and suitable conditions found to be: 90% 
acetonitrile and 10% AMF (50 mM, pH 4) as the mobile phase at 5 mL/min and a Phenomenex 
Prodigy semi-preparative column (ODS(3), 10 micron, 250 * 10 mm). In total 30 sample fractions 
were collected over a 10 min run after passing through the UV detector before being placed in an 
automated gamma counter to determine the radioactivity in each fraction. 
6.5.3 Biodistribution and Dosimetry  
For this study, a total of twenty-four rats (280-360 g) were anesthetised (Isoflurane: 3-4.5% 
induction, 2.5-3.5% maintenance at 1.5 L/min medical oxygen) under non-recovery anaesthesia and 
cannulae surgically placed in the tail vein in an aseptic manner. The rat’s body temperature was 
maintained during the procedure with a heating mat regulated by rectal probe feedback. The rats 
were maintained under terminal anaesthesia for the duration of the procedure. The rats received an 
intravenous administration of ca. 10 MBq of [18F]C2tBu or [18F]C2DiMe. Post administration, rats 
were left for 5, 15, 30/45 or 60 mins (n = 3 per time point) prior to being killed by exsanguination 
under heavy anaesthesia. Blood samples were collected into tubes with anticoagulant and processed 
to plasma (centrifuge spin: 7500 x g, 5 mins at +40C). Tissue samples from the organs of interest 
were collected, briefly submerged in ice-cold phosphate-buffered saline and weighed after the 
excess fluid was removed. Blood, plasma and tissue samples were evaluated for levels of 
radioactivity in a 1480 Wizard gamma counter. 
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Biodistribution Data Analysis 
Blood, plasma and tissue radioactive counts were decay corrected to the time of injection for each 
rat and expressed as the percentage dose per gram of wet tissue (%ID/g) and standardised uptake 
values (SUV): 
      (
               
                  
)      
    
               
                                  
 
Data was analysed using GraphPad Prism 5.0 software (GraphPad Software Inc., CA, USA) and the 
average activity concentration (%ID/g or SUV) for each time point (n = 3 per time point at 5, 15, 30 
and 60 min) were plotted for each tissue of interest (mean ± sem). 
Dosimetry Data 
The average activity concentration (tissue %ID/g, adjusted by the weight of each rat relative to the 
mean group weight) of each tissue was decay corrected to the incubation time point (either 5, 15, 
30/45 and 60 min). These values were integrated to obtain the time integral of the total 
disintegrations per Bq per ml of tissue over the length of the study.   To account for the decay of the 
activity in each tissue beyond the last measured time point (60 min), the last measured relative 
activity concentration was multiplied by (18F half-life in hours/ln(2)) ,  so that no further excretion or 
redistribution was assumed. To estimate the corresponding values in man, these integrals  were 
multiplied by the ratio of the mean body mass of the rats to the total body mass of the Cristy-
Eckerman ‘adult male’  hermaphrodite human dosimetry  phantom. This value was then multiplied 
by the mass of each phantom organ to give the [18F]C2tBu and [18F]C2DiMe residence time (in hours) 
for that organ. As the Cristy-Eckerman phantom models the small intestine and contents as a single 
organ, the approach taken was to apportion the total mass (1100 g) of the phantom in the 'worst 
case' scenario so that the total residence time of the tissues studied did not exceed the maximum 
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possible value for 18F. This resulted in masses of the small intestine wall and contents of 600 and 
500 g respectively. 
The residence times calculated above were then entered into OLINDA v 1.1. software (Vanderbilt 
University, Nashville, TN, USA). Since OLINDA assumes that the electron dose to the stomach comes 
from the contents only this underestimates the stomach electron dose. The stomach dose was 
therefore generated by running the program twice, with the activity concentration in the OLINDA 
stomach organ given first by the total wall plus contents activity (to account for the gamma dose), 
then with the wall activity only. The stomach wall electron (Beta) dose is then given by the dose 
from the wall and contents estimate plus 2.29 times the wall estimate (this follows from the 
assumptions used to derive the electron dose and the ratio of the phantom stomach wall mass to 
contents mass). 
6.5.4 Small Animal PET  
Three rats (321-360 g) for each tracer were anesthetised (Isoflurane: 3-4.5% induction, 2.5-3.5% 
maintenance at 1.5 L/min medical oxygen) under non-recovery anaesthesia and cannulae surgically 
placed in the femoral artery and tail vein in an aseptic manner, for blood sampling and dosing 
respectively. The rat’s body temperature was maintained during the procedure with a heating mat 
regulated by rectal probe feedback. The rats were maintained under terminal anaesthesia for the 
duration of the scanning procedure. A CT was performed for attenuation correction. Following 
which, one dynamic PET scan (60mins, Siemens Inveon PET-CT) was performed following i.v. bolus 
administrations of [18F]C2tBu and [18F]C2DiMe. Blood samples were collected to obtain a plasma 
curve and metabolite correction. The dynamic listmode scanning data was histogrammed with the 
following frames (frame #, seconds): 10, 3; 6, 5; 8, 30; 5, 60; 6, 300; 2, 600, to produce a sonogram. 
The sinogram was reconstructed using 2D filter-back projection (FBP) algorithm with Fourier rebin. 
The image data were corrected for injected dose and expressed in SUV. Regions of interest were 
drawn on organ volumes (list organs) using ITK-SNAP software and time activity curves generated. 
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7.0 CONCLUSIONS AND FUTURE WORK 
7.1 Research Conclusions 
The primary aim of this PhD was to investigate the use of novel lipophilic phosphonium cations as 
imaging agents of apoptosis by targeting the mitochondrial membrane potential. This thesis was 
separated into four distinct results chapters, each detailing the work carried out in that field of 
research. This final chapter will summarise the results and findings in each section and discuss any 
future work that could further these investigations. 
7.1.1 The Synthesis of the Phosphonium Cations 
Chapter 3 focused on the synthesis of a novel library of phosphonium cations that could easily be 
labelled with fluorine-18. The design was inspired by the promising work of Madar et al on the tracer 
[18F]FBnTP, combined with the favourable conditions of the CuAAC reaction.1,2 The new design is 
shown below in Figure 7.1 
 
Figure 7.1: Structure of proposed new design of the phosphonium cation 
The synthesis started by preparing the alkyne-functionalised phosphonium cations, which were used 
as the precursor to the CuAAC reaction in both radiolabelling and synthesis of the reference 
compound. Four different alkyne chain length analogues were successfully synthesised (3-6 
carbons). 
In order to prepare a range of compounds with varying lipophilicities, functionalisation on the 
phenyl ring was also carried out. The initial thought was to introduce fluorine atoms onto the phenyl 
rings. This was known to generally increase to the lipophilicity and form strong bonds with carbon 
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atoms. Having synthesised a series of different fluorine-functionalised phosphines, problems arose 
when trying to form the cation with the alkyne. The electron withdrawing nature of the fluorine 
atoms were believed to reduce the ability for the phosphorus lone pair to act as a nucleophile. 
Having researched Tolman’s electronic parameters and carried out some phosphorus-selenium NMR 
experiments, methyl functional groups were chosen instead to alter the lipophilicity.  
The alkyne precursors were successfully synthesised for the tracers and are shown in Figure 7.2. 
 
Figure 7.2: Structures of the new functionalised phosphonium alkyne compounds 
To form the reference compounds of the tracers, the alkyne-phosphonium cations were reacted 
with fluoroethylazide under CuAAC conditions. Initial attempts with triphenylpropargylphosphonium 
bromide (4) proved unsuccessful but the other seven reference compounds were synthesised after 
the reaction conditions were optimised. 
Finally, the chapter introduces a method to allow further functionalisation of these tracers. The 
removal of one of the phenyl rings allows for the addition of a different group which could be 
another imaging modality probe, whilst retaining the radiolabelling methodology. The successful 
synthesis of two (alkyne)diphenylphosphine compounds which were then reacted with two small 
benzyl moieties to form the phosphonium cation, proved this could be done. The initial work into 
trying to attach a rhodamine fluorophore was started but unfortunately the desired final compound, 
shown in Figure 7.3, was not achieved within the time frame of the project. 
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Figure 7.3: Structure of proposed compound as a precursor to a dual-imaging probe 
To fulfil the aim of this work, continued attempts to synthesise the above compound will need to be 
carried out. Reaction conditions should be investigated to aid formation. If the reaction was still 
unsuccessful, a different route could be investigated. This could involve forming the phosphonium 
cation prior to rhodamine addition. An example reaction scheme is shown in Figure 7.4.3,4 
 
Figure 7.4: Proposed alternative route to rhodamine-labelled phosphonium cation precursor for CuAAC reaction 
Protection of the terminal alkyne may be required to prevent it reacting but this could be removed 
prior to labelling with 18F without affecting the reaction time. Functionalisation of RH-B may also be 
necessary to make it more reactive and this could be done by converting it to the acid chloride.5 
7.1.2 Radiolabelling of the Phosphonium Cations 
The aim of Chapter 4 was to describe and discuss the steps involved in carrying out the 
radiochemistry required to produce the new library of 18F labelled phosphonium cations. A fully 
automated set-up was implemented to perform both the reaction and the purification.  
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The first step of the radiochemistry was the synthesis of the [18F]FEA. As this was a well-known 
labelling precursor, the preparation of this from 2-azidoethyl-4-tosylate was noted in the literature 
and followed. Both the drying of the fluoride and the radiolabelling was carried out using a 
microfluidic platform called the Advion NanoTek® before being transferred into a vial prior to the 
CuAAC reaction. The purification of [18F]FEA was completed via distillation into a vial containing the 
CuAAC reaction mixture. Both these steps and the transfer of the mixture onto the semi-preparative 
HPLC column were carried out using a helium flow, an a-valve tower and a 6-port/2-way HPLC valve 
completing the fully automated system.  
All seven novel phosphonium cations (Figure 7.5) were successfully labelled and isolated with high 
RCP.  
 
Figure 7.5: Structures of all 7 new 
18
F labelled triazole phosphonium tracers 
The lipophilicity of each compound was measured as a reading of log D. This demonstrated that a 
series of compounds with a wide range (-0.34 - 2.03) of lipophilicities had been achieved.  
The research went on to investigate the possibility of synthesising two different tracers in one 
reaction vial. This proved possible with the synthesis of both [18F]C2tBu and [18F]C2DiMe in equal 
amounts. The differences in lipophilicity made it possible to isolate both tracers in >99 RCP via semi-
prep HPLC. Given the success of this reaction, an attempt to produce three tracers was carried out. 
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There was no competition in reaction rates between the three reactions taking place and thus 
[18F]C2Me, [18F]C2tBu and [18F]C2DiMe were all formed and again isolated successfully.  
7.1.3 Testing the New Tracers Under In Vitro Conditions 
Chapter 5 focused on the in vitro analysis of selected tracers. Initial uptake studies in 38C13 cells 
were carried out on [18F]C2 which showed very low accumulation, probably due to the tracer’s low 
log D value.  [18F]C2tBu was the next tracer analysed due to it having the highest log D value at 
around 2.03 and hence an expected higher uptake in the cells. A surprising result was seen; the 
uptake increased disproportionately and the accumulation was >40% of the administered dose.  
The next stage involved investigating the accumulation response to the initiation of apoptosis. The 
cells were treated with Cisplatin prior to the uptake assay and a significant drop in uptake was seen 
12 hours post treatment. When performing a similar assay with the membrane uncoupler, CCCP, the 
expected result was not seen. There was no significant drop in uptake and at higher concentrations, 
an increase was seen. An in-depth investigation was then carried out to try and determine why this 
result was occurring. Both [11C]MeTPP and RH-123 were used to ensure that CCCP was causing the 
desired effect on the cells. If lower concentrations of CCCP were considered for the [11C]MeTPP 
assay, then a small drop in accumulation was seen. For the RH-123 assay, post protein correction 
results showed the desired trend. This indicated that CCCP was causing a decrease in the membrane 
potential. 
To gain a better understanding of the results, different cell lines and another tracer were 
investigated. [18F]C2DiMe acted as the comparison tracer and uptake assays showed a 10-fold 
decrease in the percentage uptake of administered dose into 38C13 cells. Despite this difference in 
uptake, the response to Cisplatin was the same, with a 70% decrease after 24 hours. CHO-K1 cells 
were used and both the uptake and response to CCCP investigated for [18F]C2tBu and [18F]C2DiMe. 
The uptake of both tracers was found to be similar with accumulation being approximately 7% and 
5% respectively. Although small, a drop in accumulation was seen for both tracers at low CCCP 
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concentrations. At higher concentrations, the uptake was found to be greater than the control, with 
[18F]C2tBu being significantly higher. 
It was hypothesised that the uptake of [18F]C2tBu may have a mode of facilitated uptake in both 
38C13 and Ramos cells, resulting in such a high accumulation. Ion transporters across the membrane 
may be present in these cell lines but not in simple CHO-K1 cells giving rise to the large difference in 
uptake measured. Another hypothesis was that the tracers can passively cross into the cell 
independently of the membrane potential and then bind to an unknown target.  
Further work is needed to confirm how the tracers are entering the cells and how they become 
trapped. Assays involving isolated mitochondria could help determine whether the uptake of the 
two tracers is dependent on the mitochondria itself, or whether the cell is aiding some of the 
transport. To help determine whether the second hypothesis has any truth, work on the rhodamine-
phosphonium tracer needs to be undertaken and then the uptake into the cells visualised via optical 
imaging.  
7.1.4 Testing the New Tracers Under In Vivo Conditions 
The final results chapter discusses the results seen for the in vivo analysis of both [18F]C2tBu and 
[18F]C2DiMe. The metabolic stability, biodistribution and PET/CT scanning studies were performed 
on a series of healthy rats to determine both tracers’ biological behaviour in live subjects. 
Firstly, confirmation of both tracers’ relative metabolic stability was assessed by determining the 
amount of parent compound in the plasma over time. [18F]C2DiMe showed a slightly higher rate of 
metabolism with 40 % of the parent compound present after 60 minutes compared to 60 % for 
[18F]C2tBu.  
After interpreting the biodistribution and the PET/CT scan data, it was clear that the two tracers had 
very different behaviour. It was evident that there was a much higher uptake in the myocardium for 
[18F]C2DiMe, enabling this to be an appropriate cardiac imaging agent. [18F]C2tBu on the other hand, 
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showed very little cardiac uptake and in fact the accumulation in the liver was so high it masked any 
other organs in close proximity. The data also suggested a different route of excretion for the two 
tracers, where [18F]C2tBu was via the hepatobiliary system and gastrointestinal tract and 
[18F]C2DiMe via the renal route. Both tracers did however, have good accumulation and stable 
retention in tissues with high proliferative capacity e.g. bone marrow, thyroid and spleen, indicating 
that the mitochondria could play an important role in the uptake of these tracers. 
This investigation showed that two structurally similar tracers could show very different behaviour in 
in vivo models. The next stage of research would to be to determine their uptake in tumours using 
xenograph models and see if by treating the tumour with anticancer drugs a drop in signal could be 
seen, hence determining their suitability to image cancer and monitor response to treatment.  
In order to gain a better understanding of why the accumulation in the myocardium is different for 
the two tracers, the isolated rat model could be utilised. Looking at the uptake, solely in the heart 
and of that of the parent compound, a direct comparison could be made. This model could also be 
used to help determine the suitability of [18F]C2DiMe to be employed as a cardiac imaging agent for 
various cardiovascular diseases (e.g. hypoxia or ischemia).6  
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8.0 APPENDICES 
8.1 Crystal Structure of (4-butanol)diphenyl(benzyl)phosphonium bromide 
(33) 
 
Crystal data and structure refinement for 33 
 
Identification code     NL1314 
Formula      C23 H26 O P, Br 
Formula weight      429.32 
Temperature      173(2) K 
Diffractometer, wavelength    Agilent Xcalibur 3 E, 0.71073 Å 
Crystal system, space group    Monoclinic, P 21/n 
Unit cell dimensions     a = 9.1984(2) Å  = 90° 
       b = 10.1608(3) Å   = 96.643(2)° 
       c = 21.6618(5) Å   = 90° 
Volume, Z      2010.99(9) Å3, 4 
Density (calculated)     1.418 Mg/m3 
Absorption coefficient     2.133 mm-1 
F(000)       888 
Crystal colour / morphology    Colourless tablets 
Crystal size      0.32 x 0.25 x 0.11 mm3 
 range for data collection    2.757 to 27.967° 
Index ranges      -11<=h<=11, -11<=k<=12, -21<=l<=26 
Reflns collected / unique    10843 / 4158 [R(int) = 0.0220] 
Reflns observed [F>4(F)]    3546 
Absorption correction     Analytical 
Max. and min. transmission    0.820 and 0.601 
Refinement method     Full-matrix least-squares on F2 
Data / restraints / parameters    4158 / 1 / 239 
Goodness-of-fit on F2     1.028 
Final R indices [F>4(F)]     R1 = 0.0328, wR2 = 0.0651 
R indices (all data)     R1 = 0.0431, wR2 = 0.0684 
Largest diff. peak, hole     0.403, -0.321 eÅ-3 
Mean and maximum shift/error    0.000 and 0.001 
 
Bond lengths [Å] and angles [°] for 33 
P(1)-C(20)  1.792(2) 
P(1)-C(2)  1.796(2) 
P(1)-C(14)  1.797(2) 
P(1)-C(7)  1.799(2) 
C(2)-C(3)  1.532(3) 
C(3)-C(4)  1.520(3) 
C(4)-C(5)  1.496(3) 
C(5)-O(6)  1.418(3) 
C(7)-C(8)  1.512(3) 
C(8)-C(13)  1.384(3) 
C(8)-C(9)  1.395(3) 
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C(9)-C(10)  1.387(3) 
C(10)-C(11)  1.377(3) 
C(11)-C(12)  1.384(3) 
C(12)-C(13)  1.382(3) 
C(14)-C(15)  1.389(3) 
C(14)-C(19)  1.392(3) 
C(15)-C(16)  1.393(3) 
C(16)-C(17)  1.378(3) 
C(17)-C(18)  1.382(3) 
C(18)-C(19)  1.384(3) 
C(20)-C(21)  1.387(3) 
C(20)-C(25)  1.393(3) 
C(21)-C(22)  1.387(3) 
C(22)-C(23)  1.378(4) 
C(23)-C(24)  1.381(3) 
C(24)-C(25)  1.375(3) 
C(20)-P(1)-C(2)  108.98(10) 
C(20)-P(1)-C(14) 107.45(10) 
C(2)-P(1)-C(14)  110.04(10) 
C(20)-P(1)-C(7)  108.86(10) 
C(2)-P(1)-C(7)  110.74(10) 
C(14)-P(1)-C(7)  110.69(10) 
C(3)-C(2)-P(1)  112.96(14) 
C(4)-C(3)-C(2)  113.56(18) 
C(5)-C(4)-C(3)  115.8(2) 
O(6)-C(5)-C(4)  112.2(2) 
C(8)-C(7)-P(1)  113.67(14) 
C(13)-C(8)-C(9)  118.8(2) 
C(13)-C(8)-C(7)  120.38(19) 
C(9)-C(8)-C(7)  120.8(2) 
C(10)-C(9)-C(8)  120.5(2) 
C(11)-C(10)-C(9) 120.0(2) 
C(10)-C(11)-C(12) 119.9(2) 
C(13)-C(12)-C(11) 120.3(2) 
C(12)-C(13)-C(8) 120.6(2) 
C(15)-C(14)-C(19) 119.56(19) 
C(15)-C(14)-P(1) 122.34(17) 
C(19)-C(14)-P(1) 118.06(16) 
C(14)-C(15)-C(16) 120.2(2) 
C(17)-C(16)-C(15) 119.7(2) 
C(16)-C(17)-C(18) 120.3(2) 
C(17)-C(18)-C(19) 120.3(2) 
C(18)-C(19)-C(14) 119.9(2) 
C(21)-C(20)-C(25) 119.3(2) 
C(21)-C(20)-P(1) 122.59(17) 
C(25)-C(20)-P(1) 118.10(16) 
C(22)-C(21)-C(20) 120.1(2) 
C(23)-C(22)-C(21) 120.1(2) 
C(22)-C(23)-C(24) 119.9(2) 
C(25)-C(24)-C(23) 120.4(2) 
C(24)-C(25)-C(20) 120.1(2) 
